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Background: Oncolytic viruses (OV) are encouraging new immunotherapies for cancer. OVs, 
replicate in cancer cells inducing immunogenic cell death (ICD) and activating antitumour 
immunity. To date, clinical use has focused on intratumoural delivery due to concerns over 
inadequate tumour targeting following systemic administration. We hypothesise that 
magnetising OVs and magnetic guidance strategies will improve their systemic delivery by 
protecting the viruses from inactivating immune mechanisms but at the same time promote 
anti-tumour immunity.  
Methods: To investigate this, we synthesised and characterised complexes of magnetised 
oncolytic herpes simplex virus (HSV1716) co-assembled with biocompatible magnetic 
nanoparticles (MAG) derived from magnetotactic bacteria (AMB-1) to give MAG-OV 
complexes. Characterization of the physical, chemical and oncolytic potential of MAG-OV 
was performed. The safety and efficacy of this nanomedicine in combination with magnetic 
guidance strategies was assessed in vivo.  
Results: Stable MAG-OV complexes of ~160nm diameter successfully infected human and 
murine breast cancer cells in a dose-dependent manner, and induced tumour oncolysis. 
Following MAG-OV infection a significant increase in viral replication (ICP0, gB, ICP8), ICD 
(HMGB1, CALR, ATP) and apoptotic (CASP 3, CASP8, FASL) signals were detected. 
Intravenous delivery of MAG-OV resulted in reduced tumour burden in the presence of 
magnetic guidance (MAG-OV 448.3mm³ vs. HSV1716 670.6mm³; p ≤ 0.05, n=6-9 mice/group) 
and an increase in tumour-infiltrating T-cells, NK cells and neutrophils. Furthermore, MAG-
OV were protective in the presence of neutralising Abs both in vitro and in vivo. 
Conclusion: This study indicates that MAG are more small and uniform in size and form 
complexes with OV in such a way that the virus does not change its properties. MAG-OV is 
able to enter and replicate inside breast cancer cells, at the same time inducing tumour cell 
death as good as OV alone but with the addition of protecting the virus from neutralising Ab 




































1.1 Introduction   
Oncolytic viruses (OVs) are emerging as new cancer immunotherapies in clinical and 
preclinical studies. These OVs comprise of a set of therapeutically useful and non-pathogenic 
viruses capable of selectively infecting and destroying tumour cells without causing damage to 
healthy cells. Such can arise via direct tumour cell oncolysis or through improving tumour cell 
death in combination with other treatments for example radio- and chemotherapy (Goldufsky 
et al., 2013, Russell et al., 2012, Almstätter et al., 2015a).  In addition, OVs can be modified to 
increase tumour cell death via the induction of potent host anti-tumour immune responses 
(Achard et al., 2018). Tissue infectivity of OVs is a fundamental feature that is determined by 
tropism for a particular cell type and natural specificity for tumour cells has already been 
demonstrated by many OVs (Howells et al., 2017). Tumour cells are attractive to OVs as these 
cells avoid immune detection and destruction in addition to resisting apoptosis and translational 
suppression, all these properties are active in normal cells and work to prevent viral infection 
and spread (Russell, Peng and Bell, 2012). Numerous OVs for example, Herpes simplex virus 
(HSV), vesicular stomatitis virus (VSV) and adenovirus (Ad) are under examination as cancer 
therapies and to date the first FDA approved OV for clinical use is Amgen's T-VEC (an 
oncolytic HSV) in melanoma (Almstätter et al., 2015a). In addition, H101 adenovirus has been 
approved for head and neck cancer in China (Garber, 2006, Yuan et al., 2003)  
In spite of these hopeful developments, use of OVs in the clinic comes with many challenges, 
such as innate host antiviral immune responses (e.g. neutralising antibodies and complement), 
OV pathogenicity, together this results in poor targeting to tumour sites particularly following 
administration into circulation. Success of oncolytic virotherapy has therefore relied on direct 
injection of the OV into the tumour. This approach is useful for superficial or accessible 
tumours but systemic delivery is necessary for the therapy of metastatic disease or hard to reach 
tumours (e.g. in the brain). To overcome this several approaches have been taken to improve 
systemic OV delivery to tumours and these will be discussed later. The overall objective is to 
exceed the ‘viremic threshold’ above which the virus infects a critical number. To achieve this, 
it is necessary to develop strategies that avoid OV deactivation by serum factors (antibodies 
and complement), reduce OV imprisonment in the liver and spleen, direct the OVs to the 
tumour vascular endothelial cells and selectively enhance virus permeability.   
One such approach to achieve this is magnetic targeting of the OVs. Magnetic nanoparticles 
(MNPs) mixed with adenovirus (Ad) or vesicular stomatitis virus (VSV) has been shown to 
increase viral entry into a cell in the presence of an applied external magnetic field, a technique 
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known as magnetofection (Almstätter et al., 2015a, Tresilwised et al., 2012b). The MNPs serve 
as a metal shield to protect the OV (Sapet et al., 2012) and this has the potential to prevent the 
virus from unwanted attack in the blood stream. Moreover, an external magnetic field could be 
used to guide the therapy to the tumour improving its tumour targeting potential and at the 
same time avoiding delivery to healthy tissues and organs. This approach is the focus of this 
PhD thesis and in this chapter an introduction to immunotherapy using oncolytic viruses and 
the challenges of oncolytic virotherapy will be discussed. 
1.2 Breast Cancer 
Breast cancer is described to be the leading cause of death among women below 40 and the 
second leading killer among women aged over 40 (Silverstein et al., 2016). Although early 
stage Breast Cancer (BC) has been treated with a high success rate, the challenge is in managing 
late stage breast cancer. This suggests there are limitations of existing therapeutic options to 
control advanced breast cancer (Silverstein et al., 2016, Goldhirsch et al., 2009). It is reported 
that advanced stage BC tends to develop resistance to conventional chemotherapies, which 
only leaves patients with palliative care options (Brocato et al., 2014). Current available 
therapeutic options for breast cancer treatment can be divided into three main categories: 
cytotoxic, hormonal and immunotherapeutic options (Confortini and Krong, 2015). All of these 
therapeutic categories proved to be less efficacious in the context of controlling advanced 
breast cancer, and often yield toxic effects such as neurological and cardiac disorders which 
drastically affect the quality of life as well as development of new primary cancers (Chen et 
al., 2013, Roukos et al., 2009). Though combination therapies involving two or more categories 
of the above-described therapeutic options proved to be useful in terms of high response rate 
and survival rate, resistance to these therapies is still an issue (Davies and Hiscox, 2011). A 
new avenue for treating breast cancer, is the application of oncolytic viruses which represent 
an engineered version or are derived from naturally occurring viruses (Holl et al., 2016). 
1.3 Cancer Immunotherapy 
Cancer immunotherapy is now considered the fifth pillar of cancer therapy and is rapidly 
advancing to join the level of surgery, radiation, cytotoxic chemotherapy and targeted therapy.  
The role of the immune system in cancer was first highlighted by Virchow et al over 150 years 
ago.  Virchow found that cancers developed inflammation and this was accompanied with the 
infiltration of white blood cells. Afterward, many reports showed that tumours regressed in 
response to acute associated infections including hepatitis, tuberculosis, smallpox, influenza 
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and gonorrhoea (Balkwill and Mantovani, 2001, Nauts and McLaren, 1990). The potential 
relationship between cancer and the immune system was embraced by William Coley. Coley’s 
experiments included direct injection of Gram-positive (Streptococcus pyogenes) and Gram 
negative (Serratia marcescens) bacteria into tumours or metastatic lesions. Despite some 
negative indicators such as treatment related deaths and reporting contradiction, Coley’s toxins 
resulted in spontaneous reduction in numerous tumours including lymphoma and sarcoma 
(Nauts and McLaren, 1990) and this led to development of the Bacillus Calmette–Guérin 
(BCG) vaccine for bladder cancer (Fuge et al., 2015). 
A major challenge for immunotherapy is to make non-responder patients into responders. This 
will likely require the use of powerful combination immunotherapies that successfully control 
the cancer immunity cycle, which achieves the balance between the recognition of non-self and 
the prevention of autoimmunity (Chen and Mellman, 2013). Cancer treatments lead to tumour 
cell death as well as release of tumour antigens. Dendritic cells then present these antigens in 
the tumour-draining lymph nodes to control and stimulate tumour immunity. Tumour-specific 
T cells then infiltrate into the circulation to penetrate the tumour mass. Additional tumour 
antigens that prolong the cycle are released by T cell-mediated cancer cell lysis. Tumour 
immunity could be enhanced at each step of this cycle by numerous opportunities for 
therapeutic intervention (summarised in Table 1.1). Understanding the deficiencies of the 
tumour microenvironment in antigen processing and presentation and the type, quality, number 
and infiltration of immune cells and the pathways that control them as well as developing novel 
immunotherapeutic agents and defining synergistic drug combinations are critical for 
continuing clinical achievement. This will also provide an opportunity to treat patients who do 










Table 1.1: Active connections between cancer and the immune system. 
  
Abbreviations: APCs, antigen-presenting cells; GM-CSF, granulocyte-macrophage colony stimulating factor; 
TLR, toll-like receptor; STING, stimulator of interferon genes; CTLs, cytotoxic T lymphocytes; CTLA-4, 
cytotoxic T lymphocytes antigen-4; NK, natural killer; CAR, chimeric antigen receptor; TCR, T cell receptor; 
TIL, tumour-infiltrating lymphocyte; NK, natural killer; PD-1, programmed death-1; PD-L1, programmed death 
ligand-1; IDO, indoleamine dioxygenase; A2AR, adenosine A2A receptor (Emens et al., 2017). 
Cancer immunotherapies (CI) , such as preventive and therapeutic cancer vaccines (Garland et 
al., 2007, Kantoff et al., 2010), immune checkpoint inhibitors (Hodi et al., 2010, Robert et al., 
2014, Topalian et al., 2014), bi-specific T-cell engagers (Topp et al., 2011), Car T cells and 
OVs  are now accepted as cancer treatments (Andtbacka et al., 2015). These are highlighted in 
Figure 1.1. One of the most advancing fields of CI is antibodies to inhibit immune checkpoint 
molecules. To date, they have shown spectacular results but only in a subset of malignancies, 
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including melanoma (Emens et al., 2017). Recently, meta-analysis of a monoclonal antibody 
(mAb) which targets the immune checkpoint receptor cytotoxic T-lymphocyte-associated 
antigen-4 (CTLA-4), showed that 20% of metastatic melanoma patients survived 10 years later 
with no evidence of disease after receiving a single round of treatment (Schadendorf et al., 
2015). The survival rate of 10-year was below 10% before this treatment (Luke et al., 2017). 
Adding a checkpoint inhibitor as a combination therapy such as nivolumab, a monoclonal 
antibody that targets the PD-1 receptor on T-cells, demonstrates even more potential when used 
with ipilimumab. This resulted in a 50% response rate in metastatic melanoma (142 patients) 
(Postow et al., 2015).  
Combination therapy with other treatment modalities (“immuno-oncology”) has also revealed 
success in other types of malignancies and are demonstrating outstanding benefits (Langer et 
al., 2016, Patel et al., 2017). A previous study demonstrated that combination therapy using 
stereotactic ablative radiotherapy (SABR) and anti-PD1 antibody induced significant reduction 
of non-irradiated tumours in preclinical animal models of melanoma and renal cell carcinoma 
(Park et al., 2015). Recently, prostate cancer patients have been treated with anti-CTLA-4 
(Ipilimumab) resulting in an increase in the level of T-cells in tumours and increase expression 
of PD-1 and VISTA inhibitory checkpoints. Suggesting that mixtures of checkpoint inhibitors 
targeting CTLA-4, PD-1, and VISTA would appear promising (Gao et al., 2017). 
There are also several challenges with cancer immunotherapies particularly checkpoint 
inhibitors for example immune-associated toxicity, treatment resistance, and clinical advantage 
restricted to only a portion of patients. A group of toxicities identified as immune-related 
adverse events, which is a form of autoimmune-like reactions resulting from an increased 
efficiency of the immune system, are often associated with immunotherapies like immune 
checkpoint inhibitors. These toxicities can generate symptoms, such as fatigue or fever, or can 
lead to damage to specific organ that leads to rash, pneumonitis, colitis and adrenal or thyroid 
insufficiency, among many others (Naidoo et al., 2015, Michot et al., 2018, Picchi et al., 2018). 
Therefore, these adverse events need to be understood comprehensively so clinicians can avoid, 
diagnose and suitably treat each specific reaction when using immune checkpoint therapy. 
Interruption of treatment and a short course of steroids resolve most adverse events. Colitis 
refractory of steroids and serious pneumonitis may need treatment with biological agents such 





Figure 1.1: The recent advancement and growth of cancer immunotherapy acceptance. 
A timeline shows regulatory approvals in the United States from 2010.  
OVs are becoming increasingly recognised as immune stimulators via an overabundance of 
tumour antigens emitted by viral-induced destruction of cancer cells (Choi et al., 2016). 
Clinical trials of other OVs are underway for the treatment of different types of cancer, and 
some of these trials are combined with other kinds of cancer therapies. The following section 
will discuss OVs in more detail.  
1.4 Oncolytic Virotherapy 
Oncolytic virotherapy is an emerging cancer treatment modality that has attracted attention 
through the last ten years because of its achievements in clinical trials, high cancer specificity, 
tumour regression and low toxicity. OV are non-pathogenic viruses, which have the aptitude 
to selectively target and replicate inside tumorous tissues in the absence of producing any 
damage to healthy tissues (Russell and Peng, 2007). The most important feature of OV is 
cellular tropism, this decides which tissues are favourably infected, then later, what disease is 
initiated. For example, hepatitis B virus damages hepatocytes, rabies virus damages neurons, 
influenza leads to damage of airway epithelium and HIV damages T helper cells. Most 
naturally arising OVs contain a special tropism for tumour cells and these can be genetically 
engineered to increase immunity as well as express proteins, that assist in tumour cell death 
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(Russell et al., 2012). OVs can kill tumour cells using different mechanisms. Death of cells via 
apoptosis, autophagy or necrosis is not considered to be the sole mechanism for inducing 
tumour cell death following viral infection. This is because the OV is able to take control of 
the molecular cell death machinery of the infected tumour cells, enabling cells to die after 
exploiting available cellular resources for the structure and assembly of new viruses (Russell 
et al., 2012). Besides destruction of infected cells, OVs are able to kill uninfected tumour cells 
via indirect techniques for example disrupting the tumour vasculature, inducing antitumor 
immune responses or via the overexpression of transgene-encoded proteins produced from 
engineered OVs (Russell et al., 2012). 
A whole library of novel OVs have been developed for cancer therapy including parvoviruses, 
reovirus, Newcastle Disease Virus, Moloney leukaemia virus, mumps virus, these viruses 
contain a tropism for tumour cells, whilst other viruses for example Vesicular Stomatitis Virus, 
measles, adenovirus, Herpes Simplex Virus and vaccinia have been engineered or adapted to 
make them tumour-specific (Patel and Kratzke, 2013). The main advantages and disadvantages 















Table 1.2: The advantages and disadvantages of current OVs that are being used as cancer 
treatments in clinical studies. 
 
Clinical trials combining OVs with chemotherapy or radiation have been shown to lead to high 
frequency tumour responses. For example, the combination of oncolytic reovirus alongside 
paclitaxel were demonstrated in a phase I/II clinical trial in 31 patients with advanced head and 
neck cancer (Karapanagiotou et al., 2012). The combination of reovirus plus paclitaxel was 
well tolerated where one patient had a complete response, 6 patients had partial responses, 2 
patients had major clinical responses, 9 patients had stable disease, and 8 patient’s disease 
progressed. This has now led to a randomized phase III study. H101 is a genetically modified 
type 5 adenovirus approved by Chinese regulators in 2005. This virus expresses the viral early 
gene (E1B) that encodes a protein that is 55-kDa in size (E1B-55KD), this allows E1B to 
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interact with cellular P53 resulting in cell inactivation but enabling the virus to replicate. Head 
and neck cancer patients treated with chemotherapy plus intratumoural H101 showed 
significant improvement compared to chemotherapy alone (Russell et al., 2012). JX594 (Pexa-
Vec), is also engineered to express GMCSF, this is an oncolytic vaccinia virus. In a study by 
Park and colleagues, patients with non-resectable hepatocellular carcinoma were given 
intratumoural injections of this virus in a phase I clinical trial. The virus was shown to have 
limited toxicity and in relation to the Response Evaluation Criteria in Solid Tumours 
(RECIST), 3 patients had limited response, 6 had constant disease, and 1 had developed disease 
(Park et al., 2008). This has since developed into a phase II trial where high- or low- dose JX-
594 was infused into liver tumours of 30 patients on days one, fifteen and twenty-nine of 
treatment. Injection caused demonstrable viral replication and GM-CSF expression. However, 
patient survival was remarkably dependent on dosage, with high doses of virus significantly 
prolonging patient survival compared to low doses (Heo et al., 2013a). Furthermore, in a phase 
3 clinical trial, patients squamous cell carcinoma of the head and neck (SCCHN) and squamous 
cell carcinoma of the oesophagus (SCCE), were treated using Cisplatin plus 5-fluorouracil (PF) 
or PF with adenovirus H101. An overall 39.6% response rate was observed, however when PF 
was given with adenovirus H101 a remarkably greater response of 78.8% was observed 
(Goldufsky et al., 2013).  
Many OVs are currently being used in Phase I/II clinical trials worldwide. However, for OVs 
to be more accepted as off the shelf anticancer agents, issues such as efficacy and safety should 
be open to pharmacological study in humans. Of all current OVs that are being studied, the 
first one that has become an approved and licensed as a cancer therapeutic in the Europe and 
US is the oncolytic herpes simplex viruses (HSV). The FDA approved Herpes simplex-1 virus 
(HSV- 1) or Talimogene Laherparepvec (T-VEC) in 2015. This has been modified to express 
GM-CSF an activator of immune cell proliferation and is injected directly into parts of a 
melanoma that a surgeon cannot eliminate (Hughes et al., 2014). Table 1.3 describes the 
features of HSV that have led to clinical success.  HSV1716 will be the OV used in this PhD 






Table 1.3: Features of HSV that has made this virus clinically relevant.  
 
1.5 Clinical trials and development of oncolytic HSV 
The clinical activities of oncolytic HSV has significantly accelerated. For example, the 
engineered HSV (T-VEC) expressing granulocyte-macrophage colony-stimulating factor 
(GM-CSF) has been administered intratumourally to 50 patients with metastatic malignant 
melanoma (Eissa et al., 2018). This is thought to lead to direct tumour oncolysis and GM-CSF 
expression should stimulate closure of the tumour vasculature and induce anti-tumoural 
immunity as mentioned above. The study showed that the OV was tolerated well with 
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promising efficacy and improved patient survival compared to GMCSF alone. Despite these 
promising results, response rates were not evident in patients with visceral metastatic disease 
(Senzer et al., 2009). In another study, 93% of patients with SCCHN had complete remission 
when administered directly into the tumour with T-VEC strain when combined with 
radiotherapy and cisplatin (Russell et al., 2012). The main HSV currently in clinical progress 




























Table 1.4: The oncolytic HSV’s in clinical trials. References are given where possible but in 
numerous cases there is no published data so the clinical trial identifier (from cliniicaltrials.gov) is 
given. 
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Abbreviations: HNSCC, Head and neck squamous cell carcinoma; SCCHN, Squamous cell carcinoma 
of the head and neck; GMCSF, Granulocyte-macrophage colony-stimulating factor.  
1.6 The mechanism of action of HSV on tumour cells 
HSV-1 has been genetically engineered for virotherapy and considered the most common 
herpes virus. There are a number of HSVs currently used in the cancer setting including T-Vec, 
G207, G47Δ, HSV1716, is a selectively duplicating oncolytic HSV type I virus, it replicates in 
actively dividing cells however not in terminally differentiated cells. It has double stranded 
DNA and causes the common cold sore and genital warts. It has about 80 known genes that 
have been sequenced and encoded within their whole genome. It can be genetically engineered 
to have beneficial transgenes which can induce immune mediated killing of tumour cells (Kaur 
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et al., 2012a). In vivo and in vitro experiments have presented data where this virus replicates 
in actively dividing cells in diverse tumour cell types such as mesothelioma, melanoma, 
glioma, non-small cell lung carcinoma, medulloblastoma, and human embryonal carcinoma, 
reviewed in (Mace et al., 2008). 
Both copies of the RL1 gene that translate the neurovirulent ICP-34.5 protein have been deleted 
from HSV1716. ICP-34.5 allows the virus to kills normal cells. So, deleting such a gene ensures 
that the virus is no longer able to replicate in normal tissues (Benencia et al., 2008). 
HSV1716 is tumour specific due to the fact that tumour cells having reduced expression of 
protein kinase R (PKR) compared to healthy cells. When a healthy cell becomes infected with 
this virus, PKR dimerizes and undergoes phosphorylation leading to phosphorylation of the -
subunit of the Eukaryotic Initiation Factor 2 (transcription factor eIF2). This prevents more 
protein production from arising inside the cells, stopping the virus from replicating as shown 
in Figure 1.2. However, due to the oncogenic stimulation of the mitogen-activated protein 
kinase (MAPK) signalling pathway, PKR is down regulated in cancer tissues, enabling 
uninhibited virus replication (Kaur et al., 2012b).  
The efficiency and safety of HSV1716 has nowadays been assessed and defined in many 
progressive tumours for example squamous cell carcinoma of the skin (see Table1-4). A novel 
phase I/IIa study of HSV1716 therapy for Malignant Pleural Mesothelioma (MPM) opened in 
Sheffield in November 2012 (NCT01721018). This trial established an acceptable safety 
profile of intra-pleural HSV1716 with evidence of viral replication and anti-tumour 
immunogenicity in 12 patients  (Danson et al., 2017). This supports further studies in 
mesothelioma, possibly involving combination with immune checkpoint inhibitors.  The 
following sections will discuss the mechanisms of HSV infection, cell mediated killing 
mechanisms and the antitumour response. 
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Figure 1.2: HSV-1 mechanism of action in healthy cells.       
1. HSV1716 gets in the host cell and starts replication. 2. dsRNA produced by annealing of 
Complementary RNA. 3. PKR linked to dsRNA, dimerizes resulting in activation and auto 
phosphorylation. 4. elF2α phosphorylated by Phosphorylated PKR. 5. The stopping translation of host 
cell caused by Phosphorylated elF2α and thus prevents viral replication. 6. HSV presented ICP34.5 that 
creates a protein complex with PP1α. 7. elF2α dephosphorylated by ICP34.5 PP1α complex resulting 
in viral replication 8. Replication can continue unimpeded.  
Abbreviations: HSV, herpes simplex virus; PKR, protein kinase R; P, phosphorylation; PP1α, protein 
phosphatase 1 alpha; eIF2α, eukaryotic initiation factor 2; ICP, infected cell polypeptide. 
 
1.7 HSV infection and host cell defence mechanisms against infection 
1.7.1 Virion and genome of HSV-1. 
It is known that HSV1716 is a deletion mutant of HSV-1 which is a human neurotropic virus.  
The morphological structure of this HSV-1 virion, is distinguished by a core dsDNA genome 
surrounded by a central icosahedral capsid, which is further surrounded by the tegument. In 
turn, this tegument is enclosed by the envelope, which is a protein-containing lipid bilayer. The 
tegument is a substance formed of different viral proteins (Kelly et al., 2009) whereas the 
envelop mainly contains lipids obtained from the  membrane of the host cell, into which are 
inserted HSV glycoproteins. Most of viral functions such as HSV-1 entry into the cell, cell 
fusion, cell-to-cell spread and immune evasion is arranged by membrane glycoproteins 
(Carmichael et al., 2018). 
 The HSV-1 genome is 152 kb long as illustrated in Figure 1.3A. It is a linear two-fold stranded 
DNA containing two unique regions, long and short (called UL and US). Internal repeats (IRL 
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& IRS) are linked to these regions in either orientation. Further, terminal repeats (TRL and 
TRS) are located at the non-linker end of the unique regions. Within L or S regions are a large 
portion of the known genes named according to their location. The immediate – early (IE), 
early (E) genes or late (L) genes as described in Figure 1.3 are considered the main class of 
HSV-1 genes.  
 
Figure 1.3: A. Genome of wild type HSV 1. B. shows the deletion in HSV1716. Both copies of the 
RL1 gene that translate the neurovirulent ICP-34.5 protein have been deleted from HSV1716. ICP-34.5 
allows the virus to kills normal cells. Therefore, deleting such a gene ensures that the virus is no longer 
able replicate in normal tissues. 
1.7.2 HSV viral entry into host cells 
HSV1716 utilizes indistinguishable cell receptors from wild type HSV-1 to infect cells. 
Associations of a few viral glycoproteins, specifically gB, gD and the heterodimer including 
gH and gL is included with entry of HSV-1 into the host cell  (Campadelli-Fiume et al., 2007). 
Receptors on the surface of the host cell connect with these glycoproteins that are located on 
the surface of the enveloped virus.  
Interaction between viral gB and cellular heparan sulphate is considered the earliest contact 
(Shukla and Spear, 2001). Then, the cellular receptors for HSV-1 entry, which incorporate 
HSV entry mediator (HVEM), nectin-1 and 3-O-sulphated heparin sulphates, interact 
specifically with gD. The coordinated effectiveness of gB and gH/gL are required for 
membrane fusion, thus the nucleocapsid obtains access to the cell and infection begins. The 
primary access for infection of central and peripheral nerve cells is Nectin-1, while HVEM 
expression is more confined to cells of lymphoid origin (Simpson et al., 2005). HSV-1 entry 
mediators have an extensive bioavailability and a wide range of human tumour cell types are 
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permissive to HSV1716 infection (Karasneh and Shukla, 2011). Fusion of the virus envelope 
with the plasma membrane lets the virus penetrate the cell resulting in viral nucleocapsid being 
inserted into the cytoplasm of the cell. Then, the genome discharges into the nucleus by binding 
of the capsid to the nuclear pore to initiate the transcription, replication of viral DNA and 
progeny nuclear capsid assembly. 
1.7.3 HSV replication 
HSV-1 gene expression takes place through a very controlled cascade starting with the 
generation of the immediate early (IE) proteins. The α regulatory proteins, ICP 0, 4, 22, and 27 
manage the expression of all classes of viral genes. The proteins that are primarily associated 
with synthesis of viral DNA, are the β or early (E) gene products for example the viral 
thymidine kinase (TK)(Roizman, 1996).  The γ or late (L) proteins for example the VP16, gD 
and gC are considered the last batch of viral proteins produced and are the proteins mainly 
involved in virion structure and assembly (Batterson and Roizman, 1983, Fenwick and Walker, 
1978, Read et al., 1993).  
The γ or late (L) gene class is additionally divided into the γ1 and γ2 sets, where γ2 expression 
is totally reliant on viral DNA synthesis. The completed cycle of HSV-1 replication results in 
eventual damage of the cells.  
1.7.4 Activation of the MEK pathway is necessary for HSV replication  
MEK is a main controlling kinase triggered via mitogen-activated protein kinase (MAPK) 
kinases (A-RAF, B-RAF, and C-RAF) that functions to promote cell survival (Ballif and 
Blenis, 2001, von Gise et al., 2001, Xia et al., 1995). Therefore, MEK and its only identified 
substrate, MAPKs (ERK1 and ERK 2), are triggered in many tumours as a result of tyrosine 
kinase receptor activation (Hoshino et al., 1999), dysregulated growth factor secretion 
(Pouyssegur et al., 2002), activating mutations in RAS isoforms, and somatic activating 
missense mutations of B-RAF (Davies et al., 2002). Activated MEK plays a main role in 
suppression of PKR resulting in replication of ICP34.5 mutant virus and destruction of tumour 
cells (Smith et al., 2006). 
As mentioned above, cells from different tumour tissue types can be infected equally well by 
HSV1716, as confirmed via the equal expression of early viral proteins expressed following 
viral entry (Smith et al., 2006). This suggests that function of variances in overall viral protein 
synthesis, rather than differential infectivity could be one of the reasons why there is variability 
in viral production in different tumour cell types. The occurrence of mechanisms in tumour 
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cells that circumvent the PKR-mediated antiviral response could be important for replication 
of HSV1716. Many early studies have shown that the difference in capability of numerous 
human tumour cell lines to HSV1716  infection was reliant on the stimulation status of the 
endogenous MAPK kinase (MEK) which can prevent the activation of PKR, (Figure 1.4) 
(Smith et al., 2006).  
 
Figure 1.4: The shutdown of host protein synthesis in the presence of HSV1716 infection is 
blocked by MEK pathway activation in cancer cells. In ICP34.5 (-) mutants, the MEK activated 
pathway in tumour cell will block PKR activation, and in the absence of ICP34.5 protein, will result in 
translation initiation and viral replication. 
1.7.5 Proliferating cell nuclear antigen (PCNA) is important for HSV replication 
Previously, PCNA has been recognised as additional molecular mechanism that participates to 
the selectivity of HSV for tumour cells. PCNA has been used as a diagnostic and prediction 
cell-cycle marker because it plays a role in proliferation of cancer cells and cancer 
transformation (Bologna-Molina et al., 2012). PCNA levels are very high in cycling cells for 
instance active tumour cells, however levels can normally be much lower than in non-cycling 
cells. So PCNA could be used as a proliferation cell marker (Bologna-Molina et al., 2012). 
Previous studies have shown that HSV neurovirulence factor ICP34.5 forms a complex with 
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PCNA in vitro and in vivo via its 63-amino-acid carboxyl domain which is preserved in hamster 
GADD34, and mouse MyD116 (Brown et al., 1997, Harland et al., 2003). This suggest that 
both viral and cellular proteins complex in vitro and in vivo with PCNA and offers solid 
evidence for the importance and biological relevance of these interactions. Indeed, PCNA is 
required for HSV replication and recent studies have highlighted that the HSV DNA that enters 
the cellular nucleus does not have histones (these are responsible for the cellular packaging of 
DNA into structural units called nucleosomes), but once inside the nucleus histones cover the 
viral DNA. Using SiRNA knockdown of PCNA and a cytosine arabinoside chemical inhibitor, 
they demonstrated that PCNA is necessary for histone deposition and in the absence of this 
process PCNA viral replication was significantly reduced (Sanders et al., 2015). 
 One of the components of oncolytic specificity that could define its efficiency is tumour 
expression of PCNA. The in-situ PCNA profiles have been studied in histological sections of 
tumour biopsies that were gained from patients experiencing craniotomy (Detta et al., 2003). 
They found that PCNA expression was positive in 10 metastatic tumour biopsies (3 melanoma, 
4 carcinoma and 3 adenocarcinoma) via IHC and reinforced the replication of HSV1716. 
HSV1716 replicated effectively in tumour cells, where PCNA was previously involved in DNA 
replication, even in the absence of ICP34.5. In spite of this, the association between the PCNA 
levels and reactivity to HSV1716 in a large group needs to be confirmed. 
1.7.6 Cell death pathways and HSV 
1.7.6.1 Autophagy 
Autophagy acts as a primary cellular conservation mechanism that includes the lysosomal 
degradation of unnecessary or dysfunctional proteins and organelles. The process of autophagy 
provides essential cellular energy that ensures cellular survival during starvation. Autophagy 
proteins, which targets viral components for degradation of lysosomal, plays an antiviral role, 
and has a role in activating immune responses against viral infection (Alexander et al., 2007). 
ICP34.5 interferes with autophagy via binding Beclin-1 during wild-type HSV-1 infection. 
Beclin-1 acts as an important component of numerous extremely regulated complexes 
controlling the development and maturation of autophagosomes (Alexander and Leib, 2008). 
Cancer cells often exhibited disorder in autophagy resulting in increased tumorigenesis. 
HSV1716 cannot bind Beclin-1 to block autophagy because of the ICP34.5 deletion (Figure 
1.4). However, HSV-1 has US11, a late gene product of HSV-1, that is identified to obstruct 




Indeed, two anti-autophagic proteins are encoded by HSV-1, suggesting autophagy develops a 
strong anti-viral influence. Nevertheless, HSV-1 can replicate in vitro in autophagy deficient 
cells (Murine embryonic fibroblasts (MEFs)) as good as in wild type cells (Alexander et al., 
2007). A further study demonstrated that a HSV-1 mutant that had a mutation in ICP34.5 was 
neuro-reduced in mice suggesting that the neurovirulence of wild type HSV because of the 
ICP34.5 protein binding with Beclin-1 is contributing to the inhibition of autophagy by HSV-
1 (Orvedahl et al., 2007).  
A study carried out by a Masters student (Anna Claudia Lima) at the University of Strathclyde 
in collaboration with Virttu Biologics looked at autophagy with HSV infection in a number of 
human tumour cell lines, such as Hep3B, HuH7 (liver cancer) and A2780 (ovarian cancer). The 
autophagy response to HSV infection in the in vitro human cancer cell lines studied was 
variable and independent of ICP34.5 status (this data was presented as a poster at 8th 
International Oncolytic Viruses meeting, 2014, Oxford, UK). 
1.7.6.2 Apoptosis  
Host cell apoptotic pathways are activated by HSV-1 infection as a defence mechanism to 
suppress the spread and replication of the pathogen. HSV-1 infection induces host cell 
apoptosis via the first class of viral genes (IE genes) expression (Sanfilippo and Blaho, 2006).  
Cytopathic effect (CPE) is referred to the major biochemical changes that is induced by 
productive HSV-1 replication in infected cells. Apoptosis is also activated by the virus in 
transformed or tumour cells, but not primary cells. Production of virus ICP27 during an 
apoptotic-prevention window leads to delay of the apoptotic process from damaging the virally 
infected cells, which eventually enables the beginning of productive viral replication (Aubert 
et al., 1999). Viral proteins including the immediate early proteins ICP4, ICP24 and ICP27, 
which act to control apoptosis during viral infection, have been recognised.  Loss of any of 
these proteins results in viruses that activate apoptosis (Thomson, 2001). Previous studies have 
demonstrated that deletion of either ICP4 or ICP27 resulted in reduced expression of early and 
late viral gene products. This suggest that immediate early protein ICP4 or ICP27 have 
regulatory functions (Samaniego et al., 1997).  
Apoptosis can be prevented by other early HSV gene products such as US3 (Leopardi et al., 
1997), Glycoprotein D (Zhou and Roizman, 2001),  R1 (Langelier et al., 2002) and latency 
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associated transcripts (LAT) (Nguyen and Blaho, 2009). Single loss of any of these late viral 
genes do not result in apoptosis to the same extent as the ICP4 or ICP27 deleted viruses. This 
suggest that the late viral genes have unnecessary roles or are able to inhibit apoptosis during 
HSV infection.  
Herpes Simplex Virus Dependent Apoptosis (HDAP) is a process of death used by cells that 
infected with recombinant viruses with modifications in the anti-apoptotic viral gene. HDAP 
was firstly studied with transformed cell lines in vitro, then when studies were developed to 
comprise non transformed lines essential variations were detected (Aubert and Blaho, 2001). 
Transformed, tumourigenic cells are sensitive to HDAP while primary, non-transformed cells 
are resistant to HDAP. So far,  two HDAP sensitivity regulator proteins have been identified, 
P53 and telomerase, two known key oncogenes (Nguyen et al., 2007). Therefore, HSV 
infection increases killing in cancer cells, but not normal cells via HDAP. HDAP is reliant on 
caspases. A study used specific caspases inhibitors in HEp-2 cells and found that caspase 9 
inhibitors were able to suppress HDAP, whereas inhibitors of caspase 8 did not. This suggests 
that HDAP is dependent on  the intrinsic pathway of apoptosis (Aubert et al., 2007).  
 Possibly, As HSV virus is able to induce apoptosis in cancer cells but not in normal cells, this 
difference could be exploited in tumour therapy. HSV1716, like wild type HSV-1 is able to 
keep viral proteins that prevent host cell apoptosis. HSV1716 produces progeny virions, 
preventing cell apoptosis so that viral replication occurs before the host cell is damaged. On 
the other hand, HSV1716 infection might still leading to tumour cell death, through HDAP, if 
the production of the viral proteins that prevent apoptosis was blocked. Thus, combination of 
HSV1716 with antitumour drugs that prevent viral replication could result in tumour cell death 
through HDAP.  
As HDAP occurs through the intrinsic pathway and relies on caspases, looking for increased 
levels of specific caspases could help measure this enhanced HDAP. Increased apoptosis could 
be detected by measuring the levels of caspase 3/7, and the differentiation between intrinsic 
and extrinsic pathways could be identified by measuring caspase 8 or 9. 
1.8 HSV induces immunogenic cell death  
OV infected tumour cells promote anti-tumour immunity (Bartlett et al., 2013) and this likely 
a result of immunogenic cell death (ICD). Understandably, ICD is one of the cell death types 
that involves the adaptive arm of the immune system. Further, ICD stimulates innate and 
tumour-specific immune cells and generates an anti-tumour immune response, which is able to 
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eradicate the uninfected cancer cells in primary and metastatic sites (Figure 1.5) (Bartlett et 
al., 2013).  HSV-1 RH2 have been shown to induce DAMPs from squamous cell carcinoma 
SCC cells to induce cell death. In this study they showed that high mobility group box 
1(HMGB1) and ATP were released into the extracellular space, while calreticulin (CRT) 
translocated to the cell membrane after being infected with (RH2) (Takasu et al., 2016). 
Coxsackievirus B3 virus have also been shown to induce ICD in human non-small cell lung 
cancer cells (NSCLC; A549, H1299, and H460), including cell surface CRT and release of 
ATP as well as HMGB1 (Miyamoto et al., 2012). 
                                        
 
Figure 1.5: OVs induce ICD of cancer cells that leads to antitumor immunity. After delivering the 
OV into the tumour either intra-tumourally or systemically, replicating OV in tumour and/or stromal 
cells present eat me signals, DAMPs and PAMPs, on the cell surface and then release danger signals. 
APC engulfs apoptotic bodies, and TAAs are offered together with MHC complex and co-stimulatory 
molecules. DCs are activated and matured by released DAMPs (and PAMPs) and TAAs are cross-
offered to naïve T-cells. Complete eradication of the tumour mass may be enhanced by causing 
cytotoxic immune response against the tumour, including CD4 and CD8 T cells. Antitumor immune 
responses can be helped by other immunotherapies targeting T cells, DCs and the immunosuppressive 
TME.  
The interaction between HSV1716-mediated tumour damage and immune response has been 
demonstrated in a syngeneic murine intracranial melanoma model (Miller and Fraser, 2000). 
They found HSV1716 significantly prolonged survival compared with mock-treated mice. 
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Moreover, they reported complete tumour regression in 60% of the animals treated with 
HSV1716. There was no change detected between mock and HSV1716 treated groups in the 
mean survival rates when SCID mice (no adaptive immune system) were used compared to 
immunocompetent animals. Also, no significant change was found in the mean survival rates 
of the mock vs. HSV1716 treated mice when leukocytes were depleted using 
cyclophosphamide in the syngeneic model before and during HSV1716 administration (Miller 
and Fraser, 2000). Together this suggest that adaptive immune cells are essential for promoting 
this effect of HSV1716. After viral therapy, infiltration of immune cells into the tumour was 
also studied.  The main early infiltrating cells were macrophages and CD4+ T cells, while 
polymorphonuclear leukocytes such as NK cells, CD8+ T cells, microglia cells and B cells also 
infiltrated into the tumour (Miller and Fraser, 2000). NK cells significantly infiltrated on day 
7 post therapy, with significant CD4+ T cells infiltration seen on day 12. Staining of HSV-1 
antigen was positive in the tumour mass. Treated mice showed downregulation of MHC class 
I expression 3 days post viral therapy when compared with mock-treated mice. These data are 
in agreement with prior studies that demonstrate downregulation of MHC class I expression 
with HSV-1 through ICP47 (Jugovic et al., 1998).  
Indeed, various rodent cancer cell lines are unaffected by HSV -1, because the natural hosts for 
HSV-1 are humans. Transfected mice cell lines and HSV1716 replication-competent cell lines, 
were used to produce tumours in 4 strains of knockout mice (CD4-/-, CD8-/-, NK-/-, and RAG2-
/-) as well as syngeneic C57/BL6 mice. An increase in survival was only shown in 
immunocompetent C57/BL6 mice when treated with HSV1716. This suggests that the 
prolongation in survival, which is seen after HSV1716 therapy, was a result of the cells of the 
immune system (Miller and Fraser, 2003).  
A study by Thomas et al., demonstrated that direct tumour injections of HSV1716 was able to 
inhibit primary tumours growth and improve survival in a 4T1 mouse mammary tumour model. 
This improvement in survival resulted in reduction in lung metastasis. The establishment of a 
second challenge of 4T1 tumours also decreased tumour size following HSV1716 therapy. 
Inflammatory cells, for example neutrophils, were noticed in HSV1716-treated tumours on day 
12 post injection of tumour cells. In addition, HSV1716-treated tumours showed an increase in 
CD4+ and CD8+ T cells compared to the mock-treated tumours. Growth of 4T1 tumours was 
not reduced after HSV1716 therapy in SCID mice, proposing a function for the T cell infiltrates 
(Thomas and Fraser, 2003).  
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 In addition, Benencia et al., established the vaccination effect of intra-tumoural injection of 
HSV1716 in a mouse model of ovarian cancer. They found that tumour growth was reduced 
significantly by HSV1716, as well as increased mouse survival. Further, mouse ovarian tumour 
cells displayed a significant increase in expression of gB and gD and were easily phagocytosed 
by dendritic cells (DCs) after HSV1716 infection. Heparin and anti-HSV gB and gD reduced 
the improved phagocytosis of tumour-infected cells via DCs. This proposed that collaborations 
between DCs and tumour apoptotic bodies are improved by viral infection (Benencia et al., 
2008). 
The type of cell death induced following HSV infection dictates the type of immune response 
that follows. The induction of antitumour immunity requires ICD that involves the adaptive 
arm of the immune system. We encourage systemic delivery of HSV into the tumour to induce 
ICD.  
1.9 Systemic delivery of HSV 
OV have been modified to increase potency by expressing genes that induce cytotoxicity 
(Doronin et al., 2000), increase virus replication (Le Boeuf et al., 2013), stimulate  killing of 
bystander cells (Freytag et al., 1998), and improve antitumour immunity (Melcher et al., 
2011a). However, these enhancements will not induce effective antitumour responses without 
successful delivery of virus to the tumour. Traditionally, OV is delivered directly to the tumour 
by intratumoural injection. However, some of the tumour may contain numerous small nodules 
spread out over a large area. In addition, direct injection is not always possible for tumours that 
are not accessible. Systemic delivery is needed for such inaccessible tumours. Furthermore, 
systemic delivery of some OVs can stimulate antitumour immune responses greater than direct 
intratumoural injection. For example, Bridle et al showed that a single intravenous dose of 
Vesicular stomatitis virus expressing human dopachrome tautomerase (VSV-hDCT) into mice 
bearing intracranial B16 tumours resulted in the induction of antitumour immunity (Bridle et 
al., 2010). 
Although, there are numerous advantages for efficient systemic delivery of HSV, there are 
several barriers that need to be overcome (Figure 1.6). In circulation, the virus can encounter 
numerous factors that prevent its delivery to the tumour and the host immune system is unable 
to distinguish between a therapeutic HSV and a pathogenic virus. Therefore, intravenous HSV 
can encounter circulating factors such as antibodies. These antibodies neutralise virus directly 
by specific binding, or mark them for destruction via complement and several immune cells 
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(Ferguson et al., 2012). This is particularly pertinent to viruses that the body has already 
encountered. Serum proteins as well as circulating cells in the bloodstream also neutralise HSV 
by nonspecific binding (Ferguson et al., 2012). Virus is also cleared from the bloodstream by 
organ sequestration, such as the liver, spleen and lung. As these tissues comprise macrophages 
that filtrate the blood from circulating pathogens (Fisher, 2006). Adaptive immunity produces 
an extra obstacle to intravenous delivery of HSV. As it capable of growing a significantly more 
potent and specific immune response to the virus compared with its innate counterpart. 
Definitely, many of the OVs including vaccinia virus (Heo et al., 2013b), reovirus (White et 
al., 2008), measles virus (Galanis et al., 2010) and HSV (White et al., 2012) have infected most 
of the human population resulting in developing immunologic memory to these viruses. 
Previous preclinical (Power et al., 2007, Ilett et al., 2009, Iankov et al., 2007) and clinical 
(White et al., 2008, Adair et al., 2012) studies have shown that the amount of infectious virus 
that can be delivered to the tumour is significantly reduced by neutralising antibodies. Delivery 
of OV into the tumour bed can also be affected by physical barriers for example tumour 
extracellular matrix and high interstitial fluid pressure within the tumour resulting in restricted 
extravasation of OVs into the tumour (Wojton and Kaur, 2010).  Although, there are many 
barriers to systemic delivery of OVs, previous clinical trials have suggested that OV can be 
delivered into the tumour intravenously by using high doses of virus that perhaps saturate the 
neutralising mechanisms that exist within the human body (Breitbach et al., 2011a, Adair et 
al., 2012).  In spite of this revolutionary success in the field, there is still space for progress 
particularly with respect to systemic delivery.  
 
Figure 1.6: Virus neutralisation during systemic delivery. Firstly, virus are neutralised by binding 
with circulating antibodies in the blood stream and complement proteins resulting in marking them for 
destruction by immune effector cells. Interaction of the OV with circulating blood cells could result in 
virus sequestration. Furthermore, the reticulo-endothelial system such as the liver are able to filter 
viruses from the blood. The tumour extracellular matrix and high interstitial fluid pressure are also able 
to limit the extravasation of virus into the tumour.    
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However, as mentioned earlier the most common threat to OV treatments such as HSV1716 is 
neutralising antibodies from prior encounters with such a common virus. As a result, strategies 
have been planned to beat this, such as the usage of cell-carriers. There has been considerable 
interest into the advantages of using live cells to carry OV to tumours at the same time as 
avoiding antiviral immunity recently (Power and Bell, 2008). The ability of cells to migrate 
into tissues naturally has led them to be appropriate cell delivery targets for OVs. This has been 
demonstrated for immune cells for example macrophages and dendritic cells. Jennings et al., 
demonstrated that overcoming antibody neutralisation can be achieved by inserting reovirus 
onto either immature dendritic cells (iDC) or Lymphokine-activated killer and dendritic cell 
LAKDC and reovirus-loaded LAKDC, these were ideal vectors for delivering reovirus to  
ovarian cancer in vitro and stimulated innate and adaptive immunity (Jennings et al., 2014). 
Macrophages in particular have the advantage in that they home to highly inaccessible hypoxic 
areas of tumours (Muthana et al., 2011a). Researchers in Sheffield have exploited this for the 
delivery of adenovirus protected by macrophages in preclinical mouse models of prostate 
cancer (Muthana et al., 2011a). The same group also demonstrated that viral delivery by 
macrophages significantly increased the trafficking of macrophages to prostate tumours in mice 
following chemotherapy and radiotherapy (Muthana et al., 2013). Cell delivery is an attractive 
approach but clinical studies have demonstrated natural cell trafficking has not been simple. 
Numerous cell types have been used, such as T cells (Morgan et al., 2006), macrophages 
(Griffiths et al., 2000) and stem cells (Studeny et al., 2004). Most of these types of cells have 
been located in tumours (albeit in small numbers) following administration but they were also 
found to enter other organs and tissues and this not only weakens the treatment but also 
increases the risk of toxicity in other parts of the body if they transfer therapeutic cargo such 
as viruses. 
In a recent paper by Muthana et al., tiny MNPs (Super Paramagnetic Iron Oxide:SPIO) were 
inserted into cells (monocytes/macrophages) and injected intravenously into tumour bearing 
mice and subsequently directed into the prostate tumours implanted under the flanks of mice 
using an external magnetic field. Using this approach, they showed a 3-fold increase in cell 
delivery (Muthana et al., 2008b). This approach has also been used for delivering anti-cancer 
drugs, antibodies and for inducing magnetic hyperthermia (Tran and Webster, 2010). 
Furthermore, Muthana et al., demonstrated that prostate tumour-bearing mice that received 
HSV1716-carrying macrophages (also loaded with MNPs), which were directed into primary 
and metastatic tumour sites using magnetic resonance targeting with an MRI scanner, showed 
marked reduction of the primary tumour than those that received naked HSV1716  (Muthana 
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et al., 2015b). We propose to use a similar magnetic guidance strategy for delivery and targeting 
of HSV1716 to tumours but without the need for cells. In order to do this, we must consider 
how to magnetise our OV and which magnetic nanoparticles (MNPs) are the most suitable. 
Below is a review of the types of MNPs used in biomedical research and their application. 
1.10 Magnetic nanoparticles (MNPs) 
Magnetic nanoparticles (MNPs) have been exploited in biomedical applications including 
hyperthermia, targeted drug delivery and gene delivery. The most vital properties of MNPs in 
all biomedical applications are biocompatibility, tunable nanomagnetism, low toxicity and 
exact localization at the biological target. Fe3O4 MNPs have been most commonly used in bio-
applications because of their unique features, such as strong magnetic susceptibility and 
superior biocompatibility, one of these bio-applications is gene delivery (Zhou et al., 2014). 
Moreover, It is well known that Fe3O4 MNPs have a big surface area-to-volume ratio, so this 
kind of MNP tend to conglomerate resulting in low colloidal constancy in physiological 
circumstances (Dias et al., 2011). There are some major challenges with respect to the use of 
MNPs in cancer therapy that still need to be addressed. For example, how to increase the uptake 
of Fe3O4 MNPs in tumour cells whilst decreasing accidental side effects to normal cells. 
Moreover, how to keep the MNPs from clearance by the reticuloendothelial system (RES) so 
as to increase blood circulation time and ensure they reach their target tissue still needs to be 
addressed (Sun et al., 2010a, Xie et al., 2007). 
Since the 1970s, interest in MNPs for drug delivery systems has been recognised. The use of 
magnetic fields to guide the MNP-drug conjugates to a specific site because of their 
ferromagnetism is very attractive. In the last few years, MNPs loaded with anticancer drugs 
(e.g. carboplatin, doxorubicin, paclitaxel, 5-fluorouracil, epirubicin, etc.) were guided by an 
external magnetic field to tumour sites. Chao et al. established that growing tumours could be 
shrunk significantly in mice with hepatocellular carcinomas using doxorubicin-coupled MNPs 
and external magnetic devices to achieve local enhancement (Chao et al., 2012a).  
1.10.1 Iron oxide particles 
The most widely used application of iron oxide in the clinic is as MRI contrast agents and 
because of the extensive scattering of Fe3+ in the human body and low toxicity these particles 
can be exploited for clinical use (McBain et al., 2008, Buyukhatipoglu and Clyne, 2011).    
Understanding the structure and property relationship of iron oxide MNPs have led scientists 
to harness their properties, tailoring and tuning the desired structure, shape and size of the 
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MNPs (Dadfar et al., 2019). US Food and Drug administration (FDA) have accepted iron oxide 
MNPs in biomedicine because of their numerous advantages. Certainly, an advantage of iron 
oxide MNPs is that they are simple to manufacture, non-toxic, biocompatible and can be super 
paramagnetic. g-Fe2O3 (maghemite) and Fe3O4 (magnetite) are considered the two major 
structures of iron oxide particles in medicine to date (Hervault and Thanh, 2014). 
1.10.2 Coated iron oxide MNPs 
In biomedical applications MNPs are often covered with natural polymers (proteins and 
carbohydrates), artificial organic polymers (polyethylene glycol), polyvinyl alcohol, poly-L-
lactic acid), silica and gold (Kami et al., 2011). Using these compounds can improve chemical 
and physical stability of the MNPs and their toxicity is reduced (Selvan et al., 2005, Sotiriou 
et al., 2011). TransMAGPEI iron oxide MNPs stabilised with polyethylenimine (PEI) were the 
first MNPs used for gene delivery (Mykhaylyk et al., 2012). PEI is a popular choice of coating 
as this improves cationic gene transport with high effectiveness of transfection in the lungs of 
mice (Thomas et al., 2005). However, it is highly toxic to cells. The authors found that 
modifying the PEI to remove the N-acyl groups decreased cytotoxicity and improved its 
plasmid DNA transfer effectiveness 21 times in vitro, in addition to 10,000 times in mice. They 
also showed that siRNA delivered with PEI coated MNPs missing N-acyl groups inhibited 94% 
influenza virus infection in the lungs of mice (Thomas et al., 2005). In a study by Sanchez and 
colleagues, a new nanomagnetic approach for gene delivery and cell separation. They used 
gene vectors associated with MNPs (PEI-modified silica-iron oxide) to transfect target cells 
such as hematopoietic stem cells (human and mouse) and human mesenchymal cells when 
being passaged and isolated using a magnetic field cell separation column. Superior target cell 
purity and retrieval was yielded using this method (Sanchez-Antequera et al., 2011).  
The adjustment of the MNP surface has also been demonstrated with chitosan (CS) because of 
excellent features such as low immunogenicity, amphiphilicity and biodegradability (Park et 
al., 2010, Amidi et al., 2010, Rinaudo, 2006). For instance, the core shell nanocomposites 
decorated by simple coacervation methodology with CS improves the intravenous transfer of 
the anticancer agent gemcitabine to cancer tissue in a murine tumour model (Arias et al., 2012). 
MNPs are very quickly cleared via the reticuloendothelial system (RES) once injected into 
circulation and this limits their circulation time. Coating the MNPs with polyethylene glycol 
PEG has been revealed to remarkably increase blood circulation enabling the MNPs to reach 
their target. PEGylation provides stability, biocompatibility and hydrophobicity (Liu et al., 
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2012, Shah et al., 2012). Lui et al, synthesised PEGylated MNPs and found they showed great 
impedance to phagocytosis by macrophages in vitro in addition to minimum uptake via the 
liver and spleen in mice with tumours. This improved tumour imaging by MRI and required 
only low doses of MNPs. These properties are basically a result of the considerable protecting 
effect of the PEG coating and their stability in physiological circumstances (Liu et al., 2011a). 
The most strong points of MNPs are biocompatibility, tunable nanomagnetism, low toxicity 
and exact localization at the biological target. Therefore, Many MNPs have been used in 
preclinical models of cancer using the coatings described above as well as other coatings, these 
are summarised in Table 1.5 






Tumour  Reference 
 
Iron oxide nanoparticles 
with starch coating 
Mitoxantrone Squamous cell carcinoma 
VX-2 (rabbit) 
subcutaneous (hind limb) 
(Alexiou et al., 2000) 
Iron oxide nanoparticles 




Breast cancer cell line 
MDA-MB-231 (human) 
(Alphandéry et al., 
2011) 




Melanoma cell line B16-F10 
(mouse) subcutaneous (rear 
limb above stifle) 









(Bruners et al., 
2010) 
Iron oxide nanoparticles 
(Fe3O /gold) 
Doxorubicin Hepatoma cell line H22 
(mouse) subcutaneous 
(right flank) 
Chao et al., 2012) 
Iron oxide nanoparticles 





Breast cancer cell line 
HBT3477 (human) 
subcutaneous (abdomen) 
(DeNardo et al., 2007) 
Iron oxide nanoparticles 
with dextran coating 
Hyperthermia (alternating 
magnetic field) 
Breast cancer cell line MDA-
MB-231 (human) 
subcutaneous (between the 
shoulder blades) 
(Silvio et al., 2011) 
Iron oxide nanoparticles 
with PEG coating 
Arginine-glycine-aspartic 
acid or chlorotoxin 
Glioblastoma cell line U87 
(human) subcutaneous 
(Dürr et al., 2013) 
Iron oxide nanoparticles 
(Fe 3 O 4) 
Hyperthermia (alternating 
magnetic field) 
Breast cancer cell line 
(human) subcutaneous 
(abdomen) 
(Dürr et al., 2013) 
Iron oxide nanoparticles 
with dextran coating and 
binding for tumor-
specific antigen uMUC-1 
siRNA against BIRC5 Breast cancer cell line BT-
20 (human) subcutaneous 
(Kumar et al., 2010) 
Iron oxide nanoparticles 
(Fe3O4) coated with poly 
lactic acid 
Arsenic trioxide Osteosarcoma cell line 
MG-63 (human) 
subcutaneous (flank) 
(Dürr et al., 2013) 
Iron oxide nanoparticles 
with polylysine coating 
NM23-H1 gene (an anti-
metastatic gene) 
Melanoma cell line B16F10 
(mouse) 
(Li et al., 2008) 
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Iron oxide nanoparticles 
with polyethylenimine 
coating 
Plasmid DNA comprising a 
cytokine gene 
Fibrosarcoma (Plank et al., 2011) 
Iron oxide nanoparticles 
with dextran coating 
Herpes simplex virus vector Gliosarcoma cell line 9L 
(rat) brain 
(Dürr et al., 2013) 
Iron oxide nanoparticles L6 IgG monoclonal antibody Lung carcinoma cell line 
LX-1 (human) brain 
(Remsen et al., 1996) 
Iron oxide nanoparticles 
with dextran coating 
Human adenovirus type 5 
early region 1A (E1A) 




(Shen et al., 2010) 
Iron oxide nanoparticles 
(Fe3O4) within liposomes 
Hyperthermia (alternating 
magnetic field) combined 
with dendritic cells 
Melanoma cell line B16 
(mouse) subcutaneous 
(right flank) 
(Tanaka et al., 2005) 
Mn x Zn 1 – x Fe 2 O 4 





Ovarian cancer cell line 
SKOV3 (human) 
subcutaneous (right side) 
(Dürr et al., 2013) 
Iron oxide nanoparticles 
covered with starch, 







Ovarian cancer cell line 
ID8-Defb29/Vegf-a 
(mouse) intraperitoneal 
(Toraya-Brown et al., 
2013) 
Iron oxide nanoparticles 
(Fe3O4) 
Adenoviruses Pancreatic carcinoma 
cell line 181RDB-fLuc 
(human) subcutaneous 
(right flank) 
(Tresilwised et al., 
2010c) 
Iron oxide nanoparticles Hyperthermia (alternating 
magnetic field) 
Pancreatic carcinoma cell 
line 181RDB-fLuc (human) 
subcutaneous (armpit) 






Buccal pouch carcinoma 
HCDB1 (hamster) 
(Wu et al., 2011) 
Iron oxide nanoparticles 




Prostate cancer (Johannsen et al., 
2007) 






Glioblastoma (Maier-Hauff et al., 
2011) 
 
1.10.3 Challenges of MNPs 
1.10.3.1 High variation in size and physical aggregation of MNPs 
The high variation in size and physical aggregation displayed by chemically synthesised MNPs 
is a concern that has been raised by many researchers. For example, Raguraman and colleague 
reported this concern (Raguraman and Suthindhiran, 2019). They found that synthetic MNPs 
agglomerated inside the cell which subsequently damage the redox system causing mortality. 
However, Florea et al., demonstrated high cell uptake of PEI coated MNPs in Cos1 (green 
monkey fibroblasts) and airway epithelial cells (calu-3) but this correlated strongly with PEI 
toxicity (Florea et al., 2002). Similarly, Thomas and co-workers found that PEI coated MNPs 
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facilitated gene transfer into the A549 lung carcinoma cells in vitro and into the lungs of mice 
but this also was highly toxic to cells (Thomas et al., 2005). This needs to be addressed if these 
particles are to be applied clinically (Blanco-Mantecon and O’Grady, 2006).  
1.10.3.2 Toxicity of nanoparticles 
A major issue that still needs to be addressed regarding MNPs in medicine is toxicity. Toxicity 
is largely affected by MNP dose, chemical structure, size, surface chemistry, biodegradability, 
pharmacokinetics, solubility, bio-distribution,  structure and shape (Tran and Webster, 2010). 
The main tool which is used to reduce the toxicity of MNPs is modifying their surface 
properties (Park et al., 2006). Many of the current studies on MNP toxicity have been in vitro 
investigations, which whilst useful could be unreliable due to their simplicity. In vivo studies 
in preclinical animal models should be done to completely understand the MNP toxicity along 
with clinical studies in humans.  
One should also treat the in vitro data with caution as it has been described that some of the 
typical cell viability assays (such as MTT and neutral red (NR) assays) are affected by the 
MNPs leading to false results because of MNP/dye interfaces (Monteiro-Riviere et al., 2009). 
Consequently, checking the toxicity of MNPs should be done using a combination of different 
assays. 
 As mentioned above MNPs have mainly been utilized in MRI applications as contrast agents. 
The first generation of MNPs, such as Feridex are coated with dextran and are fast removed 
from the blood via RES. Feridex has been used to detect tumours (primary and metastasis) in 
normal liver tissue, and was FDA-approved in 1993 for this application via intravenous 
injection. New MNPs like those described above are being developed by researchers 
worldwide. Some of these should become approved for clinical use in the coming years. 
1.10.3.3 Controlling and guiding MNPs via an external magnetic field 
Controlling MNP drug transporters to the chosen place for treatment is considered one of the 
major challenges faced in MNP-based therapeutics. Targeting systems which use these MNPs 
depend on using an external magnet located near the target tissue (Muthana et al., 2008b, Lübbe 
et al., 1996, Lemke et al., 2004, Kettering et al., 2007). The magnetic field which is used by 
this strategy cannot penetrate a tissue depth more than 12 cm, thus the permanent magnet is not 
useful for targeting tissues deep in the body (Goodwin et al., 1999, Neuberger et al., 2005). As 
previously suggested by Shapiro, dynamically controlled magnetic fields could be utilized to 
deliver magnetic transporters to deep tissue targets (Shapiro, 2009). This could also be achieved 
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using the powerful magnets in MRI machines. A recent study from the University of Sheffield 
demonstrated that MRI could be used to magnetically guide magnetic cell therapies carrying 
the OV (HSV1716) to tumours located in the prostate and lungs of mice.  This significantly 
improved the number of cells trafficking to tumours and resulted in a reduction in primary and 
metastatic tumour burden (Muthana et al., 2015a). The magnets in use today in MRI are in the 
0.5 T to 3.0 T range, while the magnet that we used in this study is 0.7 T. In this PhD project a 
naturally occurring MNPs called magnetosomes will be used and therefore will be discussed 
in more detail below. 
1.10.4 Magnetotactic bacteria and magnetosomes 
Another type of MNPs is magnetosomes. Most of magnetotactic bacteria contain 
magnetosomes, which consist of magnetic iron particles providing species-specific features as 
shown in Figure 1.7. Magnetotactic bacteria (MTB) are a Gram-negative motile group that 
have the ability to produce magnetic nanoparticles called magnetosomes, through a controlled 
biomineralization process (Bazylinski and Frankel, 2004). Adopting iron in ionic state from 
the environment is considered one of the most unique features of the magnetotactic bacteria. 
These bacteria produce magnetosomes and potentially use it as a compass to navigate in the 
direction of the earth's magnetic field (Alphandéry, 2014). Magnetite-producing spirillum 
named Aquaspirillum (now Magnetospirillum) magnetotacticum strain MSR-1 is considered 
the first MTB cultivated in axenic culture (Blakemore, 1975).  Study in these microorganisms 
was delayed for a long time because of the obstacles in isolating and cultivating different 
species of MTB. However, over the last 30 years, different kinds of MTB were isolated in 
axenic culture because of the important developments in culture approaches for different kinds 
of MTB, mainly since 2011 (Lefevre and Bazylinski, 2013). Moreover, the number of 
publications which use MTB and magnetosomes in diverse biotechnological applications has 
also significantly increased since 2011. Today, there are around 25 MTB species in axenic 
culture (Lefevre and Bazylinski, 2013). In spite of this, there are a rare species that are 
accessible in cell line sources, containing the American Type Culture Collection (ATCC) or 
the Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures 




 Figure 1.7: Transmission electron microscopy (TEM) images. A. Magnetotactic bacteria 
(magnetospirillum magneticum AMB-1) contain magnetosomes (black dots) B. Magnetosomes isolated 
from magnetotactic bacteria at higher magnification (Al-Janabi et al, 2015 unpublished data). 
Magentosomes have a uniform morphology and are approximately 40-50nm in diameter.  
Magnetosomes isolated from magnetotactic bacteria display uniform morphology and unique 
structure with narrow-size distribution (Lins et al., 2000, Schüler and Frankel, 1999). The 
M.gryphiswaldense strain is able to create iron oxide MNPs of cubic-octahedral shape, which 
have an average size range of 35-50 nm (Zeytuni et al., 2012, Greene and Komeili, 2012). 
Magnetosomes have a membrane lipid bilayer admixed with special proteins. For example, 
free fatty acids and neutral lipids; in addition to glycolipids, sulfolipids, and phospholipids 
which include phosphatidylserine and phosphatidylethanolamino are present on the 
magnetosome membrane isolated from M. magnetotacticum MS-1 (Gorby et al., 1988). 
Magnetosomes have high surface negativity on the membrane as a result of the lipid 
composition and the occurrence of polarizable primary amino groups (Tanaka and Matsunaga, 
2000). Below is a comparison of magnetosomes to the chemically synthesised MNPs described 














Table1.6: Compares magnetosomes derived from M. gryphiswaldense with chemically synthesised 
MNPs (Fischer et al., 2011, Liu et al., 2010, Sun et al., 2008a). 
 
The magnetic mineral crystals of magnetosomes exhibit unique magnetic and physical features 
that considered essential in their use in many biotechnological applications. These mineral 
crystals display a uniform crystal morphology reliant on the species of MTB, such as a small 
crystal size range, comparatively high chemical purity and limited crystallographic deficiencies 
(Bazylinski et al., 1995, Bazylinski et al., 1994). There are diverse crystals shapes of 
magnetosome among types of MTB; however, generally, one species of MTB produces crystals 
of a particular morphology (Bazylinski and Frankel, 2004, Balkwill et al., 1980). Currently, 
three shapes of magnetosome crystals were observed in MTB with only minor differences and 
include, roughly cubic (cuboctahedral) (Mann et al., 1984a, Mann et al., 1984b, Kiseleva et al., 
2015); elongated prismatic (appear rectangular in projection) (Blakemore, 1975); and bullet or 
tooth-shaped (anisotropic) (Lefevre et al., 2011, Li et al., 2015, Mann et al., 1988) (Figure 
1.8).  
                   
                Magnetosomes 
 
      Chemically synthesized MNPs 
 
Regular morphology and small size distribution 
(25–55 nm). 
 
Typically, measuring 1–100 nm in diameter often not 
uniform 
 
An inorganic component of Fe3O4 with high 
purity.  
 
An inorganic nanoparticle core. 
 
Stable single-magnetic-domain particles. 
 
Single magnetic domain particles. 
 
Biocompatible surface with negative charge and 
good dispersal because of polarized primary amino 
groups in the bilayer lipid membrane of 
magnetosome. Easy integration with varied 
bioactive molecules due to the plenty of primary 
amino groups on the magnetosomes surface. 
 
Coating of surface provides good stability under 
physiological circumstances and permits for the 
functional ligand integration.  
Large-scale production methods are needed   Comparatively easy to manufacture. 
 






Figure 1.8: Transmission electron microscopy (TEM) images of different crystal shapes of 
magnetite magnetosome crystals that organise into chain(s) within magnetotactic bacteria. 
Magnetite magnetosomes A. bullet-shaped purified from magnetotactic Nitrospirae, B. prismatic 
purified from magnetotactic Alphaproteobacteria, and C. cuboctahedral purified from Aquaspirillum 
magnetotacticum. Figure taken from (Vargas et al., 2018). 
Magnetite magnetosome are mineralized under strict genetic and (bio) chemical control by a 
process called biomineralisation (Gorby et al., 1988, Komeili, 2012, Amemiya et al., 2007). 
MTB uses particular genes named ‘mms’ (magnetic particle membrane specific) or ‘mam’ 
(magnetosome membrane)  genes to encode proteins that contribute to formation of 
magnetosome membrane, uptake of iron, magnetic crystal nucleation and gathering of the 
magnetosomes into chains (Murat et al., 2010, Komeili, 2012, Grunberg et al., 2004, Amemiya 
et al., 2007). However, particular steps of magnetosome biomineralization require further 
investigation and could be different reliant on the species of MTB (Komeili, 2012, Faivre and 
Godec, 2015).   
Although, magnetosomes have some features superior to those appeared in synthetic iron 
particles as described above (Xie et al., 2009). The fastidious and microaerophilic growth 
features of MTB are considered a common problem in the production of biogenic iron particles 
(Yan et al., 2012, Heyen and Schuler, 2003). As cultures of MTB results in a low yield of 
magnetite and purification techniques of magnetosomes from cultures are showed very time-
consuming compared to the production of synthetic MNPs (Xu et al., 2014). Many strategies 
for culturing of MTB in bioreactors have been suggested (Heyen and Schuler, 2003, Liu et al., 
2010, Zhang et al., 2011, Sun et al., 2008)  and commonly utilise Magnetospirillum strains 
growing in batch, fed-batch, and semi-continuous cultures (Araujo et al., 2015). For example, 
cultures of MTB under very low O2 tensions or anaerobically results in much higher of 
magnetite yields (Heyen and Schuler, 2003). Therefore, a usual effective method in large-scale 
cultivation of MTB is strict control over O2 tension during growth (Sun et al., 2008). 
Magnetosome production is also effected by other medium components, for example nitrogen, 
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carbon and iron sources and concentrations (Heyen and Schuler, 2003, Liu et al., 2010, Zhang 
et al., 2011). Recent study have shown that final biomass concentration is increases by lower 
concentrations of lactic acid in the feed of M. gryphiswaldense MSR-1, while cellular 
magnetism is increased by a high concentration. Therefore, it is important  to balance the 
production of biomass and magnetosomes in the design of these fermentation processes 
(Fernández-Castané et al., 2018). It is essential to note that, these techniques are considered 
environmentally friendly procedures with comparatively good reproducibility, low cost, and 
high yield as mentioned by Xu and colleagues (Xu et al., 2014).  
The mixture of these chemical/physical/magnetic features, alongside with the properties of 
magnetosome membrane, leads the magnetosomes to be unique and value investigation for 
their possible in biotechnology, nanotechnology and nanomedicine applications. 
1.10.4.1 Applications of MTB and Magnetosomes  
So far, whole MTB and magnetosomes have been considered in many applications, such as 
drug delivery, DNA and antigen recovery/detection, cell separation, food science, 
hyperthermia, enzyme immobilization, MRI image contrast and bioremediation (Table 
1.6&1.7). 
Table 1.7: This table shows applications of whole MTB. 
  
Sun et al., used magnetosomes from Magnetospirillum gryphiswaldense MSR-1 bacteria as 
magnetic-targeted drug carriers to establish an anti-tumour influence of doxorubicin-loaded 
magnetosomes in EMT-6 and HL60 cancer cell lines. Moreover, cardiac toxicity was 
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remarkably decreased in doxorubicin-loaded magnetosomes in a rodent tumour model of liver 
cancer compared with doxorubicin alone (Sun et al., 2007). Magnetosomes have gained 
attention as diagnostic and therapeutic agents because of their physical properties (Lee et al., 
2011, Hartung et al., 2007). Their use in magnetic hyperthermia was recently considered 
advantageous because of their specific absorption rate (SAR), this was numerous orders of 
magnitude greater than the chemically synthesised MNPs that are currently used in magnetic 
thermotherapy (Alphandéry et al., 2012, Alphandéry et al., 2011a, Lee et al., 2011, Hartung et 
al., 2007, Hergt et al., 2005). Magnetosomes can therefore tolerate high heating effects when 























Table 1.8: This table shows applications of magnetosomes. 
 
Magnetosome studies in the field of biomedical science are still in their infancy and the toxicity 
of this kind of particles has not yet been fully evaluated (Xiang et al., 2007). For example, as 
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these particles are derived from bacteria, there could be some immunogenicity associated with 
their use, however this requires further investigation. Indeed, magnetosomes that extracted 
from gram negative magnetotactic bacteria possess endotoxins at their surface, which need to 
be removed for medical applications (Le Fèvre et al., 2017). However, these particles do hold 
promise particularly given their small and uniform size as well as their biocompatibility.  
1.11 Hypothesis and Aims 
OVs are fast becoming accepted anti-cancer therapies but there is a critical need to overcome 
the challenges of systemic delivery if this is to become an accepted cancer treatment 
particularly for hard to access tumours or metastatic disease. Our overarching hypothesis is that 
magnetising OVs and magnetic guidance strategies will protect the viruses from inactivating 
immune mechanisms they encounter in circulation resulting in improved tumour targeting 
located in primary and metastatic sites in preclinical models of breast cancer. In doing so this 
will promote antitumour immunity.  
To test our hypothesis, we aimed to: 
Develop a stable nanomedicine whereby HSV1716 is co-assembled with magnetosomes 
derived from magnetotactic bacteria AMB-1. The magnetosomes will serve to protect the OV 
from deactivating immune responses and increase the targeting of the virus from circulation to 
the tumour in the presence of a magnetic field. 
To achieve this our specific objectives were to: 
1. Magnetise the OV ‘HSV1716’ with magnetosomes (MAG-OV) and characterise 
the physicochemical and biological properties of the nanomedicine. 
2. Characterise the oncolytic potential of MAG-OV.  
3. Investigate the magnetic targeting efficacy of MAG-OV in mammary tumours in 
the presence and absence of neutralising antibodies and assess the anti-tumour 







































2.1.1 List of reagents 
Reagent Company 
1% Eosin Sigma-Aldrich 
1% Penicillin and Streptomycin Lonzo BioWhittaker Ltd 




Absolute Ethanol  Thermo Fisher Scientific 
Acetone Thermo Fisher Scientific 
Agarose Sigma-Aldrich 
Cryo-M Bed Optimal Cutting Temperature 
Compound (OCT)  
VWR International 
Dimethyl Sulfoxide (DMSO)  Sigma Aldrich 
Dispase II  Gibco 
DPX Mounting medium  Sigma Aldrich 
Dulbecco’s Modified Eagle’s Medium (DMEM) 
Ultraglutamine, 4.5g/L glucose Lonza DMEM 
medium 
Lonzo BioWhittaker Ltd 
Eosin Y  Thermo Fisher Scientific 
FcR blocking reagent, mouse  Miltenyi Biotec 
Growth Factor Reduced (GFR) Matrigel  Corning 
Haematoxylin Solution Gill No. 2  Sigma Aldrich 
Immune-mount Sigma-Aldrich 
Iscove’s Modified Dulbecco’s Medium (IMDM)  Lonza 
L-Glutamine (4mM) Lonzo BioWhittaker Ltd 
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Normal Goat Serum  Vector Laboratories 
Nuclease free water  Qiagen 
Paraformaldehyde  Sigma Aldrich 
Phosphate Buffered Saline Lonzo BioWhittaker Ltd 
PI Thermo Fisher 
PrecisionPlus qPCR mastermix with SYBR green 
and ROX  
Primer Design 
ProLong Gold Antifade mountant  Invitrogen 
Roswell Park Memorial Institute (RPMI) 
mediumRPMI medium 
Lonzo BioWhittaker Ltd 
Super PAP pen  Thermo Fisher Scientific 
TO-PRO-3 Thermo Fisher 
Trypan blue  Sigma-Aldrich 
Trypsin/EDTA Sigma Aldrich 
TWEEN 20  Thermo Fisher Scientific 
Zombie UV Fixable Viability kit  Biolegend 
 
2.1.2 List of materials 
Material Supplier 
Coverslips Scientific Laboratory Supplies 
Fisherbrand 384-well skirted PCR plate  Thermo Fisher Scientific 
Superfrost Plus Microscope Slides Thermo Fisher Scientific 
Tissue culture flasks (Nunc EasYFlask) 25cm2; 
75cm2; 125cm2 





2.1.3 List of equipment and Apparatus  
Equipment and apparatus Company 
Applied Biosystems 7900 Real-time PCR machine  Applied Biosystems 
Automated Cell Counter BIO-RAD 
Bench centrifuge SANYO 
Compound light microscope Olympus 
FACSCalibur Becton Dickinson 
Incubator SANYO 
Laminar airflow hood Heraeus 
Light microscopy  Leica 
LSR II Flow cytometer  BD Bioscience 
Micropipette Eppendorf 
MS2 meters Bartington Instruments 
NanoBrook Zeta PALS Brookhaven instrument 
Nanodrop Thermo Scientific 
Nikon A1 Confocal  Nikon 
PIPETBOY INTEGRA 
Plate reader  Thermo Scientific 
Refrigerator BioCold 
Sensitive balance Sartorius 
Shaking platform  Luckham 
Sonicater  Bioruptor 
Spectrophotometer Varian Associates 
Water bath Grant 
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2.1.4 List of Primers  
All primers were either designed using NCBI primers blast or previously published. Parameters 
used when designing primers included exon-exon junction, product length and GC ratio) (Ye 
et al., 2012). Primers were validated using melt-curve analysis and a standard curve was used 
to assess the efficiency of these primers. All of the primers were purchased from Sigma and 
dissolved in nuclease free water and stored at -20oC on arrival. Of note, all primers were 
designed by a post-doctoral research fellow in the group (Dr. Emer Murphy). 
Primer Name Primer Sequence 
ATGS Forward: 5’- TCTGGATGGGATTGCAAAATG -3’  
Reverse: 5’- TTTCTTCTGCAGGATATTCCATG -3’ 
Bcl-2 Forward: 5’-GGAAGTGAACATTTCGGTGAC -3’  
Reverse: 5’-GCCTCTCCTCACGTTCCC -3’ 
CASP3 Forward: 5’- AAAGCACTGGAATGACATC-3’  
Reverse: 5’- CGCATCAATTCCACAATTTC-3’ 
CASP8 Forward: 5’- CTACAGGGTCATGCTCTATC-3’  
Reverse: 5’- ATTTGGAGATTTCCTCTTGC-3’ 
CXCL10 Forward: 5’-GAATTTCCCCAGCATCCCAAAG-3’  
Reverse: 5’-TGCCTTCTGCACTCCCTTTATC-3’ 
FasL Forward: 5’--ATCCCTCTGGAATGGGAAGA -3’  
Reverse: 5’-CCATATCTGTCCAGTAGTGC -3’ 
gB Forward: 5’-TGTGTACATGTCCCGTTTTACG -3’  
Reverse: 5’- GCGTAGAAGCCGTCAACCT -3’ 
HSP90AA1 Forward: 5’- ATATCACAGGTGAGACCAAG-3’  
Reverse: 5’- GTGACTGACACTAAAGTCTTC-3’ 
HSP90B1 Forward: 5’- TTCAAAGGAAAGTGATGACC-3’  
Reverse: 5’- GCATCATATCATGGAAGTCG-3’ 
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HSPA1A Forward: 5’- AATTTCCTGTGTTTGCAATG-3’  
Reverse: 5’- AAAATGGCCTGAGTTAAGTG-3’ 
ICP0 Forward: 5’-AAGCTTGGATCCGAGCCCCGCCC -3’  
Reverse: 5’-AAGCGGTGCATGCACGGGAAGGT -3’ 
ICP8 Forward: 5’-GACATTACGTTCACGGCCTTCGAAGCCAG -3’  
Reverse: 5’-GGCCGAGTTGGTGCTAAATACCATGGC -3’ 
IFNy Forward: 5’-TGCAGGTCATTCAGATGTAGCGGATA -3’  
Reverse: 5’-TCATGTATTGCTTTGCGTTGGACA -3’  
IL-10 Forward: 5’-GCCTAACATGCTTCGAGATC-3’  
Reverse: 5’-CTCATGGCTTTGTAGATGCC-3’ 
IL-1B Forward: 5’- GCCACCTTTTGACAGTGATGAG -3’  
Reverse: 5’-AGCTTCTCCACAGCCACAAT-3’ 
LC3B Forward: 5’- GTGGAAGATGTCCGGCTCAT -3’  
Reverse: 5’- TGGTCAGGCACCAGGAACTT -3’ 
NF-kB Forward: 5’-ACCTGAGTCTTCTGGACCGCTG-3’  
Reverse: 5’-CCAGCCTTCTCCCAAGAGTCGT-3’ 
TGf- B Forward: 5’- AGCGACTCGCCAGAGTGGTTA-3’  
Reverse: 5’- GCAGTGTGTTATCCCTGCTGTCA-3’ 
TNF Forward: 5'-CCAGGAGAAAGTCAGCCTCCT-3'  
Reverse: 5'-TCATACCAGGGCTTGAGCTCA-3' 
VEGF Forward: 5’-GAAGTTCATGGACGTCTACCAG  
Reverse: 5’-CATCTGCTATGCTGCAGGAAGCT-3’ 
House Keeping gene (GAPDH)
  
 
Forward: 5’- TGCACCACCAACTGCTTAGC -3’  
Reverse: 5’- GGCATGGACTGTGGTCATGAG -3’ 
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2.1.5 List of commercial kits  
Kit Company 
ENLITEN ATP kit Promega 
HMGB1 ELISA Kit  Shino-Test 
Precision 2X q-PCR Mastermix PrimerDesign 
Precision Nanoscript 2 RT Kit  PrimerDesign 
RNeasy Mini Kit QIAGEN 
 
2.1.6 List of solutions 
Solution Instructions 
DAPI staining solution 50µg/ml DAPI in PBST 
FACS buffer DPBS with 0.5% FBS 
PBST 250µL TWEEN 20 in 50ml DPBS 
Tumour dissociation medium IMDM with 0.2mg/ml collagenase type IV and 2mg/ml 
dispase II 
 
2.1.7 List of software 
Software Supplier 
Fiji https://imagej.net/Fiji [184] 
Flow Jo TreeStar Inc 
GraphPad Prism 7 Graph Pad Inc. 
Primer Blast National Institute of Health, USA 
 
2.1.8 Human Materials 
Human platelet-depleted waste buffy coats were supplied by the Sheffield Blood Transfusion 
Service. All patients donating blood gave informed consent to the Sheffield blood Transfusion 
Service and the University of Sheffield Ethics Committee has approved all procedures. This 
was carried out under ethics SMBRER 139. 
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 Most of the chemicals utilized in this project were obtained from Sigma and Sigma Aldrich. 
All water that was used for this project was Ultrapure MilliQ (18MΩ cm), degassed and 
sparged with N2 before use. 
2.2 Methods  
2.2.1 Preparation of Magnetosomes (MAG) 
MAG were prepared from purified magnetotactic bacteria AMB-1 using established protocols 
(Staniland et al., 2007). Preparation of MAG was carried out in assistance with Ms. Zainab 
Taher in Chemical department at Sheffield University. Details are explained in the following 
sections. 
2.2.1.1 Bacterial culture 
The strain magnetospirillum magneticum AMB-1 used in this project was kindly provided by 
the Matsunaga group, Tokyo Institute of Agriculture and Technology, in both anaerobic and 
microaerobic conditions in liquid medium (Arakaki et al., 2008). This bacteria can produce 
internal magnetite particles with a size of 50-100nm that are cuboctahedral shaped (Arakaki et 
al. 2008). AMB-1 was grown in a cabinet within microaerobic conditions consisting of 1% O2 
and 99% nitrogen at 30.1 C° in liquid culture medium (see 2.2.1.2) which is specific to AMB-
1 bacteria. 
2.2.1.2 AMB-1 culture medium 













Table 2.1 AMB-1 growth medium. 
Ultrapure MilliQ water 2000ml 
KH2PO4 1.36g 




Succinic acid 0.74g 
 
All these components were added to the water in the order provided in (Table 2.1). 1M NaOH 
was used to adjust the AMB-1 culture medium to pH 6.75 and 400ml was aliquoted into 500ml-
sterilised bottles, autoclaved on a standard cycle (121 C° for 15 min at 15P) and stored in a 
Whitley VA 500 workstation cabinet (300C and 99% nitrogen). The following day, sodium 
thioglycolate was added by passing first through a cellulose nitrate membrane filter (pore size 
0.22um). Two days after this vitamins, minerals and 0.01M ferric quinate was added to the 
medium using the quantities described in Table 2.2. Ferric quinate is known to encourage 
magnetosome growth resulting in a high density of cells. The solutions in Tables 2.3-5 were 
prepared as stock solutions and were pre-sterilised with a 0.22um filter prior to adding to the 
culture medium. The nitrilotriacetic was dissolved first then, NaOH was added to adjust the pH 










Table 2.2: Welfer΄s vitamins solution. 
Ultrapure MilliQ water 1000 ml 
Biotin 2.00mg 
D-Ca-pantothenate 5.00mg 
Folic acid 2.00mg 
Lipoic acid 5.00mg 
Nicotinic acid 5.00mg 




Vitamin B12 0.10mg 
 
Table 2.3: Volume of vitamins and minerals and ferric-quinate that was added to 400ml medium. 
Solution 400ml of Medium 
Ferric quinate (0.01M) solution (Table 2.4 ) 0.16ml 
Na-thioglycolate 3% Wt 
Welfer΄s mineral (Table 2.5) 1ml 
Welfer΄s vitamins (Table 2.2) 4ml 
 
Table 2.4: Ferric quinate 0.01M. 
Ultrapure water 20ml 
FeCl3.6H2O 0.45g 
Quanic acid 0.19g 
 
The vitamin solution was kept in the dark. 
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Table 2.5: Welfer΄s mineral solution. 
Ultrapure Milliq water 250 ml 
CaCl2. 2H2O 0.10g 
CoSO4. 7 H2O 0.18g 
CuSO4. 5H2O 0.01g 









Nitrilotriacetic acid 1.50g 
ZnSO4. 7H2O 0.18g 
2.2.1.3 AMB-1 inoculation 
Bacteria (1ml) stocks stored at -80 C° were thawed and transferred into small glass bottles of 
AMB-1 culture medium (75ml) and left for one week in a Whitley VA 500 workstation cabinet 
(30 C ͦ and 99% nitrogen) to reach maximum density. 75ml was decanted into 400ml glass 
bottles of medium and incubated for four weeks. The light scattering in UV/Visible 
spectrophotometer (Varian Associates) was used to check the density of cells in medium at 
600nm, where 1ml of cultured bacteria was compared to 1 ml of media only. Optical density 
measurements were recorded every 8 hr for 72 hr then on a weekly basis until the fourth week. 
2.2.1.4 Harvest and lysis of AMB-1 cells 
The MAG were extracted from AMB-1 bacteria bycentrifugation of culture media in 50ml 
falcon tubes at 4700 rpm for 45 min at 40C. The pellet was transferred into 1.5ml eppendorf 
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tubes andpositioned for 1 day on a strong neodymium magnetic rack (0.1-1 T) to separate them 
from the original medium. The pellet was resuspended in 1.5ml eppendorf tubes (10mM Tris-
HCl buffer (pH 7.4), and the AMB-1 cells were sonicated for 1 hour using microprobe tip 
sonication (Sonics USA) to lyse the cells. After the sonication a neodymium magnet was used 
to separate the MAG from other cellular debris. 10mM Tris-HCl buffer (pH 7.4) was used to 
wash the MAG four times followed by resuspension in DPBS (pH 7.4).   
2.2.1.5 Sterilization of MNPs 
70% ethanol was used to sterilize the MAG. 1 ml of MAG (0.2mg/ml) were mixed with 9 ml 
of 70% ethanol, vortexed for 15 s and kept at RT for 30 min. The sample was centrifuged at 
3800 rpm for 10 min and air-dried in a Laminar airflow hood. Sterilised water was used to re-
suspend the pellet (Li et al., 2013)  
2.2.1.6 Sonication of MNPs  
Sonication (Bioruptor® Sonication System, Diagenode) was used to reduce MNP aggregation. 
Before use the MNPs were resuspended in Roswell Park Memorial Institute (RPMI) culture 
medium and sonicated on the highest setting for 10 min at 4℃. 
2.2.2 Culturing of breast cancer cells 
Breast cancer cell lines (MDA-MB-231 and MCF7) were purchased from the ECACC. MDA-
MB-231 is a human caucasian breast adenocarcinoma originally derived from pleural effusion 
of a 51-year-old metastatic breast cancer patient. This is a triple negative breast cancer (TNBC) 
cell line for the oestrogen, progesterone and human epidermal growth factor HER2 receptors. 
MCF7 cells were originally derived from human Caucasian breast adenocarcinoma patient. 
These are oestrogen receptor positive. MDA-MB-231 cells were cultured in T75 flasks (Fisher 
Scientific®) and sub-cultured once 70-80% confluent in RPMI medium supplemented with 
10% Foetal Bovine Serum (FBS) and 1% L-Glutamine (200mM in 0.85% NaCL solution). 
MCF7 cells were cultured in Dulbeccos Modified Eagles Medium (DMEM) ultraglutamine 
with 10% FBS and 5% Non-essential Amino Acids (NEAA) (Lonza®). Cultured cells were 
incubated at 370C with 5% CO2 in an incubator.  
EO771 cells were obtained from Dr. Penelope Ottewell, University of Sheffield. This cell line 
is a spontaneously developing medullary breast adenocarcinoma derived from C57BL/6 mice 
(Sugiura and Stock, 1952). This is also a triple negative breast cancer (TNBC) cell line for the 
oestrogen, progesterone and human epidermal growth factor HER2 receptors, making it 
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difficult to target therapeutically (Johnstone et al., 2015). Furthermore, this tumour model 
naturally metastasises to the lungs in C57BL/6 mice (Johnstone et al., 2015). Cells were also 
cultured in Dulbecco’s Modified Eagles Medium (DMEM) ultraglutamine with 10% FBS and 
5% Non-essential Amino Acids (NEAA) (Lonza®). Cultured cells were incubated at 370C with 
5% CO2 in an incubator.  
TS-1 cells were provided by Professor Janet Joyce, Memorial Sloan Kettering Cancer Research 
Centre. These are HER-2 receptor positive and originally derived from the transgenic MMTV-
PyMT tumours that spontaneously develop in mammary tumours. Cells were also cultured in 
Dulbeccos Modified Eagles Medium (DMEM) ultraglutamine with 10% FBS and 5% Non-
essential Amino Acids (NEAA) (Lonza®). Cultured cells were incubated at 370C with 5% CO2 
in an incubator. 
2.2.3 Cell harvesting and seeding densities  
When cells were at 70-80% confluencey, 3ml trypsin/ETDA (170,000 U Trypsin/L and 200 
mg/L Versene) was used to detach all cells from the flask. Trypsin/EDTA was neutralised in 
an equal volume of culture medium and then centrifuged at 600g for 5 min (Sanyo® Harrier 
18/80). Cells were resuspended in culture medium and counted in trypan blue (Sigma-
Aldrich®) to determine cell viability using a TC20 Automated Cell Counter (Bio-Rad®). Live 
cells were trypan blue negative. Cells were prepared as followed and cultured for 24 hr at 370C;  
1. For flow cytometry cells were seeded on to 6 well plates at 300,000 cells/well in 2ml 
of medium. 
2. For Prussian blue assays cells were seeded into 24 well plates (Scientific Laboratory 
Supplies®) containing 13mm coverslips (BDH Cover glass), using a seeding density of 
50,000 cells/well in a final volume of 1ml of medium.  
3. For the MTT assays cells were plated at a seeding density of 1000 cells/well in a final 
volume of 200 μl of medium in 96 well plates. 
  2.2.4 Primary cells isolation  
Ficoll density gradient centrifugation was used to isolate the Primary cells from blood 
according to (Muthana et al., 2011a, Muthana et al., 2013). 50ml falcon tubes were used to 
dilute 15ml of blood with 30ml of PBS. 20ml of Ficoll-Paque was overlayed with 30ml of 
blood/PBS and centrifuged at 1400rpm with brake off for 40 min. 4 layers (Plasma, PBMCs, 
Ficoll and red blood cells) were isolated and the lymphocytes located in the central creamy 
layer were removed and washed twice in PBS. After the centrifugation, the cell pellet was 
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resuspended in complete IMDM medium (supplemented with 2% human AB serum and 4mM 
L-Glutamine). Haemocytometer cell counting machine (Bio-Rad) was used to count the cells. 
After re-suspending 50 million cells in 5 ml of complete IMDM in T75 flasks and incubating 
for 2 hr (37˚C at 5% CO2), monocytes were attached to the flask by plastic adherence and the 
non-adherent lymphocytes were suspended in the entire medium. 
2.2.5 Incubation of magnetic nanoparticles (MNPs) with cell lines  
MAG isolated from magnetotactic bacteria (Section 2.2.1) were used at approximately 
0.2mg/ml throughout this study.  This concentration of iron has been used successfully in 
previous studies for cellular uptake (Mannucci et al., 2014). The culture medium was removed 
from cells after 24 hr of seeding onto wells and 0.2mg/ml of MAG that re-suspend in culture 
medium was added to each well. Following this, the plates were located on a shaking platform 
(low speed) (Luckham® R100 Rotatest Shaker) in an incubator at 37°C for 1 hour. A further 
equal volume of medium was then added to each well. After this, the plates were kept in an 
incubator until needed.  
2.2.6 Flow cytometry (FACS) to assess MNP uptake and cell death in MDA-MB-231s 
Flow cytometry was used to assess MNP uptake by tumour cells and cytotoxicity following 
overnight incubation of cells with MNPs. Trypsin/EDTA was used to detach the cells (Section 
2.2.6) and the cell pellet was washed twice in 5ml PBS. The supernatant was discarded and 
500μl PBS was used to re-suspend the pellet. All samples were added into flow cytometry tubes 
(400μl). Cell death was assessed by adding 2μl Propidium Iodide (PI) (50 mg/ml) to each 
sample just before analysis on the FACS Calibur (BD Biosciences). 10,000 events per sample 
were measured (equivalent to 10,000 cells) and FlowJo® software used to analyse cell death 
by generating fluorescent dot plots based on a change in fluorescence against FL3-H and MNP 
uptake based on changes in forward scatter (FSC-H) and side scatter (SSC-H). 
2.2.7 Prussian blue staining to visualise MNP uptake  
Cells seeded onto coverslips were incubated overnight with MNPs and then washed twice with 
500μl PBS.  PBS was removed from the wells and 200μl of acetone was added followed by 
incubation at 4°C for 10 min and two further washes in 500μl PBS. 200μl of 1:1 dilution of 1M 
Hydrochloric acid (1 M HCL) and 2% Potassium Ferranocyanide was added to each well and 
incubated at 37°C for 1 hour. The cells were washed again in 500μl PBS and then 200μl of 1% 
eosin was added to each well. Coverslips were mounted onto glass slides using immune-mount. 
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Light microscopy (Leica DM1000) was used to assess MNP uptake by viewing the slides at 
40x magnification. Mitotic Images plus 2.0 Software was used to take the images.   
2.2.8 MTT assay to assess cell viability  
Seventy-two hours after incubation of cells with MNPs, 50μl of 3mg/ml MTT was added to 
each well and incubated at 37°C for 3 hr. The supernatant was removed and 200μl Dimethyl 
Sulfoxide (DMSO) was added to each well. A plate reader (Thermo Scientific® Multiskan FC) 
was used to measure absorbance at 540 nm; this detects differences in the dissolved purple 
formazan produced by viable cells. Microsoft Excel was used to analyse the results, in which 
the fold change over the control (no MNPs) was calculated. In this case 1 was set to the control 
and any results below 1 show reduced viability.  
2.2.9 HSV1716 oncolytic virus 
HSV1716 is one of a selectively replication competent mutants of the herpes simplex virus. 
The HSV1716 virus and Green fluorescent protein (GFP) expressing HSV1716 were kindly 
prepared by Virttu Biologics in 1.5ml aliquots at a concentration of 1x108 Particle Forming 
Units (PFU)/ml and 1x109 PFU/ml respectively. CMV-GFP expression cassette was inserted 
in the UL-43 gene to produce HSV1716 GFP. The virus stock was initially produced on 
23/07/99 and was titrated by plaque forming assay to reconfirm titre in December 2012 (1x10e9 
pfu/ml).   The stock of virus was stored at -80 °C. The GFP reporter virus allowed detection of 
HSV1716 infected cells by flow cytometry and immunofluorescence.  
2.2.10 Preparation of Magnetic Viral Complexes  
HSV1716 virus was mixed with MNPs derived from AMB-1 bacteria. To prepare the 
complexes, 200ul of DPBS containing 0.22mg MAG and 1 ml of PBS containing 1 x 108 pfu 
OV were suspended in a final volume of 1.2 ml (0.2mg/ml MAG and 1 x 108 pfu OV). 
Following this, complexes were incubated for 20 min at room temperature (RT) and the tubes 
were inverted intermittently. Complexes resulting from virus and magnetosomes were called 
MAG-OV. These were stored at 4˚C or used immediately. 
2.2.11 Characterisation of MAG and MAG-OV complex 
2.2.11.1 Transmission Electron Microscopy (TEM)  
TEM was used in the Department of Biomedical Sciences (FEI Tecnai Biotwin) operated at 
120kV with an Orius 1000 camera. TEM studies were carried out with the support of Chris 
Hill in the Department of Biomedical Science at Sheffield University. 
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2.2.11.1.1 TEM sample preparation 
Samples of either AMB-1 purified MAG or MAG-OV complexes were centrifuged at 4700 
rpm at 4°C for 45 min and the pellet transferred into 1ml eppendorf tubes resuspended in 
phosphate buffer. A droplet of this buffer was added onto carbon-coated copper grids for one 
minute and excess fluid was removed using tissue to leave a thin layer of sample over the TEM 
grid. Samples containing virus were also counterstained with 1% phosphotungstic stain, this is 
a common negative stain for viruses including HSV (Stannard et al., 1987).  
2.2.11.1.2 Preparation of MAG-OV infected cells for TEM 
Infected tumour cells (105) were fixed with 3% glutaraldehyde in 0.1M phosphate buffer (pH 
7.4) overnight at 4 °C and then washed in 0.1M phosphate buffer twice at 30 min intervals. The 
samples were then post-fixed in 2 % aqueous osmium tetraoxide for 2 hr at RT and washed in 
buffer as above. Sample dehydration was performed by passing the grids through a graded 
sequence of ethanol (75 – 100 %) and propylene oxide. Samples were inserted in araldite resin 
and dried at 60 °C for 48-72 hr. Slices approximately 0.5µm thick were cut and stained with 
1% toluidine blue in 1% Borax. Ultrathin slices of 70-90 nm thick were attached onto 200 mesh 
copper grids, stained with 3% uranyl acetate in 50% ethanol and then stained with lead citrate 
for 25 min before examination by TEM.   
2.2.11.2 MNP size determination by TEM 
TEM was carried out to measure the size of MNPs; this was taken arbitrarily from prepared 
samples. Sizes range between approximately 50 to 200nm depending on sample composition 
and were measured by analysing MNPs randomly at 100 and 200 nm magnification. Image J 
was used to measure the length of chosen particles manually.  
2.2.11.3 qNano 
Particle concentration and size distribution were determined by TRPS using a qNano 
instrument (Izon). Calibration was performed using CPC100B calibration particles (Izon) with 
a modal diameter of 114 nm diluted 1/2000 (v/v) in PBS, supplemented with 0.03% (v/v) 
Tween-20 (PBST). Samples were diluted 1/3 (v/v) in PBST and then filtered through either a 
0.2 or 0.45μm centrifugal unit. Sample and calibration samples were analysed with the same 
NP100 nanopore with the same settings for voltage, nanopore stretch and pressure. Settings 
were chosen that gave an optimum separation of particles from the background noise and a 
constant flow rate of particles. 
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2.2.11.4 Zeta potential analysis 
Zeta potential is a measurement of the magnitude of the electrostatic or charge attraction/ 
repulsion in the space separating particles, and is an essential parameter recognized to impact 
stability of MNPs (Nikam et al., 2014). The zeta potential was measured at RT on a NanoBrook 
Zeta PALS (Brookhaven instrument, NY, U.S.A) from a suspension of the sample in ddH2O. 
2.2.11.5 Magnetic susceptibility measurements (MSM) 
MS2 meters (Bartington Instruments, UK) were used to measure the magnetic susceptibility of 
particles using Bartsoft software. MSM is a method that enables the rapid quantification (1s) 
of iron particles in a sample. Water was used as a blank and each sample was measured 3 times 
for 1s in a volume of 400 μl. 
2.2.11.6 Inductively coupled plasma Atomic Emission Spectrometer (ICP-AES).  
Inductively coupled plasma (ICP) is an analytical method that is carried out for chemical 
analysis of elements. Stimulated ions and atoms which produce electromagnetic radiation was 
formed by this technique at specific wavelengths that are characteristic of a specific element, 
therefore the concentration of metals in a sample can be measured by the strength of this 
emission. Spectro-Ciros-Vision Inductively Coupled Plasma Atomic Emission Spectrometer 
ICP-AES was utilized to calculate the quantity of Fe as a ratio of metal ions for the MNPs used 
in this project. About 0.3 mg of MNPs was dissolved in aqua regia (King's water a mixture of 
concentrated nitric and hydrochloric acids) in a molar ratio of 1:1 of nitric acid and HCL. 1ml 
of the MNP sample was added to 1ml of aqua regia solution and diluted in 10ml with dH20. 
The samples were sonicated for 4 hr in a water bath sonicator, Fe content (mg/l) was determined 
as a measure of atomic absorption.  
2.2.12 Cell death and uptake of magnetic viral complexes  
The OVs HSV1716 or HSV1716-GFP were defrosted on ice for approximately 15 min. Cells 
seeded onto 6-Well Plates (Section 2.2.2) 24 hr earlier were washed with PBS and then cultured 
in 500 μl serum free RPMI for MDA-MB-231 cells or 500 μl serum free DMEM for MCF7 
cells. After that, OVs or MAG-OV complexes prepared as mentioned in Section 2.2.10 at MOI 
10 (1 x 108 pfu/ml) were added to the wells and incubated for 2 hr at 37oC followed by the 
addition of 2.5 ml of complete medium to each well. The cells and OVs were incubated for 
time periods of 1, 3 and 6 days.   
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After culture, cells were washed with 2 ml PBS and trypsin/EDTA was used to detach the cells 
as in Section 2.2.3 ready for flow cytometry. All samples were added into flow cytometry tubes 
(400μl). Cell death was assessed by adding 2μl of the viability dye TOPRO-3 to each sample 
prior to analysis on the FACS Calibur (BD biosciences). FlowJo® software was used to analyse 
the results and cell death was assessed by generating dot plots based on a change in 
fluorescence against FL-4-H. MNP uptake by cells was assessed based on changes in forward 
scatter (FL-1-H) and side scatter (SSC-H). In studies using the HSV1716 GFP viral infection 
of cells was assessed by GFP expression in the FL1-H channel.  
2.2.13 Tumour spheroid experiments 
Agarose, low melting point temperature was dissolved in DMEM (4.5 g/l glucose, no 
supplements) in the microwave followed by autoclaving the solution. 100μl warm agarose was 
added to each well of a 96-well plate (except the outer wells) using a multichannel pipette. 
After that, plates were all owed to cool and were inverted and stored at 4oC until required. 
Tumour cells were seeded into wells at 20 x 103 cells per well and the approximate size they 
grew to was 105 cells. 
After 5-7 days post- seeding in 96 well plates, OVs or magnetic viral complexes (MAG-OV) 
were added to the spheroids as described in Section 2.2.12.  The spheroid size was monitored 
using Light microscopy (Leica DM1000) at 10x magnification and Mitotic Images plus 2.0 
software was used to take images. Flow cytometry was used to assess cellular death after 6 
days of infection (as mentioned in Section 2.14). Of note, spheroids were digested into cell 
suspensions using trypsin/EDTA prior to flow cytometry.  
2.2.14 Measuring mRNA gene expression after OV infection 
2.2.14.1 RNA extraction 
Cells were infected with OV, MAG-OV and MAG alone alongside the control, untreated cells 
as described in Section 2.2.12 for 24h and then scraped from the surface of the plates and 
centrifuged at 1400rpm for 5 min. RNA extraction was performed using the Qiagen RNeasy 
Mini Kit (QIAGEN). Cells were resuspended in 350μL of RLT lysis buffer and were kept on 
ice at all times. 70% ethanol (350 μL) was added to the lysed cells and all 700 μL was 
transferred to pink filter tubes placed in a 2ml collection tube and centrifuged at 8000 rpm for 
15 s. RW1 buffer (700 μL) was then added and centrifuged at 8000 rpm for 15 s followed by 
500ul of RPE buffer and centrifugation at 8000 rpm for 15 s. This was followed by the addition 
of 500 μL RPE buffer and centrifuged at 8000 rpm for 2 min before 50 μL of RNA-free water 
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was added and centrifuged for a further 1 min at 8000 rpm to release the RNA. The 
concentration of mRNA was measured using the NanoDrop Spectrophotometer ND 1000. The 
concentration of the RNA was standardised by diluting the sample in RNase/DNase-free water 
and then stored at -80°C until required.  
2.2.14.2 Complementary DNA (cDNA) Synthesis  
High-Capacity cDNA Reverse Transcription Kit was used to prepare the cDNA for q-PCR. All 
RNA samples were normalized to the same concentration according to the following 
calculation 
          (RNA concentration desired / sample concentration) x desired volume of RNA 
The 2X RT Master Mix was prepared according to the manufacturer’s instructions as shown in 
Table 2.6 for each reaction. 
Table 2.6: Components of 2X RT Mastermix           
Reagent Volume (μL) 
10X RT buffer 2.0 
25X dNTP Mix (100mM) 0.8 
10X RT Random Primer 2.0 
MultiScribe Reverse Transcriptase 1.0 
Nuclease-free H2O 4.2 
10μL of 2X RT Master Mix was added to 10 μL of RNA samples. The thermal cycler machine, 








Table 2.7: Thermocycler parameters for generation of cDNA 
Step Time Temperature 
Step 1 10 Min 25℃ 
Step 2 120 Min 37℃ 
Step 3 5 Min 85℃ 
Step 4 Hold 4℃ 
2.2.14.3 Real-Time Quantitative Polymerase Chain Reaction (RT-qPCR) 
Real-time q-PCR was used to determine levels of mRNA expression of the genes using the 
prepared cDNA (Section 2.20.3). The 2X q-PCR Mastermix was prepared according to (Table 
2.8). 
Table 2.8: Components of 2X qPCR Mastermix.            
Reagent Volume (ul) 
SYBR green Mastermix 5 
Nuclease-free H2O 3 
Forward Primer 0.5 
Reverse Primer 0.5 
cDNA 1 
SYBR green mastermix, nuclease-free H2O, forward and reverse primers were added to each 
well of the 384 well qPCR plate at a total volume of 9μl. Following this, 1μl of cDNA was 
added to the specified wells followed by centrifugation of the qPCR plate for 2 min at 2000rpm. 








Table 2.9: q-PCR Conditions 
Total Cycles Reaction Step Cycle length Temperature 
x1 cycle Enzyme Activation 10 min 95℃ 
x50 cycles Denaturation 15 sec 95℃ 
Data Collection 1 min 60℃ 
 
The data produced was analysed using 2-ΔΔCt method of relative quantification. Melt-curve 
analysis was carried out for all primers. Good primers should have one single peak, revealing 
of one reaction product as shown in Figure 2.1. 
                                          
Figure 2.1: shows an example melt curve from a good primer pairs have a single peak. Samples 
were heated from 60°C to 95°C to create a melt-curve by using qPCR.  
 
2.2.15 Cytokine Protein Level Expression Analysis with Cytokine Bead Array (CBA) 
Cells were infected with OV, MAG-OV and MAG alone alongside the control, untreated cells 
as described in Section 2.2.12. After 24h supernatants were collected from each well. CBA 
was then performed to assess the expression levels of a series of cytokines. These human flex 
sets were obtained from BD Biosciences and included: IP-10, IL-6, IL-8, TNF, IL-10, IL-1B, 
IFN-Y and VEGF.  
Flow team performed CBA assay. Each BD™ CBA Flex Set contained two vials of Standard 
and one vial each of Capture Bead and PE Detection Reagent. The formularization of the 
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Capture Bead and PE Detection Reagent components was carried out to a 50x concentration to 
confirm product performance when multiplexed. Lyophilisation of The Standard component 
was also performed and then transferred to a 15 ml polypropylene tube for re-formation. When 
reconstituted in 4.0 ml Assay Diluent, the standard contained a protein concentration of 10,000 
pg/ml. Importantly, the lyophilized standard and other components were stored at 4°C to 
protect the capture beads and PE Detection Reagent from sustained light exposure. An Attune 
Autosampler was used to read the samples. 
2.2.16 Virus neutralization  
Neutralization experiments were performed to determine if MAG could protect OV from 
neutralizing Antibodies. Sheep anti-HSV-1 antiserum was used to neutralise the OV. This 
antibody was kindly prepared by Virttu Biologics by four consecutive monthly injections of 1 
x 10⁶ PFU HSV1716. To prepare the mixture of OV+NAb or MAG-OV+NAb, 1 x 10⁷ PFU of 
OV or MAG-OV were incubated with 100-fold dilution of antiserum for 18 h at 4°C (Conner 
et al., 2005), alongside the controls (no antibody control and no virus control). Combinations 
(OV+NAb or MAG-OV+NAb) were then transferred to the wells containing monolayers of 
MDA-MB-231 cells and incubated for 24 hr at 37° C.  Flow cytometry was performed to 
measure cell viability as mentioned in Section 2.2.12. 
2.2.17 HMGB1 ELISA 
 The supernatants of infected and uninfected control cells (MDA-MB-231 cells and MCF7) 
cells were collected and cellular debris removed by centrifugation at 6200 rpm for 5 min. 
Secreted extracellular HMGB1 in the supernatants was measured with a HMGB1 ELISA Kit 
II (Shino-Test, Kanagawa, Japan) according to the manufacturer’s protocol outlined for the 
normal sensitivity format of the assay. In brief, 10 µL of supernatant and 100 µL of sample 
diluent was added to immobilized anti-HMGB1 antibody on the well and incubated for 20-24 
hr at 37°C to allow HMGB1 to specifically bind to the antibody. Peroxidase (POD)-conjugated 
secondary antibody was then added to the sample well. Microplate spectrophotometer was used 
to read the plates at a wavelength of 450 nm. 
2.2.18 ATP assay  
 The supernatants of infected cells and uninfected control cells were first collected andells and 
debris removed by centrifugation at 6200 rpm for 5 min. ENLITEN ATP assay (Promega, 
Madison, WI, USA) was performed to measure the Secreted extracellular ATP in the 
supernatants according to the manufacturer’s protocol. In brief, 100 µL of supernatant was 
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added to the 100 µL of rL/L reagent (ATP reagent). Then, Turner Biosystems luminometer 
(TD-20/20; Promega) was used to read the plates at a wavelength of 560 nm. 
2.2.19 Immunocytochemistry 
The expression of calreticulin and appearance of HSV1716 within the cells were measured by 
immunocytochemistry. Cells (200,000/well) were seeded on small coverslips placed in 24 well 
plates and cultured overnight with complete medium as mentioned in Section 2.2.5. The 
following day, cells were infected with OV, MAG-OV and MAG alone alongside the control, 
untreated cells for 24h. The next day, cells were washed 3 times with PBST and fixed by adding 
300µl of 2% paraformaldehyde (PFA) for 15min (370C at 5% CO2). After washing, 5% Goat 
serum and 10% Murine FcR blocking solution in PBST was added for 30 min at RT to block 
the cells from non-specific binding. Primary Ab -rabbit anti human calreticulin was diluted 
1:100 (Abcam, Cambridge, UK) or sheep antiHSV1716 diluted 1:500 (Virtuu Biologics, 
Glasgow, UK) were added for 1hr at RT then washed 3 times with PBST. This was followed 
by incubation with e FITC (fluorescein isothiocyanate)-conjugated goat polyclonal antibody 
diluted 1:100 and appropriate secondary antibodies, diluted at 1:400 in PBST, for 30min at RT 
then washed 3 times with PBST. 50ng/ml DAPI solution was added for 2 min and then washed 
another three times with PBST. Finally, coverslips were removed from the wells and 1 drop of 
ProLong Gold Antifade mountant was added before attaching to glass slides. Slides were then 
kept in the dark for 1 day and imaged using the Nikon A1 confocal microscope. 
2.2.20 IN VIVO 
2.2.20.1 Murine model of breast cancer 
C57BL/6 female mice were purchased from Envigo at 6-8 weeks old and housed in the 
University of Sheffield Biological Services Unit and cared for according to the University of 
Sheffield code of ethics and Home Office regulations. All work was carried out under personal 
licence number is 1806F7C1E and Home office project licence PPL70/8670.   
Mice were allowed to acclimatise for 1 week after arrival from the supplier. Mice were injected 
into the nipple with 5x105 EO771-Luc cells using the following protocol. Inhalant isoflurane 
(IsoFlo) was used to anaesthetise mice. They were then shaved around the whole abdominal 
area to expose both nipples (inguinal group) and Hibiscrub was used to disinfect the skin.  
Following this, 5x105 EO771 cells (which were collected from flasks during their exponential 
growth phase) in 20ul PBS containing 33% matrigel/66% PBS/1% trypan blue) were injected 
into the nipple using an insulin syringe. Mice were monitored daily and weighed every three 
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days. Tumour volume was measured using callipers and also recorded every three days using 
the following equation:    
                                              Tumour volume (mm3) =  
W 2 ×  L
2
       
For the bioluminescence test, mice were injected with 100 µL of d-Luciferin subcutaneously 
for 5 Min. Then, a non-invasive in vivo imaging system (IVIS 200 System, Xenogen) was used 
to image mice under isoflurane anaesthesia delivered via a nose cone. Each group of mice 
included in this study consisted of n=8 mice/group. The number of animals were justified by a 
power calculations using the following equation: 
                                                      
Once the tumours reached ~150-200mm3 mice received the following treatments intravenously 
(i.v.). 
1. Control: Mice were injected three times i.v. (0, 5, 10 days) with 100ul PBS. 
2. MAG: Mice were injected three times i.v. (0, 5, 10 days) with 100ul MAG (10ul MAG 
+ 90ul PBS).   
3. OV: These mice were injected three times i.v. (0, 5, 10 days) with 100ul HSV1716 
(10ul OV at 106 pfu + 90ul PBS). 
4. MAG-OV without magnet: Mice were injected three times i.v. (0, 5, 10 days) with 
100ul magnetised HSV1716 (12ul MAG-OV at 106 pfu + 88ul PBS). 
5. MAG-OV+ magnet: Mice were injected three times i.v. (0, 5, 10 days) with 100ul 
magnetised HSV1716 (12ul MAG-OV at 106 pfu + 88ul PBS) in the presence of an 
external permanent magnetic array secured above the tumour (0.7 T) for 30 min. 
Once the tumours reached ~1500mm3 mice were culled by cervical dislocation, and the organs 
and tumours removed and stored in liquid nitrogen for post-mortem analysis. Of note, the 
magnet design, assembly and length of time placed above the tumour, were optimised by a 
post-doctoral research fellow in the group (Dr Priya Patel).  
2.2.20.2 HSV1716 in vivo neutralisation experiment 
Mice were injected into the nipple with 5x105 EO771 cells as mentioned in Section 2.2.20.1. 
Once the tumours reached ~150-200mm3 mice received the following intravenously. The 
following groups were included in this study with n=3 mice/group. 
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1. Control: Mice were injected three times i.v. (0, 5, 10 days) with vehicle (PBS) (in a 
volume no more than 0.2 ml). 
2. OV+ NAb (see section 2.2.19): Mice were injected three times i.v. (0, 5, 10 days) with 
100ul HSV1716 (10ul OV at 106 pfu + NAb + 90ul PBS). 
3. MAG-OV+ NAb (see section 2.2.19) + magnet: Mice were injected three times i.v. 
(0, 5, 10 days) with 100ul magnetised HSV1716 (12ul MAG-OV at 106 pfu + NAb + 
88ul PBS) in the presence of an external magnetic field for 30 min. 
Once the tumours reached ~1500mm3 mice were culled by cervical dislocation, and the organs 
and tumour were removed and stored in liquid nitrogen for post-mortem analysis. 
2.2.20.3 Tissue preparation of samples for post-mortem analysis 
Immediately following removal from the mice, tumours were divided into two parts. One of 
them was first dissected into small chunks before placing in cryobuffer (90% FCS with 10% 
DMSO) and frozen in liquid nitrogen until used for flow cytometry, RNA extraction for qPCR 
or Nanostring technology. 
The other half of the tumours were embedded in Optimal cutting temperature (OCT) and frozen 
at -80oC in preparation for cryosectioning. Frozen sections (14µM thick) were cut for 
immunofluorescence staining. 
2.2.20.4 Dissociation of EO771 cells tumours  
Ice-cold DPBS containing 2% FCS (FACS buffer) was prepared prior to thawing tumour 
chunks and washing 3 times with DPBS. Tumour chunks were then incubated with 5ml 
enzymatic dissociation solution containing 0.2 mg/ml collagenase, 2 mg/ml dispase and 
1.25ug/ml DNase I in serum-free Iscove’s Modified Dulbecco’s Medium (IMDM), for 30 min 
using a rotator in a warm room (37oC). Following this, 10% FBS was added to neutralize the 
enzymes within the medium and the dispersed specimen was passed through a 40-70µm nylon 
filter. Once filtered, the cell suspension was then centrifuged at 4500 rpm for 5 min, and the 
cell pellet was washed 3 times in 500μL DPBS for flow cytometry (see 2.2.20.5) or RNA 
extraction for qPCR or Nanostring technology (see 2.2.20.7) 
2.2.20.5 Preparation of tumour cells for flow cytometry    
Tumour chunks were dissociated as mentioned in section 2.2.20.4.  The cell pellet was re-
suspended in the correctly diluted primary antibody (Ab) and Zombie UV viability dye (1μL 
in 100μL) and incubated for 45-60 min on ice. 500μL of FACS buffer (50ml DPBS with 25µL 
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FCS) was then used to wash the samples twice to remove excess unbound antibody and the cell 
suspension was then centrifuged again in a microcentrifuge at 4500 rpm for 5 min. Finally, 
samples were re-suspended in 300ul of FACS buffer (1%FBS/PBS solution) and transferred to 
flow cytometry tubes (400μl). Flow cytometry data was analysed using the BD LSR II flow 
cytometer. Data files were further processed using FlowJo Software. Table 2.10 shows the 
antibodies used to analyse immune cell infiltration into the tumours. 
Table 2.10: Antibodies of analysing immune cells infiltration into the tumours 
Laser Filter Fluorochrome Markers Purpose 
UV 355nm 450/40 Live/Dead Blue Viability Exclude Dead cells  
 
530/30       
Violet 405nm 450/40 BV421 
  
F4/80 Macrophages cells marker  
 
530/30 BV510 CD4 T helper marker 
Blue 488nm 530/30 GFP GFP   
 
575/26 PE CD8 Cytotoxic T cells marker 
 




    
 
695/40 PercP-5.5 Ly-6G Neutrophils cells marker 
 
780/60 PECy7 CD11b Myeloid cells marker 
Red 633nm 660/20 APC CD3 Generic T cell marker 
 
730/45 AF 700 LY-6C Monocyte cells marker 
 
780/60        APC/Cy7 NK-1.1            NK cells 
A number of different controls were included to help determine if fluorescence was a false 
positive signal. 
1-Compensation control: 100ul PBS+ 1drop negative beads+1drop positive beads (Thermo 
Fisher Scientific / Cat no: A10344/ USA) +1ul of antibody of interest (each antibody of 
interest was in a separate tube) 
2-FMO (Fluorochrome Minus One): 100ul of the cell suspension + All Abs used in this 
experiment minus one Ab. 
3-SCC (Single Cell Control): 100ul of the cell suspension+ 1ul of only one Ab. 
4-Untsained: only cells.  
As multiple fluorophores were used in this study (Table 2.11), fluorescent minus one (FMO) 
controls were used to detect if fluorescence was emitted because of false positive signals or 
because of real antibody binding. FMO controls contain all Abs used in this experiment minus 
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one Ab to determine fluorescent spectral overlap from all the other fluorophores, before 
measuring the fluorescence of the antibody of interest. Flow cytometry users prefer to use FMO 
controls because of their hallmark to detect background between all fluorophores (Herzenberg 
et al., 2006). 
Table 2.11: Details of antibodies and controls used in flow cytometry experiments. 
Samples Compensation control FMO (Fluorochrome Minus 
One 






GFP Negative beads + positive 
beads + anti mouse 
antibody  
Cells + all Ab – GFP Cells + GFP 
Viability Cells+ Zombie UV dye Cells + all Ab - Zombie UV 
dye  
Cells+ Zombie UV dye 
F4/80 Negative beads + positive 
beads + F4/80 Ab 
Cells + all Ab - F4/80 Ab Cells+ F4/80 Ab 
CD4 Negative beads + positive 
beads + CD4 Ab 
Cells + all Ab – CD4 Ab Cells+ CD4 Ab 
CD8 Negative beads + positive 
beads + CD8 Ab 
Cells + all Ab – CD8 Ab Cells+ CD8 Ab 
CD11B Negative beads + positive 
beads + CD11B Ab 
Cells + all Ab – CD11B Ab Cells+ CD11B Ab 
LY-6G Negative beads + positive 
beads + LY-6G Ab 
Cells + all Ab – LY-6G Ab Cells+ LY-6G Ab 
CD3 Negative beads + positive 
beads + CD3 Ab 
Cells + all Ab – CD3 Ab Cells+ CD3 Ab 
LY-6C Negative beads + positive 
beads + LY-6C Ab 
Cells + all Ab – LY-6C Ab Cells+ LY-6C Ab 
NK1.1 Negative beads + positive 
beads + NK1.1 
Cells + all Ab – NK1.1 Cells+ NK1.1 
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2.2.20.6 Immunofluorescent staining of tumours 
Tumours sections were fixed with ice cold acetone for 10 min at RT and then rehydrated with 
PBST for 1 min. A dark humidified chamber was used for all incubations to prevent fluorescent 
antibodies from reacting with light. Tissue was surrounded using a Super PAP barrier pen. 
Following this, 5% Goat serum and 10% Murine FcR blocking solution made in PBST was 
added for 30 min at RT to block the tissue from non-specific binding. Tissue was then incubated 
with primary antibodies (Table 2.12), for 1hr at RT and then washed 3 times with PBST. 
Appropriate secondary antibodies (diluted 1:400 in PBST) were then added for 30 min at RT 
and the tissue was washed 3 times with PBST.  Tissue was stained with 50ng/ml DAPI solution 
for 2 min and then washed another three times with PBST. Finally, before adding coverslips, 
tissue was mounted with 1 drop of ProLong Gold Antifade mountant.  Slides were then kept in 
the dark for 1 day and analysed using a Nikon A1 confocal microscope. The 40x objective lens 
was used for imaging and a selection of at least 5 fields of view (FOV) were captured per 
tumour. Fiji (Fiji Is Just ImageJ), accessed via http://fiji.sc/Downloads, as previously published 
















Table 2.12: Antibodies used in immunofluorescent staining experiment. 
Primary 
Ab 














505207 Biolegend Unconj 1 in 100 Anti-rab 
AF647 






APC 1 in 200 NA NA 647 40x 
CD31 102515 Biolegend AF647 1 in 100 NA NA 647 40x 
CD4 100425 Biolegend AF488  1 in 50 NA NA 488 40x 
CD4 100425 Biolegend  PE 1 in 100 NA NA 555 40x 





AF488 1 in 25 NA NA 488 40x 




1 in 400 488 20x/40x 
IFNy 505809 Biolegend APC 1 in 100 NA NA 647 40x 
NK-1.1 108723 Biolegend APC/CY7 1 in 100 NA NA 647 40x 
PD1 135215 Biolegend PE/CY7 1 in 100 NA NA 647 40x 
2.2.20.7 Haematoxylin and Eosin staining  
Tumours sections were fixed in acetone (methanol 50:50 mix (kept in freezer) or methanol 
only) for 10-20 min. Sections were then washed 2 times in PBS andplaced in Gill’s 
Haematoxylin solution for 1 min and washed in tap water for 5 min until the water ran clear. 
Slides were placed in 70% ethanol for 3 min then 90% ethanol for a further 2 min. Following 
this sections were placed in eosin (2g eosin dissolved in 400ml 95% ethanol) for 1 min before 
rinsing slides in 100% ethanol for 5 min. Slides were then mounted using DPX mounting 
medium.  Aperio ScanScope CS with a 40x objective lens was used to scan the slides.    
2.2.20.8 NanoString gene expression analyses.  
Gene expression profile in EO771 cells tumour samples were carried out at the John van Geest 
Cancer Research Centre in College of Science and Technology at Nottingham Trent University 
as part of a collaborative study and analysed using murine pan-cancer immune profiling panel, 
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which consist of 750 immune related genes, 20 housekeeping genes. All the RNA samples 
were quality controlled using Nanodrop 8000 and 150ng of total RNA from each samples were 
used for setting up nanostring probe hybridisation overnight (20hrs) at 65˚C (each reaction 
mixture contains 5ul of RNA solution (150ng), 8ul of reporter probe and 2ul of capture probe). 
After overnight hybridization, excess probes were removed using nCounter Prep Station and 
magnetic beads and hybridised mRNA/probe were immobilised on a streptavidin-coated 
cartridge. The processed cartridge subsequently scanned using an nCounter digital analyser 
platform for generation of the raw data with a high-resolution scan (555 fov). Raw data were 
processed with nSolver Analysis Software (V.4.0), imaging quality control (QC), mRNA 
positive control QC and normalisation QC checked and all the samples were with the quality 
parameters of nanoString gene expression assays. Differential expression, pathway scoring and 
cell type scoring was performed using nSolver advance analysis module V. 2.0.115. 
Normalization of the data was performed using geNorm algorithm for the selection of best 
housekeeping genes. Genes which showed ≥ 2, fold change in their expression with a BY 
(benjamini yekutieli) P value ≤ 0.05 were considered significantly different between the 
groups. 
2.2.21 Statistical analysis 
All statistical analysis was performed using GraphPad Prism (GraphPad Inc,San Diego,CA, 
USA). Data are expressed as mean and SEM. Statistics were analysed utilizing the suitable 
statistical test and post‐test as described in the figure legends. Statistically, a p value of p<0.05 











































Cancer nanotechnology is a relatively new branch of medicine that is currently going through 
intense phases of development for cancer imaging, molecular and cellular diagnosis and for 
targeted therapies (Gharpure et al., 2015). The potential of MNPs for application in drug 
delivery and for the diagnosis of tumours is established (Kim et al., 1999, Kataoka et al., 2000). 
The development of multifunctional MNPs for the delivery of both drugs and MRI contrast 
agents for malignancies is now possible for tumour theranostics (Torchilin, 2006, Kim et al., 
2008, Peer et al., 2007). In addition, MNPs offer many opportunities, that allow for the 
combination of magnetic resonance imaging (MRI) as contrast agents and active delivery of 
chemotherapeutics in one nanocarrier system, representing a novel strategy in nanomedicine 
(Nasongkla et al., 2006).  MNPs are therefore attractive for the navigation of drugs into tissues 
from circulation in response to application of a magnetic field. The magnetic targeting of drugs 
results in an increased concentration of the drug within the tissue/organ of interest and 
consequently reduces the side effects such as toxicities as a result of systemic drug delivery. 
Superparamagnetic iron oxide (SPIO) have magnetic properties which can be used for MRI as 
a contrast agent and for the detection and characterization of tumours within the body. The 
magnetic properties of SPIOs has also been used to magnetically guide drugs to a specific 
tissue. This has led to the development of MNPs that can be used not only as MRI contrast 
agent but their ability to respond to magnetic field enables magnetic hyperthermia and magnetic  
drug targeting to diseased tissue (Senyei et al., 1978, Neuberger et al., 2005). Previous studies 
have shown that conjugation of MNPs with anticancer agents e.g. doxorubicin (DOX) and 
methotrexate (MTX) resulted in an increase in the accumulation of the drug in HeLa cells  and  
B-cells by applying an external magnetic force (Samra et al., 2013). They also found that 
Sixteen to 22% more killing effect was observed on HeLa cells than in B cells. Clinical studies 
using chemotherapeutics coated with MNPs have also been performed in cancer patients. The 
first clinical trial in humans using MNPs linked to doxorubicin were reported in 14 patients 
with advanced solid liver cancer. The authors found that the MNPs accumulated in the targeted 
tissue and were safe and not toxic (Lubbe et al., 1996). This type of magnetic targeting could 
therefore provide an opportunity to use less of a potentially toxic drug but still obtain higher 
drug concentration at the tissue of interest. 
MAG are becoming increasingly recognized as important tools in cancer treatment. These 
particles have the potential to 1) target therapy to the tumour site due to the magnetic core 2) 
improve binding to the target by displaying receptors or recognition molecules 3) kill tumours 
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if they carry a therapeutic payload.  Moreover, the MAG can be imaged using conventional 
MRI enabling the therapy to be tracked in real-time.  A study by Mahmoudi and colleagues 
showed that MAG derived from magnetotactic bacteria Magnetospirillum magneticum strain 
AMB-1 could be used to label and image pluripotent stem cell (iPSC)-derived 
cardiomyocytes (iCMs) for the regeneration of the injured myocardium in mice. The MAG-
labelled iCMs were injected into the infarcted area of the murine heart and imaged by MRI. 
They showed that MAG were robust biological contrast agents to track iCMs in mice. More 
importantly, they were cleared within one week of injection whereas SPIONs remain over 2 
weeks (Mahmoudi et al., 2016). MAG, may therefore be an excellent alternative. MNPs also 
provide the opportunity to track therapeutics with imaging modalities, which is not possible 
with current cancer treatments. Furthermore, biocompatibility, chemical stability and magnetic 
properties are considered very important for diagnostic application (Almstätter et al., 2015). It 
is, therefore, important to further understand the physicochemical characterisation of these 
particles. 
MAG have also been used to deliver anticancer medicines doxorubicin (DOX) in H22 cell-
bearing mice (Sun et al., 2011). They found that the tumour suppression rates following 
administration of DOX-loaded Bacterial MAG (DBMs), DOX, and Bacterial magnetosomes 
(BMs) were 86.8%, 78.6%, and 4.3%, respectively. DBMs, DOX, and BMs revealed mortality 
rates of 20%, 80%, and 0%, respectively. Pathological examination of hearts displayed that 
DBMs revealed a much lower cardiac toxicity compared with DOX.  
Oncolytic virotherapy is an emerging treatment modality that uses replication-competent 
viruses to destroy cancers whilst leaving healthy cells unharmed. Success of using these viruses 
has relied on direct intratumoural injection, however to target tumours deep in the body or 
metastasis it is necessary to deliver virus in circulation. So far, systemic delivery of OVs has 
been hampered by low intra-tumoural titres due to strong anti-viral host immune responses and 
sequestration by the liver and spleen resulting in poor tumour targeting (Ferguson et al., 2012). 
We propose to use magnet targeting like that described above for improving the targeting of 
OV to tumours after systemic delivery. A recent study showed that MNPs (PEI-Mag2 or SO-
Mag6-11.5) could be used to form stable complexes with OV by self-assembly (Almstätter et 
al., 2015b). This relies on electrostatic interaction of negatively charged viral particles and 
positively charged MNPs.  They found that the virus dose required for 50 % cell growth 
inhibition/oncolysis (IC50) values of the MNP-VP complexes in 7.5 % FCS under magnetic 
field-guided infection were 1.6- and 2.5-fold lower for VSV, and 11.8- and 27.4-fold lower for 
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Ad, respectively, than those of the virus alone in McA and RDB cells, confirming the higher 
oncolytic activity of the MNP-VP complexes. Understanding the oncolytic potential and the 
cell death mechanisms of OV is a rapidly evolving field. For the purposes of this work, we 
performed experiments to investigate the effects of MAG-OV in breast cancer 2D and 3D 
tumours spheroids and compared this to OV. Oncolytic HSV1716 has previously been shown 
to reduce viability of tumour spheroids (SF188, KNS42, DIPG) 72 and 96 hr post-infection 
(Cockle et al., 2017). 
The aim of this chapter was to magnetise the OV ‘HSV1716’ using MAG derived from 
magnetotactic bacteria and characterise the physicochemical and biological properties of the 
final complex (MAG-OV). The specific aims are to: 
1. Determine the physicochemical properties and toxicity of the bacterial derived 
magnetosomes (MAG) in breast cancer cell lines. 
2. Prepare the MAG-OV and measure the physicochemical properties. 
3. Measuring the Oncolytic potential of magnetic viral complexes on breast cancer cells. 
3.2 Results 
3.2.1 Characterization of bacterial derived MNPs  
The properties and physicochemical characteristics of these particles was assessed. We used 
AMB-1 derived MAG purified using established protocols (Staniland et al., 2007). In brief, 
AMB-1 was grown in a cabinet within microaerobic conditions consisting of 1% O2 and 99% 
nitrogen at 30.1 C° in liquid culture medium (see Section 2.2.1.2) which is specific to AMB-1 
bacteria. The lysed AMB-1 cells were sonicated for 1 hour using microprobe tip sonication 
(Sonics USA). After the sonication a neodymium magnet was used to separate the MAG from 
other cellular debris. 10mM Tris-HCl buffer (pH 7.4) was used to wash the MAG four times 
followed by resuspension in DPBS (pH 7.4). The properties of the purified MAG are shown in 
Table 3.1. The MAG were typically small in diameter (46 ± 5nm) as assessed by TEM. The 
electrokinetic potential (ζ) was also assessed to determine the charge of the particles. MAG 
displayed  a negative electrokinetic potential (ζ) (-9 ± 2.3 mV) on the membrane most likely a 
result of the lipid composition and the occurrence of polarizable primary amino groups (Tanaka 
and Matsunaga, 2000) this was measured using NanoBrook Zeta PALS (Table 3.1). This 
means that MAG tend to coagulate or flocculate, possibly leading to poor physical stability. 
Magnetic susceptibility is a measure of the magnetic properties of the particles which will be 
important when considering their targeting potential in response to a magnetic field. This is 
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measured in System International (SI) units as a function of iron mass (mgFe). MAG displayed 
high magnetic susceptibility (8.164e-5 SI) and the iron content of the MAG was (0.17mg/l).   
Table 3.1: The physicochemical properties of MAG purified from magnetospirillum magneticum 
AMB-1. Data are derived from N=3 independent experiments.                 
  
 
The morphological characteristics and size distribution of the MNPs was determined using 
high-resolution transmission electron microscopy (HRTEM). The diameter of MAG was 
typically (46± 5nm). qNano does not measure below 50 nm and so results data is based on 
TEM images. Interestingly, MAG have a much more uniform diameter compared to synthetic 
MNPs (Almstätter et al., 2015a) where there is a significant variation in the diameter between 
individual particles in the same sample. TEM images of magnetotactic bacteria and purified 
MAG are shown in Figure 3.1. Next, we assessed the uptake of the MAG by tumour cells.   
 
Figure 3.1: High-resolution Transmission electron microscopy of magnetotactic bacteria and 
purified MAG. A. TEM images of AMB-1 magnetotactic bacteria, grown in micro-anaerobic 
conditions in 1% O2 gas and 99% nitrogen at 30.1 C° in liquid culture medium which is specific to 
AMB-1 bacteria (scale bar-0.2um). B. MAG purified from AMB-1 were sonicated prior to TEM and 
mounted onto carbon-coated copper grids. The MAG displayed a typical cuboidal crystal shape with 
uniform size of ~46nm diameter (scale bar-100nm). Images were taken on a TEM operated at 120kV 
with an Orius 1000 camera. 
3.2.2 Breast cancer cell internalisation of MNPs  
MDA-MB-231 is a triple negative breast cancer (TBNC) cell line; patients with TNBC are 
resistant to chemotherapy and most hormonal therapies so have limited treatment options (Lee 
et al., 2011). This cell line has been used in our studies with an aim to develop new treatments 
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for this patient group. In the first instance, MDA-MB-231 cells were incubated with MAG at 
a concentration of 0.2 mg/ml for 24h. This concentration was selected based on previous 
studies carried out by Mannucci and coworkers,   they showed that HT-29 cells were able to 
effectively internalise MAG at concentration 0.2 mg/ml for 24h among the different 
concentrations tested (ranging from 0.2 to 1 mg/ml)  using Prussian Blue staining (Mannucci 
et al., 2014).  The degree of MAG uptake into cells was assessed by flow cytometry where a 
change in granularity of the cells because of taking up the MAG was detected based on changes 
in the side scatter. This was also confirmed by immunostaining the iron particles within the 
cell using the gold standard stain for iron ‘Prussian blue’ (Muthana et al., 2008a).  
As shown in Figure 3.2A, MDA-MB-231 cells were able to effectively internalise MAG 
~43%±4 (P ≤ 0.01) compared to the control untreated cells (0 %). To confirm intracellular 
MAG uptake, MDA-MB-231 cells were grown on coverslips and incubated with MAG (0.2 
mg/ml) for 24 hr. After this, cells were fixed in 200μl of acetone  at 4°C for 10 min and stained 
with Prussian blue to detect iron and counterstained with eosin to define the cytoplasm (Brace 
et al., 2009, Arcangeli et al., 1980). Coverslips were mounted onto microscope slides and light 
microscopy was used to take images. As shown in Figure 3.2B MAG were internalised by the 
MDA-MB-231 cell line and multiple particles were present within the cytoplasm of cells. It 
was difficult to quantify the number particles/cell, as the signal from the Prussian blue stain 





Figure 3.2: MAGs were internalised by MDA-MB-231 cells. MDA-MB-231 cells were incubated 
with 0.2mg/ml coated with purified MAG for 24 hr A. Flow cytometrical analysis of cells revealed 
uptake of MAG resulted in an increase in cell size and granularity compared to the control (untreated 
cells), this suggests uptake of the MAGs. Data are the mean ± SEM of n=3 independent experiments. 
B. Representative Prussian blue images of MDA-MB-231 cells incubated with MAG. Dark blue 
staining is the presence of the Prussian blue; Pink is the eosin. This was taken at x 40 Magnification 
using light microscopy (Leica DM1000). Of note, data are the Mean ± SEM (n=3) and statistical 
analysis was assessed using the T test. **p<0.01. 
3.2.3 Breast cancer cell viability following incubation with MAG 
MDA-MB-231 cells were incubated with MAG at a concentration of 0.2 mg/ml for 24h. The 
extent of cell death induced after MAG uptake was measured using the DNA binding dye 
propidium iodide (PI). This  stains dead/dying cells by flow cytometry (Brace, 2009). Cells 
were collected and washed in PBS and propidium iodide (PI) was added to all samples (50 
mg/ml) immediately before flow cytometrical analysis using the FL3-H laser (wavelength 
617nm). MDA-MB-231 cells undergo no significant change in cell death compared to control 
cells following incubation with MAG (Figure 3.2A).  
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 MTT test was also used to estimate the viability of cells in longer-term cultures of the MNPs. 
This colorimetric test estimates the decrease of yellow 3-(4,5-dimethythiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) via mitochondrial succinate dehydrogenase. While a 
decrease of MTT can only happen in metabolically active cells, the level of activity is a 
measurement of cell viability. MDA-MB-231 cells were incubated with MAG at a 
concentration of 0.23 mg/ml for 72 hr. After that, MTT reagent was added to each well 
followed by incubation for a further 3 hr. Cell death/viability was measured 
spectrophotometrically at 570nm. As shown in Figure 3.2B, and in concurrence with the flow 
cytometry data, there was no significant effect on cell viability for MAG compared to the 
control. 
Together these data suggest that the MDA-MB-231s efficiently take up bacterially-derived 
MAG without any significant toxicity to the cells.  
 
Figure 3.3: MDA-MB-231 remain viable after incubation with MAG. MDA-MB-231 cells were 
incubated with purified MAG for 24 hr. Cells were collected and flow cytometry as used to evaluate 
cell death by the addition of PI immediately prior to analysis. A. Cell death (PI+ cells) in the presence 
of MAG was not significant when compared to the control. B. MTT assay also revealed no significant 
change in cell viability in the presence of MAG. Of note, data are the Mean ± SEM (n=3) and statistical 
analysis was assessed using the T test.  
3.2.4 Characterization of MAG-OV  
Here we set out to prepare and characterise MAG-OV complexes. 200ul of DPBS containing 
0.22mg MAG and 1 mL of PBS containing 1 x 108 pfu OV were suspended in a final volume 
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of 1.2 ml (0.2mg/ml MAG and 1 x 108 pfu OV). Following this, complexes were incubated for 
20 min at RT. This is shown as a schematic in Figure 3.5.  
                           
Figure 3.4: Diagram of the self-assembly of MAG and OV. To prepare the complexes, 200ul of 
DPBS containing 0.22mg MAG and 1 ml of PBS containing 1 x 108 pfu OV were suspended in a final 
volume of 1.2 ml (0.2mg/ml MAG and 1 x 108 pfu OV). Following this, complexes were incubated for 
20 min at RT.  These were stored at 4°C or used immediately. 
We first measured the charge of the magnetic viral complexes using NanoBrook Zeta PALS. 
Co-assembly of MAG with OV (MAG-OV) resulted in a net negative charge (MAG-OV ζ = -
11 ± 5 mV). Of note, a net negative charge was detected with free OV (ζ= -13 ± 2.1 mV). The 
magnetic susceptibility of the MAG-OV complexes were slightly lower compared to respective 
unbound MAG (MAG-OV=5.438e-5 SI) as shown in Table 3.2. As expected, MAG-OV was 
larger compared to the OV and free MAG (MAG-OV Diameter = 160 ± 20nm) see Table 3.2 
and Figure 3.5.  





        
                
 
Figure 3.5: The size distribution of the OV and MAG-OV. The size distribution of OV and MAG-
OV were determined by Tunable Resistive Pulse Sensing (TRPS) using a qNano instrument (Izon). 
Graphs show representative diameter data of A. OV B. MAG-OV. This is experiment was performed 
N=1 in triplicate. 
 
Typically, TEM images revealed that multiple MAG surrounded a single virus and this tended 
to form clusters of the complex (Figure 3.6). We were unable to detect any uncoated virus in 
the samples. The same MAG-OV complex was imaged by TEM after 72h storage at 40C to 
determine if the complexes were stable. This data showed that the complexes were still intact 
(Figure 3.6).  
 
 
Figure 3.6: TEM images showing stability of MAG-OV over time. Samples containing virus were 
counterstained with 1% phosphotungstic stain, this is a common negative stain for viruses including 
HSV. Images were taken on a TEM operated at 120kV with an Orius 1000 camera. A. Representative 
image of MAG-OV after 1h of incubation and B. After 72h, to show the stability of complexes. The 




3.2.5 Transmission electron microscopy of MAG-OV cell internalisation. 
TEM was also performed to investigate the intracellular localization of MAG-OV. Infected 
tumour cells (105) were prepared as described in (section 2.2.14.1.2). Figure 3.7 shows images 
of MAG-OV internalisation in MDA-MB-231 cells. MAG-OV were observed to cluster in the 
cytoplasm or in the vesicles of the cell (e.g. Endosomes). Interestingly, free OV were seen 
throughout the cytoplasm and MAG were located within the endosomes. This suggests that 
once inside the cell the OV is able to free itself from the MAG.  Therefore, in the next section 
we investigated the oncolytic potential of MAG-OV. 
                                    
Figure 3.7: TEM images of MAG-OV inside MDA-MB-231 cells. Representative image of MAG-
OV in the cytoplasm or in the endosomes of MDA-MB-231 cells. Arrows show MAG within the 
cytoplasmic vesicles. Free OV can be seen throughout the cytoplasm. Images were taken on a TEM 
operated at 120kV with an Orius 1000 camera. The scale bars are 0.5 um.  
3.2.6 MAG-OV induce MDA-MB-231 cell oncolysis  
MDA-MB-231 cells were seeded into 6-well plates (3 x 105 cells/well) and after 24 hr, cells 
were infected with either the OV on its own or MAG-OV at MOI 10 (selected based on 
previous studies in our lab), MAG and non-infected cells were used as controls. For these 
studies we used the reporter virus HSV1716-GFP so that the GFP could be used to confirm 
virua infection.  After 1, 3 and 6 days of culture with the viruses, plates were harvested and 
flow cytometry was used to analyze the cells. The level of viral infection was measured as the 
percentage of GFP (+)/Topro-3(-) cells. In these studies, TOPRO3 was used as a viability dye 
where dead/dying cells take up the dye but live cells exclude it. As shown in Figure 3.8, MAG-
OV was able to infect the tumour cells as efficiently as the naked OV with no differences 
between these groups after 24h of culture. GFP expression was markedly reduced by day 6 of 
culture in all the treatments groups compared to the control and MAG groups (Figure 3.8). 
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This decrease in GFP expression was most likely because of cell death and indeed statistically 
significant cell death was observed with both MAG-OV and OV, compared to the control group 
at day 3 and 6 (Figure 3.9). As expected, cell death increased over time with maximum death 
measured at day 6 of culture. As shown in Figure 3.9, MAG-OV was not significant at 1, 3 
and 6 days of culture compared to virus alone. 
                                                                                                 
Figure 3.8: MAG-OV induce MDA-MB-231 cell oncolysis. Representative fluorescent dot plots of 
GFP expression following 24h incubation of MBA-MB-231 cells with OV, MAG-OV (at MOI 10), 
MAG and untreated control cells. Cells were harvested and immediately before analysis on a flow 
cytometer (machine type LSRII) 2ul of TOPRO-3 was added to each sample. GFP expression was 
measured in FL-1 (488nm). GFP infection was also assessed on day 3 and 6 post-infection. Of note, all 
dead cells were gated out of the GFP analysis. Data are the mean ± SEM of n=3 independent 
experiments and statistical analysis was assessed using the two-way Anova test with multiple 
comparisons. **p<0.01.  
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Figure 3.9:  MAG-OV induce MDA-MB-231 cell oncolysis. Representative dot plots of cell death 
following 24h incubation of MBA-MB-231 cells with OV, MAG-OV (at MOI 10), MAG and untreated 
control cells. Cells were harvested and immediately before analysis on a flow cytometer (LSRII) 2ul of 
TOPRO-3 was added to each sample. TOPRO-3 was measured in the FL-4 (640nm). Cell death was 
also assessed on day 3 and 6 post-infection. Of note, data are the mean ± SEM of n=3 independent 
experiments and statistical analysis was assessed using the two-way Anova test with multiple 
comparisons.   
3.2.7 MAG-OV induce MCF7 cell oncolysis  
Here the oncolytic ability of OV and MAG-OV on another breast carcinoma cell line, MCF7 
(originally derived from human Caucasian breast adenocarcinoma patient), was assessed. 3 x 
105 cells were seeded into 6-well plates and infected with OV and MAG-OV at MOI 10, MAG 
and non-infected cells were used as controls. Cells were incubated for different periods (1 day, 
3 days and 6 days) and analysed by flow cytometry. Cell death was measured as Topro-3(+) 
cells; virus uptake in living cells was measured as GFP (+)/Topro-3 (-) cells. After infection 
(1, 3 and 6 days). There was no significant difference between the OV and MAG-OV infection 
(Figure 3.10). On the other hand, statistically significant levels of cell death were observed 
with MAG-OV and OV compared to controls (Figure 3.11). Moreover, MAG-OV cell death 
levels were similar to virus naked cell death at all-time points (1, 3 and 6 days).  
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Figure 3.10: MAG-OV induce MCF7 cell oncolysis. Representative fluorescent dot plots of GFP 
expression following 24h incubation of MCF7 cells with OV, MAG-OV (at MOI 10), MAG and 
untreated control cells. Cells were harvested and immediately before analysis on a flow cytometer (LSR, 
II) 2ul of TOPRO-3 was added to each sample. GFP expression was measured in FL-1 (488nm). GFP 
infection was also assessed on day 3 and 6 post-infection. Of note, all dead cells were gated out of the 
GFP analysis. Data are the mean ± SEM of n=3 independent experiments and statistical analysis was 











                                              
Figure 3.11: MAG-OV induce MCF7 cell oncolysis. Representative dot plots of cell death following 
24h incubation of MCF7cells with OV, MAG-OV (at MOI 10), MAG and untreated control cells. Cells 
were harvested and immediately before analysis on a flow cytometer, 2ul of TOPRO-3 was added to 
each sample. TOPRO-3 was measured in the FL-4 (640nm). Cell death was also assessed on day 3 and 
6 post-infection. Of note, Data are the mean ± SEM of n=3 autonomous trials and statistical analysis 
was assessed using the two-way Anova test with multiple comparisons.   
 
3.2.8 MAG-OV induced tumour spheroid cell death 
2D cell cultures contrasts significantly with 3D cultures in nutrient access, cell-cell interaction 
and cellular mechanics (Edmondson et al., 2014). Spheroids were prepared as described in 
Section 2.2.16. The use of 3D spheroids has the benefit of having established oxygen-
exhausted central zones surrounded by a well-oxygenated region, mimicking small micro-
metastasis (Muthana et al., 2011a). One of the most hallmark uses of 3D cell cultures is the 
ability to replicate some of the same behaviour of in vivo conditions. Therefore, we performed 
experiments to investigate the effects of MAG-OV in breast cancer 3D tumours spheroids. 
Tumour spheroids were prepared with the human cancer cell lines MDA-MB-231 and MCF7 
cells (2 x 104 cells seeded onto 2% agarose-coated 96-well plates). Five days later (day 5), 
spheroids were infected with OV and MAG-OV at MOI 10 and incubated for a further 6 days; 
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non-infected spheroids were used as controls. In these studies, light microscopy images were 
taken after 6 days of infection, to image changes in the shape of spheroids. We observed that 
MAG-OV elicited as much damage to the MDA-MB-231s (Figure 3.12A) and MCF7 
spheroids cells as the OV group (Figure 3.13A). Spheroids were harvested and washed after 3 
days of infection and cell viability of enzymatically-dispersed spheroids was analysed by flow 
cytometry. As expected the OV and MAG-OV groups showed significant cell death compared 
to the control spheroids in both MDA-MB-231 and MCF7s (Figure 3.12B & Figure 3.13B). 
                     
Figure 3.12: MAG-OV infects and kills MDA-MB-231 spheroids. Tumour cells were seeded into 
wells of a 96 well plate, that contained agarose dissolved in DMEM, at 20 x 10³ cells per well and the 
approximate size they grow to was 105 cells. After 5-7 days of seeding OV or magnetic viral complexes 
(MAG-OV) were added to the spheroids as described in section 2.2.15. A. shows MAG-OV and OV 
increased the necrotic core of MDA-MB-231 spheroids. Images were taken by light microscopy 6 days’ 
post infection. This was taken at 10x Magnification. B. Infection with OV and MAG-OV induced 
tumour spheroid cell death. Representative fluorescent dot plots of dispersed MDA-MB-231 Spheroids.  
TOPRO3+ cells were measured by flow cytometry 3 days’ post-infection. The percentage of cell death 
is shown (TOPRO-3+). While no significant changes in viability were detected between OV and MAG-
OV, both virus groups induced significant cell death compared to the control untreated spheroids. Data 
are the mean ± SEM of n=3 independent experiments and statistical analysis was assessed using the 
one-way Anova test with multiple comparisons. *p<0.05.  
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Figure 3.13: MAG-OV infects and kills MCF7 spheroids. Tumour cells were seeded into wells, that 
contain agarose dissolved in DMEM, at 20 x 10³ cells per well and the approximate size they grow to 
was 105cells. After 5-7 days of seeding the cells in 96 wells plate, OVs or magnetic viral complexes 
(MAG-OV) were added to the spheroids as described in section 2.2.15. A. MAG-OV and OV increase 
the necrotic core of MCF7 spheroids. Images were taken by light microscopy 6 days’ post infection. 
This was taken at 10x Magnification. B. Infection with OV and MAG-OV induces tumour spheroid cell 
death. Representative fluorescent dot plots of 3D MCF7 Spheroids.  TOPRO3+ cells were measured by 
flow cytometry 3 days’ post-infection. The percentage of cell death (TOPRO-3+). While no important 
changes in viability were detected between OV and MAG-OV, both virus groups induced significant 
cell death compared to the control untreated cells. Data are the mean ± SEM of n=3 independent 
experiments and statistical analysis was assessed using the one-way Anova test with multiple 
comparisons. **p<0.01 ***p<0.001.  
3.3 Discussion 
3.3.1 Characterisation of MAG  
The physio-chemical characteristics of MAG was investigated. MAG have an advantage in that 
the particles have a small size distribution and their size can be better managed during 
production, resulting in more uniform particles with average size of 46 ± 5 (Byrne et al., 2011). 
This offers an advantage over chemically synthesised particles that are often irregular and not 
uniform in size. Recently, studies have also confirmed that MAG purified from 
Magnetospirillum gryphiswaldense MSR-1 displayed uniform arrangement of particles 
whereas MNPs were clustered (Raguraman and Suthindhiran, 2019). They also found that the 
MAG have higher crystallinity than synthetic MNPs and this is related to the biomineralization 
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property of MTB in producing MAG. The high variation in size and physical aggregation 
displayed by chemically synthesised MNPs is a concern that has been raised by many 
researchers. For example, Raguraman and colleague reported this concern (Raguraman and 
Suthindhiran, 2019). They found that synthetic MNPs agglomerated inside the cell which 
subsequently damage the redox system causing mortality. However, Florea et al., demonstrated 
high cell uptake of PEI coated MNPs in Cos1 (green monkey fibroblasts) and airway epithelial 
cells (calu-3) but this correlated strongly with PEI toxicity (Florea et al., 2002). Similarly, 
Thomas and co-workers found that PEI coated MNPs facilitated gene transfer into the A549 
lung carcinoma cells in vitro and into the lungs of mice but this also was highly toxic to cells 
(Thomas et al., 2005). This needs to be addressed if these particles are to be applied clinically 
(Blanco-Mantecon and O’Grady, 2006). It is clear that MNP needs to be sufficiently small (10–
50 nm) for biomedical applications (Issa et al., 2013). This will have numerous benefits as 
outlined below: 
1. Small MNPs will be more stable and aggregate less if their magnetic interaction is 
decreased.   
2. Small MNPs can stay in the circulation after injection and pass through the capillary 
systems of organs and tissues avoiding vessel embolism. 
3. Small MNPs have a high saturation magnetisation that leads to control the movement 
of the particles in the blood by moderate external magnetic field. 
4. Being very small, the particles can avoid precipitation due to gravitation forces. 
5. Small MNPs will have small dipolar interactions, because the dipole-dipole interactions 
rely on the radius of the particle. This will minimize particle aggregation.  
    
This study shows that MAG display higher magnetic susceptibility (8.164e-5 SI), suggesting 
MAG are more likely to be attracted to a magnetic field. This is important, as the goal of this 
study is to apply a magnetic guidance strategy to target our complexes to tumours. 
Interestingly, the electrokinetic potential of the MAG was negative (-9 ± 2.3 mV) (Table 3.1). 
Studies have also shown that the zeta potential of MAG in the colloidal state was stable and 
negatively charged (−17.4 mV), showing they were well dispersed (Raguraman and 
Suthindhiran, 2019). This negative charge is because of the presence of lipid membrane around 
MAG (Sun et al., 2011). 
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3.3.2 MAG internalisation and viability by breast cancer cells 
In the first instance bacterially derived MAG to be internalized by breast cancer cells was 
investigated. MAG was taken up successfully and this was confirmed using two approaches. 
Flow cytometry was used to assess changes in cell size and granularity after uptake and 
Prussian blue staining to visualize the occurrence of iron within the cells. MAG uptake by cells 
was not detected efficiently by flow cytometry (Figure 3.1). This may be due to the MAG size 
(MAG ~46 nm) thus after uptake of smaller MAG perhaps flow cytometry could not detect the 
changes in cell granularity. However, from the Prussian blue images it was clear that MAG 
were abundant in the cells (Figure 3.1). MAG were not toxic to breast cancer cells (Figure 
3.2).  Other studies have also confirmed that MAG are not toxic to tumour cells. For example, 
using the MTT assay MAG uptake had no toxicity effects on HT-29 (human colon 
adenocarcinoma grade II cell line) cells compared to untreated cells (Mannucci et al., 2014). 
In agreement with our study, Alphandery and colleagues demonstrated MAG (1 mg/ml) uptake 
by MDA-MB-231 cells resulted in improved cell viability compared to chemically synthesised 
super paramagnetic iron oxide particles (SPIOs) coated with PEG or citrate ions (Alphandéry 
et al., 2011). The latter were more toxic to cells (20%) after 72 h. Moreover, the antitumour 
activity of the MAG after hyperthermia treatment was also demonstrated to be superior to 
SPIOs in a breast tumour xenograft following exposure to an alternative magnetic field 
(Alphandéry et al., 2011). This suggests that MAG are more responsive to a magnetic field. 
Raguraman and colleague also shown that MAG are not toxic and do not cause any potential 
risk to the environment compared to chemically synthesised MNPs in different models such as 
human red blood cells, macrophage cell lines (RAW 264.7), onion root tips (Allium cepa), 
Artemia salina (A. salina) and zebrafish embryo (Danio rerio). For example, MAG showed 
13.4% cytotoxicity at 250 μg/ml whereas the cytotoxicity induced by  chemically synthesised 
MNPs was 36.01%  for the same concentration in a macrophage (RAW 264.7) cell line 
(Raguraman and Suthindhiran, 2019). 
It would have been useful to quantify MAG uptake by MDA-MB-231 by fluorescence uptake 
using flow cytometry rather than relying on a change in cell size. This could be achieved by 
fluorescently labelling the MAG (e.g. fluorescent dyes or infrared probes). A previous report  
demonstrated that MAG can labelled with rhodamine B in order to be fluorescent with 
absorption and emission peaks (Alphandéry et al., 2017). They have added the rhodamine B in 
the growth medium of magnetotactic bacteria in addition to the iron source whilst the 
magnetotactic bacteria are growing. We are currently attempting to do this in the laboratory so 
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we can visualise uptake by tumour cells in vitro and in vivo but have found the rhodamine label 
is not expressed.  We are currently experimenting with different fluorescent labels such as 
lipophilic membrane stains (DiL and DiD). This is considered a more accurate method for 
determining MAG uptake but caution must be taken as this can change the size of the particles 
(Kircher et al., 2003, Medarova et al., 2007).  
From the Prussian blue staining and the TEM images it was evident that MAG tended to 
aggregate (Figure 3.1&3.2B). To overcome this the MAG were sonicated to reduce the 
aggregation. This is a common method that is used in the preparation of MNPs (Kouassi et al., 
2005). In this study, the MAG were sonicated for 10 min, whereas in other studies, sonication 
had been used for up to 3 hr to reduce aggregation (Hao et al., 2012). Further optimization of 
the sonication protocol is necessary and this is currently under investigation in our laboratory. 
Other steps taken to improve MAG uptake into cells included placing the cells and MAG on 
an orbital shaker during the incubation step. This was carried out by a Masters student in the 
laboratory that was under my supervision. Here we found that most MAG were internalised 
within 1 hour of incubation with the cells, we also established that no further uptake was 
evident after 24 hr. The data for this experiment was not included as the experiment was only 
performed with N=1 and therefore requires further investigation. However, incubating the 
particles for 1 hour and removing the shaker could improve the speed and efficiency of future 
experiments. This is in contrast to previous studies where shaking and longer time points were 
necessary for effective MNP internalisation (Haritha et al., 2015). 
3.3.3 Characterisation of magnetic viral complexes 
MAG possess lipids on their surface that render the particles negatively charged (Sun et al, 
2008).  Since the MAG display a negative electrokinetic potential we did not expect the self-
assembly with the OV. However, this was not the case as MAG and OV formed complexes 
(MAG-OV) and this was evident by TEM (Figure 3.6). Creating the magnetic viral complexes 
using synthetic MNPs relies on the positive electrokinetic potential of the MNP so that complex 
formation depends on electrostatic interactions with negatively charged viral particles 
(OV)(Almstätter et al., 2015a). Almstatter et al., showed that core-shell type iron oxide MNPs 
gathered with vesicular stomatitis virus (VSV) or adenovirus (Almstätter et al., 2015). Their 
complexes were between 500-900 nm in diameter and by TEM it was evident that MNP-OV 
complexes formed but the MNPs were not very defined and formed aggregates, whereby the 
MNPs appeared to be on top of each other making the TEM images unclear. This probably 
results from magnetic di-pole-dipole interactions between the MNPs. We used a similar 
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approach in this study, however MAG-OV were smaller in size and exhibited a lot less 
aggregation than the MNP-OV showed in the Almstatter study (Almstätter et al., 2015a). 
MAG-OV have a negative electrokinetic potential and retained their magnetic susceptibility 
(Table 3.2). This complex formation is most likely a result of MAG possessing polarizable 
primary amino groups, enabling self-assembly based on the homo-bifunctional cross linking 
agents for example aliphatic binary aldehyde, diisothiocyanates, diisocyanates, 
di(succinimido) aliphatic esters, and their derivatives (Sun et al., 2011). However, 
hydrophobicity may also cause them to stay together as both of them contain hydrophobic 
proteins on their membrane. 
3.3.4 Oncolytic potential of magnetic viral complexes on breast cancer cells 
Uptake of the MAG-OV complexes was determined using flow cytometry and TEM. These 
complexes were efficient in infecting MDA-MB-231 and MCF7 cells after 24 h of culture 
displaying very similar viral GFP expression as in the OV only group (Figure 3.8, Figure 
3.10).  
The localisation of the MAG-OV complexes after cell uptake was confirmed by TEM. 
Typically, the MAG-OV complexes were captured in endosomes (Figure 3.7), whilst any 
unconjugated or free MAG were grouped in the cytoplasm and only very few were detected in 
the endosomes (Figure 3.7). Infection by HSV is usually via receptors on the cell surface so 
that admission of virus can be permitted; this process requires the complex interaction of a 
number of viral and cellular membrane components (Spear and Longnecker, 2003, Spear, 
2004). There are 5 glycoproteins of viral membrane, gD, gB and the heterodimer including gH 
and gL (gH/gL) that are necessary for HSV-1 access into cells (Conner et al., 2008) and gC 
that is important for binding (Spear, 2004). HSV utilise numerous receptors for access into 
cells such as members of the tumour necrosis factor (TNF) receptor family; nectin-1 and nectin-
2, Herpesvirus entry mediator (HVEM), heparan sulphate (HS) chains on cell surface 
proteoglycans as well as two members of the immunoglobulin superfamily linked to the 
poliovirus receptor (Figure 3.14). It is becoming increasingly clear that herpes viruses can 
enter cells by exploiting the endocytic pathways, although the mechanisms remain poorly 
defined (Clement et al., 2006). Whilst it is not known which receptors HSV1716 utilises to 
enter MDA-MB-231 cells, from the TEM images we guess that the MNP-OV/MAG-OV 
complex uptake was not receptor mediated, and most probably via endocytosis.  
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Figure 3.14: Viral and cellular membrane components that contribute to HSV1716 entry. There 
are 5 glycoproteins of viral membrane (gB, gC, gD, gH and gL) that are necessary for HSV-1 access 
into cells. Virus can start binding to the cell surface through gB or gC to heparan sulphate (HS) chains 
that are located on cell surface proteoglycans. This triggers fusion of the viral envelope with a cell 
membrane by binding gD to one of its cell surface receptors that includes members of the tumour 
necrosis factor (TNF) receptor family; nectin-1 and nectin-2, Herpesvirus entry mediator (HVEM), 
heparan sulphate chains on cell surface proteoglycans as well as two members of the immunoglobulin 
superfamily linked to the poliovirus receptor in addition to the action of the of gB and gH-gL 
heterodimers. 
After confirming that the MAG-OV complexes were able to infect breast cancer cells we then 
investigated their ability to induce oncolysis. Complexes induced time-dependent cell death in 
line with the OV therapy on its own (Figure 3.9, Figure 3.11). No significant change in cell 
toxicity was detected between the MAG-OV and free OV.  
Next, we tested the oncolytic potential of MAG-OV in 3D spheroid cultures. This provides an 
opportunity to investigate the influence of MAG-OV in a more sophisticated model that is 
physiologically relevant than 2D culture (Edmondson et al., 2014). One of the hallmark uses 
of 3D cell cultures is the ability to replicate some of the same behaviour of in vivo conditions, 
albeit not completely and they are still a very simplistic model. To investigate the effects of 
MAG-OV in breast cancer 3D tumours spheroids, we performed some preliminary experiments 
where the virus was allowed to infiltrate into multicellular 3D spheroids. The main objective 
was to determine if the coated virus in MAG-OV influenced 1) delivery of the virus 2) viral 
induced cell death. A previous study showed that initial damage of a glioblastoma biopsy 
spheroid in vitro by oncolytic HSV-1-based vector (G207) was characterized by a ruffling of 
the spheroid surface (Huszthy et al., 2008). Microscopy was used to observe changes in 
spheroid shape on day 6 of infection. In these studies, MAG-OV or OV was added to MDA-
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MB-231 and MCF7 spheroids. We observed ruffled edges and a flattened morphology, 
indicating damage and cell death of the three-dimensional spheroid structure on day 6 of 
infection with both OV and MAG-OV treatment compared to untreated spheroids and MAG 
only. Interestingly, MAG-OV damaged the spheroid of MDA-MB-231s and MCF7 cells as 
efficiently as OV (Figure 3.12A, Figure 3.13A). Reassuringly, flow cytometry of 
enzymatically dispersed spheroids showed considerable cell death post infection with both OV 
and MAG-OV (Figure 3.12B & 3.13B) compared to control and MAG only group (p ≤ 0.01 
and p ≤ 0.01, respectively). Together this suggests that MAG-OV is as efficient as OV on its 
own with respect to infectivity and cell death in both monolayer and 3D cultures. Huszthy et 
al have also shown that G207 could damage spheroids obtained from glioblastoma multiforme 
GBM1 (95% of the spheroids lysed after 10 days of infection) (Huszthy et al., 2009). Therefore, 
this kind of cell cultures could help reduce animal numbers in the long run. As an alternative, 
it would be interesting to take fluorescent images to show GFP in the hypoxic necrotic areas in 
future and include other cell types for example fibroblast, endothelial cells and see how MAG-
OV changes other cell types in the TME. 
In summary, this chapter shows that MAG-OV can be assembled without having any impact 
on the oncolytic potential of the virus. MAG are more small and uniform in size and form 
complexes with OV in such a way that the virus does not change its properties. The complexes 
are still nm in size and can infect and kill tumour cells. The following chapter will focus on the 
oncolytic potential of MAG-OV and the cell death mechanisms.  
 
 











































Results from the previous chapter show that OV can form a complex with MAG derived from 
magnetotactic bacteria. The physicochemical characteristics of MAG-OV and the ability to 
infect and kill human breast carcinoma cell in 2D and 3D culture was also demonstrated. In 
this chapter, the replication potential and cell death mechanisms of the virus will be assessed. 
4.1.1 HSV1716 entry into tumour cells    
In tumour cells, entry of HSV1716 to the cell by fusion of the virus envelope with the plasma 
membrane, leads to release of the viral nucleocapsid into the cytoplasm of the cell. After the 
capsid binds to the nuclear pore the genome is then released into the nucleus where all the steps 
of transcription, replication of viral DNA and assembly of progeny nuclear capsid take place 
(Figure 4.1). HSV viral replication genes are ICP0 – immediate early (Smith et al., 2011), 
ICP8 – early (Gao and Knipe, 1989) and gB – late (Singh et al., 2012) and these can be used to 
detect viral replication. After entry into the host, ICP0 is immediately expressed. ICP0 is able 
to avoid the hosts initial immune response when degradation of various immune activating 
proteins takes place, including ND10 associated proteins, because it has ubiquitin ligase 
activity (Lanfranca et al., 2014). Initiating HSV mRNA synthesis and marking the very 
beginning of virus replication is then controlled by ICP0.  Before virus replication,  the main 
function of ICP8, which is a single-stranded DNA binding protein, is to mediate the synthesis 
of viral DNA upon co-localisation with other proteins, including UL30, UL42 and UL9 
(Uprichard and Knipe, 2003). gB is then able to control virus replication and cell entry upon 
successful viral DNA synthesis. HSV viral capsids can enter the nuclear membrane in the 
presence of gB. Previous studies demonstrated that using a gB knockout HSV mutant resulted 
in unsuccessful virus entry into the nucleus of keratinocytes (HaCaT), the virus mainly 
localised on the cell surface and cytoplasm, as a result glycoproteins gB and gH are necessary 
for the fusion between the virion envelope and the outer nuclear membrane  (Farnsworth et al., 
2007).  In this chapter the replication of OV will be assessed to ensure that the MAG do not 
interfere with this process. 
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Figure 4.1: A simplified illustration of HSV1716 replication.  HSV1716 enters tumour cells by 
fusion of the virus envelope with the plasma membrane, leads to release of the viral nucleocapsid into 
the cytoplasm of the cell. After the capsid bind to the nuclear pore the genome is then released into the 
nucleus where all the steps of transcription, replication of viral DNA and assembly of progeny nuclear 
capsid take place. 
4.1.2 HSV1716 mechanisms of cell death and influence on the TME    
The direct oncolysis of cancer cells by OV involves a mixture of apoptosis, necrosis, and 
autophagic cell death, often with one mechanism being predominant for a particular OV (see 
chapter one for details). For example, vaccinia virus has been shown to induce different cell 
death mechanisms including apoptosis, necrosis and autophagy in different human ovarian 
carcinoma cell lines including A2780, A2780CP, SKOV3ip1, IGROV1, TOV21G, and 
OVCAR-4 (Whilding et al., 2013). On the other hand, adenovirus has been shown to induce  
classical apoptosis in  human cell lines such as A549 and A2182 lung cancers (Hall et al., 1998). 
There is some evidence in the literature that HSV-1716 induces necrosis or p53-independent 
apoptosis in human ovarian cancer cells (Coukos et al., 2000). Nevertheless, there remains 
inadequate information on these mechanisms of cell death in malignant tumour cells following 
infection with OV. 
Immunogenic cell death (ICD) is a type of cell death that involves the adaptive arm of the 
immune system. ICD can activate anti-tumour immunity (Melcher et al., 2011b, Prestwich et 
al., 2008). This process leads to the production of key signals that alert APCs like dendritic 
cells (DCs). These include danger signals as well as tumour-associated antigens (TAAs), both 
required for DCs to trigger adaptive immune responses against cancer (Tang et al., 2012). The 
danger signals include damage-associated molecular pattern (DAMP) and pathogen-associated 
molecular pattern (PAMP) molecules derived from the OVs. Ground-breaking research by 
97 
 
Lindenmann and Klein almost half a century ago was the first to demonstrate increased 
immunogenicity of tumour cell antigens following influenza virus infection. In this study A2G 
mice were shown to be immunized against the Ehrlich ascites tumour following intraperitoneal 
injections of homogenized and lyophilized tumour cells which had been infected with oncolytic 
strains of influenza virus (Lindenmann and Klein, 1967). However, the mechanisms 
responsible for this immunogenicity were not understood.  
Studies have shown that some viruses produce ICD associated with the release of DAMPs. For 
example, a recent study demonstrated that DAMPS are produced by squamous cell carcinoma 
(SCC) cells after infection with HSV-1 RH2. In this study HSV-1 RH2 also resulted in 
extracellular release of high mobility group protein B1 (HMGB1) and adenosine triphosphate 
(ATP), and translocation  of calreticulin (CRT) to the cell membrane (Takasu et al., 2016). 
These are all indicators of ICD. In addition, Coxsackievirus B3 virus infection induced ICD in 
human non-small cell lung cancer cells (NSCLC; A549, H1299, and H460), including cell 
surface CRT and release of ATP as well as HMGB1 (Miyamoto et al., 2012). However, there 
are no published studies investigating cell death mechanisms and ICD by HSV1716 in breast 
cancer cells specifically and so this chapter aims to explore these mechanisms as part of its 
therapeutic efficacy. 
The benefit of the natural inflammatory response to virus infection and immune responses to 
OV are considered the main steps of viral immunotherapy (Vacchelli et al., 2013). A previous 
study demonstrated that HSV1716 induces an inflammatory response in a murine syngeneic 
model of ovarian carcinoma. This study showed that intratumoral injection of HSV1716 
resulted in upregulation of IFN-γ and CXCL10 (Benencia et al., 2005). CXCL10 is one of the 
proinflammatory chemokines that plays a role in activate T lymphocytes (Th1), NK cells, 
inflammatory dendritic cells, most macrophages and B cells (Liu et al., 2011b). Intratumoral 
injection of the third generation oHSV, G47∆-mIL12, significantly changed the 
microenvironment of glioblastoma stem cell (GSC)-derived intracerebral tumours. In this study, 
they  showed G47∆-mIL12 downregulated VEGF expression and upregulated IP-10 (CXCL10) 
(Cheema et al., 2013). 
4.1.3 Pre-existing immunity to HSV1716         
The major with problem systemic delivery of OV is pre-existing immunity, because of the 
nature of many of the OV used in medicine, many of us have already been exposed during 
childhood and development (Ferguson et al., 2012). As claimed by a new report from the World 
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Health Organization, Herpes simplex virus type 1 (HSV-1) has infected approximately 67% of 
the global population (more than 3.7 billion people under the age of 50). Therefore, many 
strategies have been developed to help overcome this and provide protection to the virus when 
in circulation. Trojan Horse delivery is one of the strategies used to protect OV from 
neutralising antibodies. An example, of this approach is using cells which are derived from the 
model organism, then infected with the OV ex vivo and then injected systemically (Ferguson 
et al., 2012). At the University of Sheffield, macrophages (infected with either adenovirus or 
HSV1716) were shown to protect the virus from neutralising antibodies when administered 
systemically (Muthana et al., 2015b, Muthana et al., 2011b). Nanomedicine approaches have 
also been developed for protecting OVs in circulation. For example, a previous study 
demonstrated that oncolytic adenovirus Ad520 could be protected against the inhibitory effects 
of serum or a neutralizing antibody in vitro when it was protected by PEI-Mag2 (fluorinated 
surfactant ZONYL FSA (lithium 3-[2-(perfluoroalkyl)ethylthio]propionate) combined with 
25-kDa branched polyethylenimine (PEI-25Br)) or PB-Mag1 (the fluorinated surfactant 
ZONYL FSE (ammonium bis[2-(perfluoroalkyl)ethyl]phosphate) combined with the cationic 
polymer polybrene (PB)) nanoparticles (Tresilwised et al., 2012b). Furthermore, aptamers 
(oligonucleotide or peptide molecules that bind to a specific target molecule) have been shown 
to protect vesicular stomatitis virus (VSV) from neutralising antibodies by blocking the Fab 
fragments of antibodies or binding to the virus. In this study, they showed that viral infectivity 
increased significantly (by more than 70%) in the presence of neutralizing antibodies in Vero 
cells (Muharemagic et al., 2014).  
The hypothesis tested in this chapter is that MAG will protect OV in our MAG-OV complex 
providing a protective shield from neutralising antibodies they may encounter in circulation.  
To test this first, we wanted to ensure that the OV in the MAG-OV complex could infect, 
replicate and kill breast cancer cells as effectively as OV alone. Secondly, the ability of the 
MAG to shield the virus from neutralising antibodies to HSV was assessed in vitro.  The 
specifics aim of the work described in this chapter was, therefore, to characterise the oncolytic 
potential of MAG-OV - with particular reference to:  
1. Oncolytic potential of MAG-OV (including apoptosis, necrosis, autophagy and ICD). 
2. Changes in the tumour microenvironment following MAG-OV: Pro-Inflammatory vs. 
Anti- Inflammatory Cytokines. 
3. Viral neutralisation of MAG-OV. 
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4.2 Results  
4.2.1 MAG-OV induces tumour cell oncolysis  
To confirm OV uptake, MDA-MB-231 cells were grown on coverslips and incubated with 
either HSV1716-GFP (OV) on its own or MAG-OV at MOI 10 and MAG alone along with 
non-infected cells as controls for 24 hr. After this, cells were fixed and stained with sheep 
antibody to detect HSV1716 (Conner et al., 2005). Moreover, 50ng/ml DAPI solution was 
added for 2 min to define the nucleus. Coverslips were mounted onto the microscope slides 
and a Nikon A1 confocal microscope was used to take images. As shown in Figure 4.2 OV 
and MAG-OV were able to infect MDA-MB-231 cells, where HSV1716 was detected within 
the cytoplasm of most cells.  
 
Figure 4.2: MAG-OV infected MDA-MB-231 cells. MDA-MB-231 cells were incubated with OV 
(MOI 10), MAG-OV (MOI 10) or MAG (0.2 mg/mL) for 24 h. Cells were fixed and stained with sheep 
antibody to detect HSV1716 and (4',6-diamidino-2-phenylindole) (DAPI) and then analysed under a 
confocal laser-scanning microscope. Scale bar = 40µm. Data are representative images from a single 
experiment. However, the experiment was repeated n=3 and showed the same result.  
  
In the last chapter MAG-OV were shown to infect and kill human breast carcinoma cell lines. 
Above we have confirmed uptake of MAG-OV was as effective as OV alone. Next, we assessed 
if MAG-OV was as effective in a panel of human and murine breast cancer cell lines. To 
analyse the oncolytic potential human MCF7 & MDA-MB-231 and murine EO771 and TS1 
cells were seeded into 6-well plates (3 x 105 cells/well) and after 24 hr, cells were infected with 
either the OV on its own or as MAG-OV at MOI 10 and MAG alone (0.2 mg/ml) with non-
infected cells used as controls. HSV1716-GFP was used as a reporter virus to visualise virus 
infectivity. After 6 days of culture, plates were harvested and flow cytometry was used to 
analyse the cells. In these studies, TOPRO3 was used as a viability dye where dead/dying cells 
take up the dye but live cells exclude it. As shown in Figure 4.3, MAG-OV were able to destroy 
the tumour cells as efficiently as the naked OV with no differences between these groups after 
6 days of culture. 
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Figure 4.3: OV and MAG-OV induce oncolysis in a panel of human and murine breast cancer 
cell lines. Cells were infected with OV, MAG-OV (at MOI 10) or MAG with non-infected cells used 
as controls. After 6 days of infection, cells were harvested and immediately before analysis on a flow 
cytometer 2ul of TOPRO-3 was added to each sample. TOPRO-3 was measured in the FL-4 (640nm). 
Of note, Data are the mean ± SEM of n=3 independent experiments and statistical analysis was assessed 
using the two-way Anova test with multiple comparisons.           
4.2.2 Viral replication genes 
Given that MAG-OV induced tumour cell death, next we wanted to determine if the virus was 
able to replicate post-infection. MDA-MB-231 and MCF7 cells were seeded into 6 well plates 
at 3×106 cells per well. Cells were then infected with OV, MAG-OV at MOI 10 and MAG (0.2 
mg/ml) alone with untreated cells as controls and cultured for 24h. Expression of viral 
replication genes was determined by qPCR. RNA was extracted after 24h of infection and used 
to synthesise cDNA. Viral replication genes included; ICP0 – immediate early, ICP8 – early 
and gB – late genes (Singh et al., 2012). Virus successfully replicated within the cells, as shown 
by the significant increase in viral mRNA expression of both OV (P ≤ 0.0001) and MAG-OV 
(P ≤ 0.0001) when compared to the control in MDA-MB-231 cell lines (Figure 4.4A). In the 
MCF7 cells, viral mRNA expression was also significant with OV (ICP0: p ≤ 0.01, ICP8: p ≤ 
0.001, gB: p ≤ 0.001) and MAG-OV (ICP0: p ≤ 0.01, ICP8: p ≤ 0.05, gB: p ≤ 0.001) compared 







































   
Figure 4.4: MAG-OV undergoes viral replication in breast cancer cells.  Breast cancer cells were 
infected with OV, MAG-OV at MOI 10 and MAG alone with untreated cells as controls. Viral 
replication genes were assessed by qPCR after 24h of infection. A. Significant increase in mRNA 
expression of ICP0, ICP8 and gB of both OV (P ≤ 0.0001) and MAG-OV (P ≤ 0.0001) in MDA-
MB-231 cells compared to the control. B. Viral mRNA expression is also significant with OV 
(ICPO: P ≤ 0.01, ICP8: P ≤ 0.001, gB: P ≤ 0.001) and MAG-OV (ICPO: P ≤ 0.01, ICP8: P ≤ 
0.05, gB: P ≤ 0.001) in MCF7 cells compared to the control.  The expression levels were calculated 
relative to the untreated cells (control) using the 2-ΔΔCT method after the data was normalised to the 
housekeeping gene, GAPDH. The data is presented as Mean ± SEM for n=3, independent experiments 
and statistical analysis was assessed using the one-way Anova test with multiple comparisons. **p<0.01; 
***p<0.001; ****p<0.0001. 
4.2.3 Cell Death Mechanisms  
Next, we wanted to assess the potential mechanisms of HSV1716 mediated cell death. Cell 
death genes were selected that marked the critical death pathways and were found to be 
upregulated following HSV1716 infection by a post-doctoral researcher in the laboratory (Dr 
Emer Atkinson, unpublished observations). These included; Caspase 3, Caspase 8– Apoptosis 
genes, ATG5, LC3B – Pro-autophagy genes, Bcl-2- anti-apoptotic gene, FasL- pro-apoptotic 
gene and HSP90AA1, HSP90B1, HSPA1A – Heat shock Proteins genes. Breast cancer cells 
MDA-MB-231 (Figure 4.5A) and MCF7 (Figure 4.5B) cells were infected with OV, MAG-
OV at MOI 10 and MAG alone with untreated cells as controls and cultured for 24h. Viral 
infection appeared to induce a significant increase in Caspase 3, Caspase 8, LC3B, FASL and 
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HSPA1A, mRNA expression (Figure 4.5) when compared to the control with both OV and 
MAG-OV treatment in both cell lines. ATGS was unaffected but HSP90AA1, HSP90B1 and 
Bcl-2 displayed a significant decrease in expression with both OV and MAG-OV infection. 
These genes are necessary for cancer cell survival and proliferation (Haase and Fitze, 2016). 
 
Figure 4.5: Increased expression of cell death markers following MAG-OV infection. Cell death 
mechanisms were investigated after 24h of infection of breast cancer cells MDA-MB-231 and MCF7 
with OV, MAG-OV at MOI 10 and MAG alone with untreated cells as controls. A. A significant 
increase in mRNA expression of HSPA1A, Caspase 3, Caspase 8, LC3B and FASL in both OV and 
MAG-OV treated MDA-MB-231 cells compared to the control. B. mRNA expression of HSPA1A, 
Caspase3, Caspase8, LC3B and FASL is also significant with both OV and MAG-OV in MCF7 cells.  
The expression levels were calculated relative to the untreated cells using the 2-ΔΔCT method after the 
data was normalised to the housekeeping gene, GAPDH. The data is presented as Mean ± SEM for n=3, 
independent experiments and statistical analysis was assessed using the one-way Anova test with 
multiple comparisons. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
4.2.4 Immunogenic cell death 
As mentioned earlier, many studies have shown that some viruses induce ICD associated with 
the release of DAMPs such as ATP and HMGB1 and/or those translocated to the cell surface 
such as calreticulin (CRT) (Takasu et al., 2016). Therefore, the release of ATP and HMGB1 
following MAG-OV infection was measured in breast cancer cells. MDA-MB-231 and MCF7 
cells were seeded into 6 well plates then infected with OV, MAG-OV at MOI 10 and MAG 
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alone with untreated cells as controls and cultured for 24h. ENLITEN ATP assay (Promega, 
Madison, WI, USA) was used to measure the secreted extracellular ATP in the cell culture 
supernatants according to the manufacturer’s protocol, using a Turner Biosystems luminometer 
(TD-20/20; Promega). Extracellular ATP levels were significantly increased in both OV and 
MAG-OV when compared with control and MAG alone (Figure 4.6). This suggests that 
HSV1716-infected breast cancer cells lead to cell membrane damage and release of ATP. 
Secreted extracellular HMGB1 in the supernatants was measured with a HMGB1 ELISA Kit 
II (Shino-Test, Kanagawa, Japan) according to the manufacturer’s protocol outlined for the 
normal sensitivity format of the assay.  Extracellular HMGB1 levels also significantly 
increased after a 24h incubation in both OV and MAG-OV treated groups when compared with 
control and MAG alone (Figure 4.6). 
 
                       
Figure 4.6: Extracellular levels of immunogenic cell death markers ATP and HMGB1 in human 
breast cancer cells. MDA-MB-231 and MCF7 cells were infected with OV, MAG-OV at MOI 10 and 
MAG alone with untreated cells as controls for 24 h, A. Shows Significant increase in Extracellular 
levels of HMGB1 and ATP of both OV and MAG-OV in MDA-MB-231 cells compared to the control 
while B. in supernatants of MCF7 cells. Data are the mean ± SEM of n=3 independent experiments and 




Calreticulin (CRT) is a DAMP that is normally located in the lumen of the endoplasmic 
reticulum. Immunogenic apoptosis leads to translocation of CRT to the surface of dying cells 
as an eat-me indicator for professional phagocytes (Obeid et al., 2006, Gold et al., 2010, Voll 
et al., 1997). The expression of CRT following HSV1716 infection was measured by 
immunocytochemistry. Cells were seeded on a small coverslip and infected with OV, MAG-
OV at MOI 10 and MAG alone alongside the control (untreated cells) for 24h and were stained 
with rabbit anti human CRT diluted 1:100 (Abcam, Cambridge, UK). Cells were then stained 
with DAPI. CRT was distributed sparsely in the cytoplasm before infection (Green colour). 
Nevertheless, its expression increased and distribution changed to accumulate at the plasma 
membrane 24 h after infection in response to both OV and MAG-OV in MDA-MB-231(Figure 
4.7A) and MCF7 (Figure 4.7B) cells.   
 
Figure 4.7: Increased expression of calreticulin (CRT) on the cell surface of human breast cancer 
cells following MAG-OV infection. MDA-MB-231 and MCF7 cells were infected by MAG, OV or 
MAG-OV at a MOI 10 for 24 h. A. Expression of CRT on the cell surface of MDA-MB-231 cells 
increased with OV and MAG-OV infection (Green colour). B. Expression of CRT on the cell surface 
of MCF7 cells increased with OV and MAG-OV infection.  Cells were fixed and stained with an anti-
CRT antibody (Green colour), F-actin staining with Phalloidin (red colour) and (4',6-diamidino-2-
phenylindole) (DAPI:Blue)) and analysed under a confocal laser-scanning microscope. All data are 




4.2.5 MAG-OV induces changes in Pro-Inflammatory cytokines and Anti- 
Inflammatory cytokines 
As mentioned above, both OV and MAG-OV successfully entered and replicated inside breast 
cancer cells, at the same time inducing ICD. Next, we assessed whether tumour cell death in 
response to OV infection influenced the tumour microenvironment using a panel of pro-
inflammatory and anti-inflammatory markers. This included pro-inflammatory cytokines (IL-
1B, TNF, CXCL10 and INF) and anti- Inflammatory cytokines (IL-10, TGF-B, NF-KB and 
VEGF). A previous study demonstrated that HSV1716 induces an inflammatory response in a 
murine syngeneic model of ovarian carcinoma. This study showed that intratumoral injection 
of HSV-1716 resulted in upregulation of IFN-γ and CXCL10 in the tumour (Benencia et al., 
2005). Furthermore, Vesicular stomatitis virus (VSV) have been shown to up-regulate pro-
inflammatory genes in CT-26 tumours 24 hr after infection. In this study, VSV upregulated 
most pro-inflammatory genes including TNF, CXCL10 and IL-6 in vivo (Breitbach et al., 
2007a). 
Therefore, we assessed the effects of MAG-OV on the production of both pro- and anti-
inflammatory genes in human breast cancer cells. The level of mRNA expression of these genes 
was measured in MDA-MB-231 and MCF7 cells infected with the OV, MAG-OV and MAG 
alone by qPCR. All samples were normalized to the untreated control cells. (Figure 4.8) shows 
fold change expression of mRNA levels. The expression of TNF were upregulated in both 
MDA-MB-231 (Figure 4.8A) and MCF7 (Figure 4.8B) cells treated with OV or MAG-OV 
compared to the untreated cells. Moreover, the expression of CXCL10 was upregulated in 
MCF7 cells (Figure 4.8B) while unchanged in MDA-MB-231 (Figure 4.8A) cells treated with 
OV or MAG-OV compared to the untreated cells. Furthermore, the expression IL-1B, NF-KB 
and VEGF were significantly downregulated in both MDA-MB-231 and MCF7 cells treated 




Figure 4.8: MAG-OV induces pro-Inflammatory cytokine mRNA expression in human breast 
cancer cells. mRNA expression of pro-Inflammatory and anti- inflammatory cytokines was measured 
in MDA-MB-231 and MCF7 cells infected with the OV, MAG-OV and MAG alone for 24h by qPCR. 
A. Shows significant downregulation in mRNA expression of IL-1B, NF-KB and VEGF and 
upregulation in TNF and INF in both OV and MAG-OV in MDA-MB-231 cells compared to the 
control. B. Shows significant downregulation in mRNA expression of IL-1B, NF-KB and VEGF and 
upregulation in TNF only of both OV and MAG-OV in MCF7 cells.  The expression levels were 
calculated relative to the untreated cells using the 2-ΔΔCT method after the data was normalised to the 
housekeeping gene, GAPDH. The data is presented as Mean ± SEM for n=3 independent experiments 
and statistical analysis was assessed using the one-way Anova test with multiple comparisons. *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001. 
Cytokines expression was also assessed at the protein level using a cytokine bead array (CBA). 
MDA-MB-231 and MCF7 cells were treated with OV & MAG-OV at MOI 10 and Mag alone 
with untreated cells as controls. Supernatants were collected 24h after culture and clarified by 
filtration. An Attune Autosampler was used to read the samples (Figure 4.9), this displays 
cytokine levels analysed including CXCL10, IL-1B, IL-6, IL-8, IL-10, INF, TNF and VEGF. 
The expression of CXCL10, IL-6, IL-8, IL10 and VEGF were significantly downregulated in 
both MDA-MB-231 (Figure 4.9A) and MCF7 (Figure 4.9B) cells treated with OV or MAG-
OV compared to the untreated cells. Like with the mRNA expression IL-10 in MCF7 cells was 
not affected in all the treatment groups. Unlike the mRNA expression IL-1B, INF and TNF 
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were not affected at the secreted protein level in both MDA-MB-231 and MCF7 cells treated 
with OV or MAG-OV compared to the untreated cells.  
 
Figure 4.9: MAG-OV induces pro-Inflammatory cytokines protein expression in human breast 
cancer cells. The protein levels of pro-inflammatory and anti-inflammatory cytokines were analysed 
after 24h of cells infection with the OV, MAG-OV and MAG alone using a cytokine bead array (CBA). 
A. Significant downregulation in protein levels of CXCL10, IL-6, IL-8, IL-10 and VEGF in both OV 
and MAG-OV in MDA-MB-231 cells compared to the control. B. Significant downregulation in protein 
levels of CXCL10, IL-8 and VEGF in both OV and MAG-OV in MCF7 cells. Data are the mean ± SEM 
of n=3 independent experiments and statistical analysis was assessed using the one-way Anova test with 
multiple comparisons. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
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4.2.6 Primary cells infection  
The ability of cells to migrate into tissues naturally has led them to be appropriate cell delivery 
targets for OVs. This has been demonstrated for immune cells for example macrophages 
(Muthana et al., 2015b). Therefore, we tried to measure the uptake of MAG-OV with primary 
cells found in circulation. Ficoll density gradient centrifugation was used to isolate the Primary 
cells from blood according to (Muthana et al., 2011a, Muthana et al., 2013). Mononuclear cells 
were infected with either the OV on its own or MAG-OV, at MOI 1, MAG (0.2mg/ml) and 
non-infected cells were used as controls. For these studies, we used the reporter virus 
HSV1716-GFP so that the GFP could be used to confirm virus infection. As shown in Figure 
4.10, MAG-OV was able to marginally infect the primary cells as efficiently as the naked OV 
with no differences between these groups after 6 hr of culture. However, we found that MAG-
OV and OV alone tended more to infect monocytes than other mononuclear cells (Figure 
4.10B). Suggesting that monocytes could be used to improve delivery of our complex in vivo.  
 
Figure 4.10: MAG-OV infected primary cells. Primary cells were incubated with OV (MOI 1), MAG-
OV (MOI 1) or MAG (0.2 mg/ml) for 6 h. MAG-OV was able to infect the primary cells as efficiently 
as the naked OV with no differences between these groups after 6 hr of culture. MAG-OV and OV 
alone tended more to infect monocytes than other mononuclear cells. Data are the mean ± SEM of n=3 
independent experiments and statistical analysis was assessed using the one-way Anova test with 
multiple comparisons. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
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4.2.7 Viral neutralisation  
Systemic delivery of OV results in low intra-tumoural titres due to pre-existing immunity that 
has established because of exposure to the virus, previous immunization, or prior oncolytic 
viral therapy (Ferguson et al., 2012). Neutralisation experiments were performed to determine 
if MAG could protect OV from neutralizing Ab in the MAG-OV complex. Sheep anti-HSV-1 
antiserum was used to neutralise the OV. This neutralising antibody (NAb) was kindly prepared 
by Virttu Biologics by four consecutive monthly injections of 1 x 10⁶ PFU HSV1716 (Conner 
et al., 2005). 100-fold dilution of sheep Ab obtained after the fourth injection and 1 x 10⁷ PFU 
of OV or MAG-OV were incubated in culture medium for 18 hr at 4°C, alongside the controls, 
no antibody control and no virus control. As shown in Figure 4.11A, cells incubated with 
OV+Nab expressed significantly less GFP after 24h of culture compared to MAG-OV+ NAb. 
This decrease in GFP expression is most likely because of OV neutralisation and indeed 
statistically significant less cell death was observed with OV+NAb compared to the MAG-
OV+ NAb after 24h of culture (Figure 4.11B).  
110 
 
                                        
Figure 4.11: MAG-OV is protected from anti-HSV neutralising antibodies and induces MDA-
MB-231 oncolysis. A. GFP expression following 24h incubation of MBA-MB-231 cells with OV, 
MAG-OV or MAG (at MOI 10) in the presence or absence of neutralising antibody.. B. The oncolytic 
potential of MAG-OV in the presence of NAb in MDA-MB-231 cells. Data are the mean ± SEM of n=3 
independent experiments and statistical analysis was assessed using the one-way Anova test with 
multiple comparisons. **p<0.01; ****p<0.0001. 
4.3 Discussion  
In this chapter, infection of the MAG-OV complex was determined by immunostaining. These 
complexes were equally efficient in infecting MDA-MB-231 cells after 24 h of culture 
displaying very similar viral GFP expression as the OV alone (Figure 4.2). Already, previous 
studies showed that the FDA approved HSV1 virus T-Vec induced 13.6 and 64.4% cell death 
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after 24 and 48 h post infection respectively at MOI 1 in a human breast adenocarcinoma cell 
line (MDA-MB-231)(Tan et al., 2015). Here we have extended the panel of established cell 
lines to include human and murine cells (MCF7, MDA-MB-231, EO771 and TS1 cells) and 
compared the oncolytic potential of HSV1716 alone (OV) or in the MAG-OV complex. MAG-
OV induced cell death in line with the OV therapy on its own (Figure 4.3) in both species. No 
significant change in cell toxicity was detected between the MAG-OV and free OV in all breast 
cancer cells. This data is reassuring and suggest that coating the OV with MAG does not affect 
the oncolytic potential of HSV1716. It also suggests that murine cells can be used for our future 
in vivo studies. This is advantageous and will allow immune parameters to be assessed 
following administration of our MAG-OV to tumour-bearing immunocompetent mice. There 
has been some speculation in the literature regarding HSV1716 in the 4T1 mouse model. Toda 
and co-workers demonstrated a small decrease in primary tumour size in the 4T1 mouse 
mammary carcinoma model.  They suggested this absence of efficacy was due to poor 
replication of HSV1716 within the 4T1 tumours as measured by the plaque assay (Toda et al., 
1999, Toda et al., 1998). It is not clear why this occurs, yet the block is not at the point of viral 
entry, like in B16 melanoma cells (Miller et al., 2001), as HSV-1 is able to infect 4T1 cells. 
More studies would be required to exactly understand why HSV-1 has a reduced capability to 
replicate in murine tumour cells and this should be investigated in the future.   
After we showed that MAG-OV was able to infect breast cancer. We therefore tested viral 
replication genes; ICP0 – immediate early (Smith et al., 2011), ICP8 – early (Gao and Knipe, 
1989) and gB – late (Singh et al., 2012) after 24h of cell infection.  As shown in Figure 4.4, 
all genes were upregulated following infection with OV and MAG-OV with the ICP8-early-
stage and gB-late-stage displaying the greatest fold change increase at the mRNA level.  This 
suggests that MAG surrounding the OV do not affect viral replication and the OV was able to 
complete its life cycle following cell infection. Indeed, from the TEM images in Figure3.7 
once the MAG-OV was inside the cell the MAG were shed and free OV was visible, this most 
likely enables the OV to replicate. This is in keeping with previous studies which showed 
shielding the oncolytic adenovirus Ad520 with silica-modified particles decorated with 25-kDa 
branched polyethylenimine(SO-Mag2) nanoparticles resulted in a significant increase in the 
replication of adenoviral DNA in tumour xenografts from 181RDB-fLuc human pancreatic 
carcinoma cells stably expressing firefly luciferase (Tresilwised et al., 2012). They showed that 
the magnetofection group displayed a significant increase (p < 0.05) in the expression of 
adenoviral DNA (hexon gene) compared with the group that received virus alone by using 
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regular PCR analysis. This is also in agreement with previous studies where Ad520-PEI-Mag2 
complexes resulted in an increase in vitro of adenoviral DNA replication exposed by Southern 
blot analysis, and an enhancement in infectious progeny virus particles compared with the 
naked virus (Tresilwised et al., 2010b). 
Next, an appreciation of the potential mechanisms of how MAG-OV induces cell death was 
investigated. Caspases are linked to apoptosis and viruses are known typically to activate 
apoptosis via caspase 8 and caspase 3 (Felt et al., 2015).  Nguyen and Blaho have shown that 
HSV infection triggers apoptosis during the early stages of viral infection leading to immediate 
early viral gene expression. They found caspase 3 contributed to apoptosis induction. However, 
anti-apoptotic genes such as Bcl-2 and NF-ĸB, which inhibit apoptosis, are produced during 
the later time-points post infection, leading to early and late viral gene expression. 
Consequently, this provide a balance between the pro- and anti-apoptotic factors during HSV 
infection (Nguyen and Blaho, 2009).  Here we found that viral infection (OV and MAG-OV) 
appeared to induce a significant increase in Caspase 3, Caspase 8, FASL and HSPA1A gene 
expression when compared to the control in both MDA-MB-231 and MCF7 cells (Figure 4.5). 
While Bcl-2 and NF-ĸB were significantly decreased following both OV and MAG-OV 
infection (Figure 4.5, Figure 4.8). Our data was taken at one-time point (24h) and therefore 
we cannot predict if changes in cell death markers occur over time. We assume that HSV1716 
was able to induce apoptosis by downregulating anti-apoptotic factors and the data of high 
expression of heat shock protein ‘HSPA1A’ gene suggest immunogenic apoptotic cell death. 
HSV-2 infection was previously shown to cause apoptosis with the activation of Caspase 7 and 
Caspase 3 in mammary gland tumour cells (Ag et al., 2010). Another study reported that HSP70 
and cleaved caspase 3 increased when HSV-1 ICP 0 mutant and wild-type HSV-1 were injected 
into mouse TUBO tumours (Workenhe et al., 2014). Together this suggests that both HSV-1 
and HSV-2 treated tumours were able to induce apoptosis and induction of heat shock protein 
e.g. high expression of HSP-70 suggest immunogenic apoptotic cell death. 
OV are also known to induce autophagy. For example, Santana et al.,  showed that HSV-1 is 
able to induce autophagy by increasing the GFP-LC3 and endogenous LC3 lipidation, and 
initiates autophagosomes in human neuroblastoma cells (Santana et al., 2012). Another study 
reported that LC3B lipidation increased when HSV-1 and a wild-type strain of HSV-2 infected 
SIRC (Statens Seruminstitut Rabbit Cornea) corneal cell line, suggesting both HSV types affect 
autophagy (Petrovski et al., 2014). Here we found that viral infection appeared to induce a 
significant increase in LC3B gene expression when compared to the control at both OV and 
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MAG-OV in both MDA-MB-231 and MCF7 cells (Figure 4.5). Suggesting that HSV1716 can 
induce apoptosis and autophagy in a coordinated fashion. In contrast, a previous study reported 
that HSV-1 ICP0 null oncolytic virus KM100 alone at MOI 10 was unable to increase the 
protein level of caspase 3 and LC3B in TUBO cells after different point time, while both 
mitoxantrone (MTX) and KM100 + MTX showed significant increase in levels of caspase 3 
and LC3B (Workenhe et al., 2013). However, the level of caspase 3 and LC3B in this study 
were measured using Western blotting (protein level), whilst in our study this was measured 
using qPCR (gene level). Furthermore, ATG5 was unaffected in our study but the cancer cell 
survival and proliferation genes HSP90AA1, HSP90B1 and Bcl-2 displayed a significant 
decrease in both the OV and MAG-OV groups. Overall, our study suggests that there are 
multiple cell death mechanisms activated following infection with either OV or MAG-OV. It 
would be interesting to measure the protein level of these markers with our MAG-OV in future 
and experiment with different time points.  
Immunogenic cell death (ICD) is one of the cell death types that includes the adaptive arm of 
the immune system (Melcher et al., 2011, Prestwich et al., 2008). The goal of ICD for dying 
tumour cells to induce the paracrine activation of dendritic cells and consequential priming of 
cytotoxic effectors, is the release of the extracellular ATP and HMGB1 along with the 
accumulation of CRT (Angelova et al., 2014, Kepp et al., 2011). Therefore, the release of ATP 
and HMGB1 following MAG-OV infection was measured in infected breast cancer cells. We 
found that extracellular ATP levels and HMGB1 levels were significantly increased at both 
OV and MAG-OV when compared with control and MAG alone (Figure 4.6). We also noticed 
the expression of CRT around the plasma membrane significantly increased with both OV and 
MAGOV, whereas untreated cells presented the diffuse distribution of CRT (Figure 4.7). 
MAG-OV infection was able to produce DAMPs from breast cancer cells as effectively as OV 
alone.  Similarly, Coxsackievirus B3 virus infection induced the in vitro ICD of human non-
small cell lung cancer cells, including cell surface CRT expression and release of ATP as well 
as HMGB1 (Miyamoto et al., 2012). Another report revealed that LG 261 glioma cells treated 
with Newcastle disease virus induced ICD, and expressed CRT and secreted HMGB1, but not 
ATP, and moreover improved the antigenicity of the cells resulted in  an increase in  infiltration 
of IFN-γ(+) T cells  (Koks et al., 2015). Furthermore, an in vitro study showed that HSV-1 ICP 
0 mutant (the entire ICP0 coding region has been removed) and wild-type HSV-1 did not 
increase the level of HMGB1 in culture, however serum HMGB1 levels, HSP70 and cleaved 
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caspase 3 were increased when these viruses were injected into mouse tumours (Workenhe et 
al., 2014).  
Next, we attempted to understand the impact of HSV1716 on the surrounding environment. 
Increasing the expression of cytokines generated upon OV infection, can result in activating 
the immune system towards the tumour cells that were infected with virus (Breitbach et al., 
2016, Singh et al., 2012). In order to assess whether OV or MAG-OV influenced the tumour 
microenvironment, a panel of pro-inflammatory and anti-inflammatory cytokines were 
measured using qPCR and cytokine bead array (CBA). As we expected, there was not a big 
deference between OV and MAG-OV in both MDA-MB-231 and MCF7 cells. In our findings 
related to the gene expression data, the expression of TNF were upregulated in both MDA-
MB-231 (Figure 4.8A) and MCF7 (Figure 4.8B) cells treated with OV or MAG-OV compared 
to the untreated cells. Moreover, the expression of CXCL10 was upregulated in MCF7 cells 
(Figure 4.8B) while unchanged in MDA-MB-231 (Figure 4.8A) cells treated with OV or 
MAG-OV compared to the untreated cells. At the protein level, CXCL10 and TNF was not in 
agreement with gene data. As the protein level of CXCL10 was significantly downregulated 
and the protein level of TNF were not affected in both cell lines treated with OV or MAG-OV 
(Figure 4.9). The protein level of INF showed a trend towards being upregulated in both 
MDA-MB-231 and MCF7 cells treated with MAG-OV compared to the untreated cells (Figure 
4.9). However, this change was not significant. A previous study showed that HSV1716 
resulted in the upregulation of IFN-γ  and CXCL10 in ovarian cancer (Benencia et al., 2005). 
Another study found increasing the expression of the TNF in the tumour and surrounding tissue 
from a HSV vector backbone resulted in an increase in the ability of tumour cell killing in the 
presence of ganciclovir (GCV) (Moriuchi et al., 1998). Suggesting that OV or MAG-OV 
influenced the tumour microenvironment by increasing the level of pro-inflammatory 
cytokines. On the other hand, the gene level of anti-inflammatory cytokines IL-1B, NF-KB and 
VEGF were decreased in both MDA-MB-231 and MCF7 cells treated with OV or MAG-OV 
compared to the untreated cells. In general, the literature does support a decrease in VEGF 
levels (Breitbach et al., 2007b, Breitbach et al., 2011b). Previous study revealed that 
intratumoral injection of the third generation oHSV, G47∆-mIL12, significantly altered the 
tumour microenvironment of GSC-derived intracerebral tumours. In this study, they have 
shown G47∆-mIL12 downregulated VEGF expression and upregulated CXCL10 (Cheema et 
al., 2013). VEGF is a pro-angiogenic marker and is important to carcinogenesis.  In many solid 
tumors, high expression of VEGF have been associated with poor clinical consequence (Dent, 
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2009). The reduction of VEGF with HSV1716 therefore has the potential to inhibit 
angiogenesis.  
At the protein level, the expression of IL-6, IL-8, IL10 and VEGF were also significantly 
downregulated in both MDA-MB-231 and MCF7 cells treated with OV or MAG-OV compared 
to the untreated cells except the expression of IL-10 in MCF7 cells was not changed (Figure 
4.9). The cytokine bead array (CBA) was used to measure the extracellular level of these 
proteins therefore we assume that the intracellular proteins level have been changed. It would 
have useful to also assess intracellular protein expression with western blots. Also assessing 
protein expression over more than a single timepoint would have been useful in case protein 
secretion was missed.   
OV neutralisation following systemic delivery is a major hindrance to success of this therapy 
for tumours that are inaccessible (Figure 1.7).  In vivo studies have already shown OVs are 
cleared after a few days following infection of mice bearing gliomas (Andreansky et al., 1997, 
Mineta et al., 1994). In addition, Extracellular Enveloped Virus (EEV) (one of the 
morphologically distinct infectious forms of virions that produced by the prototype of the 
poxvirus family) can avoid both complement and neutralising antibodies by protecting itself in 
an envelope derived from host cells (Ichihashi, 1996, Law et al., 2002, Smith et al., 1997, 
Vanderplasschen et al., 1998). This envelope is formed when the outer intracellular enveloped 
virus (IEV) membrane fuses with the plasma membrane. In this thesis, we hypothesised that 
MAG would protect the virus from neutralisation. As shown in Figure 4.10, MAG-OV+ NAb 
were able to infect the tumour cells as efficiently as the MAG-OV after 24h of culture. Cells 
incubated with OV+Nab expressed significantly less GFP after 24h of culture compared to 
MAG-OV+ NAb. This decrease in GFP expression is most likely because of OV neutralisation 
and indeed statistically significant reduced cell death was observed with OV+Nab compared 
to the MAG-OV+ NAb after 24h of culture (Figure 4.10). Suggesting that MAG-OV could 
minimise the interaction of HSV1716 with neutralising Ab because of MAG protecting the 
virus. Studies available in the literature examining the neutralisation of HSV1716 are limited. 
However, there are many attempts to overcome the problem of virus neutralisation. For 
example, Muthana et al., have tried to protect the virus from neutralisation using cell carriers, 
in this study magnetic resonance targeting using MRI was used to steer magnetically labelled 
macrophages carrying Ad-CMV-GFP into primary and metastatic tumour sites (lungs) in mice 
(Muthana et al., 2015b). A previous study attempted to overcome the problem of virus 
neutralization by using Nanomedicine approaches. They found that oncolytic adenovirus 
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Ad520 can be protected  against the inhibitory effects of serum or a neutralising antibody in 
vitro when it was protected with PEI-Mag2 or PB-Mag1 nanoparticles (Tresilwised et al., 
2012a) 
In this study we used sheep serum but it would be interesting to use other inhibitory effects to 
neutralize the HSV1716, such as using human serum derived from donors who have high, 
medium or little/no HSV antibodies to asses MAG-OV neutralisation.   
Taken together these data suggest that MAG-OV is able to enter and replicate inside breast 
cancer cells, at the same time inducing tumour cell death as good as OV alone but with the 
addition of protecting the virus from neutralising Ab. Nevertheless, this inference is based on 
in vitro data. Therefore, the next chapter will study whether MAG will improve targeting of 
OV in the presence of external magnetic field gradients and examine whether our complex can 


































Targeting delivery and immunotherapy of MAG-OV 

















There are numerous studies documenting the targeted delivery of MNPs in tumour-bearing 
mice using an external magnetic field to guide the particles to the tumour (Kyrtatos et al., 2009, 
Arbab et al., 2004, Riegler et al., 2010, Landázuri et al., 2013, Riegler et al., 2013). A previous 
study showed that HAI-178-FMNPs, an anti-α-subunit of ATP synthase antibody, (HAI-178) 
monoclonal antibody-conjugated fluorescent MNPs, could be injected intravenously into 
gastric cancer-bearing nude mice under the application of an external alternating magnetic field 
with 63 kHz and 7 kA/m for 4 min (Wang et al., 2014a). This resulted in reducing tumour 
growth compared to the control group (treated with saline), suggesting that HAI-178-FMNPs 
has a therapeutic function for gastric cancer in vivo. Moreover, the copolymer of reducible 
polyamidoamine (rPAA) self-assembled with superparamagnetic iron oxide nanoparticles 
(SPIONs) was used to deliver doxorubicin (DOX) in mice in a xenograft of the MDA-MB-231 
tumour cells through i.v. injection and inhibited tumour growth efficiently. Here they used a 
magnet that was left on the tumour for 1.5 h following injection (Chen et al., 2014).    
Furthermore, a recent study showed that using MNPs with an OV offered high cellular uptake 
within a minute and was considered a key advantage for the non-invasive targeting of OVs in 
vivo. In this study, Almstätter et al. used a selected core-shell type iron oxide MNPs in 
combination with either adenovirus (Ad) or vesicular stomatitis virus (VSV) intratumourally 
in orthotopic hepatocellular carcinoma (HCC) bearing rats in the presence of a magnet placed 
on the surface of the tumour nodule opposite to the injection site (Almstätter et al., 2015).  They 
found that MNP-VP complex accumulated in the tumour at the side of where the magnet was 
placed. In addition, VSV titre and non-heme iron content of SO-Mag-VSV complex-injected 
tumours increased compared to naked VSV-injected tumours (30 min post infection).  
Whilst direct intratumoural administration is possible for accessible tumours and has the 
potential to attain high concentrations of MNPs without the complications of systemic toxicity, 
this can also lead to undertreated regions in the tumour, thus allowing untreated tumour areas 
to progress (Hilger et al., 2005, van Landeghem et al., 2009). Importantly, intratumoural 
administration will not be useful for targeting small metastatic tumour growths or inaccessible 
tumours. Intravenous injection would be a better alternative as this would generally reach 
tumours adequately, even small tumours (Hainfeld et al., 2011, Hainfeld et al., 2013) and is 
less invasive than direct tumour injection. Furthermore, the distribution of intravenous 
injection is more comprehensive than the punctate distribution from direct intratumoural 
injections (Hilger et al., 2002, Huang and Hainfeld, 2013). Previous work has shown that 
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polyethyleneimine-modified iron oxide nanoparticles could be injected intravenously into mice 
with brain tumours under the application of an external magnetic field (50 mT) (Chertok et al., 
2010). This resulted in selective accumulation and retention in GBM (brain) tumours in 
comparison to control animals, which did not undergo magnetic targeting. Further, studies at 
the University of Sheffield have shown that macrophages loaded with MNPs could be injected 
systemically into mice with prostate tumours and attracted from the circulation to the implanted 
tumour (on the flank) in mice using a 0.5T external magnetic placed directly above the tumour 
(Muthana et al., 2008a).  
A recent study by Khierkah and co-workers showed that magnetic targeting of drugs could 
be used to treat intramedullary spinal cord tumours of the central nervous system. They used 
biocompatible iron oxide magnetite (Fe3O4) conjugated to doxorubicin. The iron particles 
were coated with gold and electrostatic interactions were used to attach the chemotherapy to 
the MNPs (DOX-MNP). They used a rat model whereby human glioblastoma multiforme 
tumour cells were implanted into the thoracic spine parenchyma. At the same time, they also 
implanted a 1 cm, 0.01 Tesla neodymium magnet sub-dermally overlying the tumour cell 
injection site to create a magnetic field at the tumour site. MNP-DOX nanoparticles were 
then introduced into the lumbar intrathecal space once the tumour was established and 
guided by the implanted magnet to the tumour site (Kheirkhah et al., 2018). Whilst exciting, 
surgically implanting the magnet could have serious adverse effects and result in 
complications from the surgery. In addition, this magnet was in place throughout the whole 
time of the experiment and it is unclear if this may have affected the animals.  
Wang and co-workers showed that magnetic targeting of MAG + near infrared (NIR) could 
be used to treat hepatoma 22 (H22) cells injected subcutaneously into the right flank region 
of mice. They used MAG extracted from Magnetospirillum magneticum strain AMB-1 with 
NIR light stimulated photothermal therapy (PTT) with nanomaterials. The rectangular-pyr-
amidfrustum pole of the C-shaped magnet were placed on the tumour for 4 hr following 
injection of the purified MAG (4.0 mg/ml) intravenously. They found that all the tumours of 
mice in MAG + MF + NIR group completely disappeared. Suggesting that magnetic targeting 
could be used to increase the therapeutic efficiency of PPT with MAG after intravenous 
injection (Wang et al., 2018a). 
OVs are extremely immunogenic and stimulate both innate and/or adaptive immune responses, 
in addition to the hallmark of the direct oncolytic effect (Takasu et al., 2016). As a result, OV’s 
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are considered to be a cancer immunotherapy. Stimulating the immune system using HSV1716 
to destruct the tumour has been studied in a syngeneic murine intracranial melanoma model 
(Miller and Fraser, 2000). In addition to reducing tumour growth infiltration of CD4+ T cells 
and macrophages, as well as CD8+ T cells, B cells, NK cells and microglia cells into the 
tumour, were examined after viral infection. Specifically, CD4+ T cells and macrophages were 
increased after viral administration (Miller and Fraser, 2000). Furthermore, HSV (G207) 
therapy of mouse CT26 colon adenocarcinoma tumours inhibited the growth of contralateral 
tumours as well as a second challenge of tumour cells in immune-competent mice (Toda et al., 
1999). This study suggested that HSV increased mouse survival as a result of infiltrating 
cytotoxic T-cells.  
Therefore, we will study both the magnetic targeting potential of our MAG-OV complex as 
well as the virus's ability to induce anti-tumour effects in mammary tumours. A detailed 
investigation of the immune activity of our MAG-OV is essential due to the combination of 
using an OV and bacterial-derived MAG. As mentioned earlier, MAG have the potential to 
activate the immune system particularly if the bacterial derived proteins are not stripped from 
the MAG, so it is important to determine if this activates the immune system and if this could 
result in adverse effects. 
In addition to investigating the anti-tumour efficiency of MAG-OV, we will also determine 
whether MAG can protect OV from neutralizing Ab in an in vivo immunocompetent mouse 
model. We have used an immunocompetent mouse model whereby C57/BL6 mice were 
injected into the nipple with the luciferase labelled breast cancer cell line EO771-Luc. This cell 
line is a spontaneously developing medullary breast adenocarcinoma derived from C57BL/6 
mice (Sugiura and Stock, 1952). This is also a triple negative breast cancer (TNBC) cell line 
for the oestrogen, progesterone and human epidermal growth factor HER2 receptors, making 
it difficult to target therapeutically (Johnstone et al., 2015). Furthermore, this tumour model 
naturally metastasises to the lungs in C57BL/6 mice (Johnstone et al., 2015). As the cell line is 
luciferase labelled, bioluminescence imaging using the IVIS was used to monitor tumour 
growth and metastasis.  
The specific objectives of the study were to characterise the targeting of MAG-OV in vivo 




1. Tumour targeting and therapeutic efficacy of MAG-OV in the E0771 mammary 
carcinoma model. 
2. Stimulation of immune effector cells by MAG-OV. 
3. MAG-OV protection from neutralising antibodies. 
 
5.2 The antitumour efficacy of MAG-OV in the E0771 mammary carcinoma model 
5.2.1 In vivo study Design 
C57BL/6 female mice were purchased from Envigo at 6-8 weeks old and housed in the 
University of Sheffield Biological Services Unit and cared for according to the University of 
Sheffield code of ethics and Home Office regulations. All work was carried out under personal 
licence number is 1806F7C1E and Home office project licence PPL70/8670.  
Mice were injected into the nipple with 5x105 EO771-Luc cells, and monitored daily, and 
weighed every three days. Tumour volume was measured using callipers and also recorded 
every three days. Each group of mice included in this study consisted of n=6-9 mice/group 
because some of mice have not developed tumours. Once the tumours reached ~150-200mm3 
mice received the following treatments intravenously (i.v.), see (Figure 5.1) for a schematic of 
the study. 
1. Control: Mice were injected three times i.v. (0, 5, 10 days) with 100ul PBS. 
2. MAG: Mice were injected three times i.v. (0, 5, 10 days) with 100ul MAG (10ul MAG 
+ 90ul PBS).   
3. OV: These mice were injected three times i.v. (0, 5, 10 days) with 100ul HSV1716 
(10ul OV at 107 pfu + 90ul PBS). 
4. MAG-OV without magnet: Mice were injected three times i.v. (0, 5, 10 days) with 
100ul magnetised HSV1716 (12ul MAG-OV at 10⁷ pfu + 88ul PBS). 
5. MAG-OV+ magnet: Mice were injected three times i.v. (0, 5, 10 days) with 100ul 
magnetised HSV1716 (12ul MAG-OV at 10⁷ pfu + 88ul PBS) in the presence of an 
external permanent magnetic array secured above the tumour (0.7 T) for 30 min. 
Once the tumours reached ~1500mm3 mice were culled by cervical dislocation, and the organs 
and tumour were removed and stored in liquid nitrogen for post-mortem analysis. Of note, the 
magnet design, assembly and length of time placed above the tumour, were optimised by a 





Figure 5.1: Treatment scheme in C57BL/6 female mice with a mammary carcinoma. Mice were 
injected into the nipple with 5x105 EO771-Luc cells. Each group of mice included in this study consisted 
of n=6-9 mice/group. Once the tumours reached ~150-200mm3 mice were injected three times i.v. (0, 
5, 10 days) with 100ul of PBS, MAG, OV and with and without MAG-OV. Once the tumours reached 
~1500mm3 mice were culled by cervical dislocation, and the organs and tumour were removed and 
stored in liquid nitrogen for post-mortem analysis. 
5.2.2 Magnetic guidance of MAG-OV shrinks primary mammary tumours and 
promotes survival 
In this in vivo experiment, we used an external magnet to guide MAG-OV from circulation into 
primary mammary tumours. Mice were intravenously treated with three doses of MAG, OV, 
MAG-OV without magnet (MAG-OV WM), MAG-OV with magnet (MAG-OV+M) or PBS 
as a control and monitored over time. There was no change in body weight in all treatment 
groups compared to the PBS treated mice in the 2 weeks post therapy (Figure 5.2A). However, 
a significant change in average tumour volume was observed in mice receiving MAG-OV with 
magnet compared to the mice receiving PBS on day 12 after treatment (p = 0.0002). In addition, 
a significant change in average tumour volume was observed in mice receiving OV compared 
to the mice receiving PBS on day 12 after treatment (p = 0.0036). While no significant change 
was observed in mice receiving MAG or MAG-OV without magnet compared to the mice 
receiving PBS. In theory, the MAG-OV without magnet should be the same as OV- not seeing 
any effect suggests that either the MAG are not letting the virus have its effect or without the 
magnetic guidance perhaps the two are separating and not enough is getting to the tumour. This 
requires further investigation. In addition, the average tumour volume was significantly smaller 
in the MAG-OV+M -treated group than in the OV group at day 15 after treatment (p = 0.0062), 
(Figure 5.2B). This indicates that magnetic targeting is improving the efficacy of this 
treatment. Furthermore, Figure 5.2C shows most of the mice in MAG-OV+M group resulted 
in a significant increase in survival compared to the others groups. For the bioluminescence 
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imaging (BLI), mice were injected with 100 µL of d-Luciferin subcutaneously for 10 Min. 
Then, a non-invasive in vivo imaging system (IVIS 200 System, Xenogen) was used to image 
mice. Based on the detection and quantitation of the photons produced by the oxidation of 
luciferin by luciferase enzymes. Bioluminescence imaging of mice receiving MAG-OV+M on 
day 12 of treatment showed this marked reduction in the size of the primary tumour, (Figure 
5.2D). For all the following experiments and the rest of this chapter MAG-OV+M (in the 
presence of the magnetic field) will be referred to as MAG-OV. 
                                                                                                                           
Figure 5.2: Magnetic targeting of MAG-OV shrinks primary mammary tumours. EO771 tumour-
bearing mice were monitored daily for tumour growth with calipers and weighed every three days. A. 
No change in body weight was recorded for treated animals compared to untreated mice for up to 2 
weeks post-therapy. B. A significant change in average tumour volume was observed in mice receiving 
MAG-OV in the presence of a magnet (red line: MAG-OV+M) compared to the mice receiving PBS 
on day 12 after treatment. C. Moreover, MAG-OV+M treated mice demonstrated a significant increase 
in survival compared to the others groups. D. For the BLI, mice were injected with 100 µL of d-
Luciferin subcutaneously for 10 Min. Then, a non-invasive in vivo imaging system (IVIS 200 System, 
Xenogen) was used to image mice. Based on the detection and quantitation of the photons produced by 
the oxidation of luciferin by luciferase enzymes. BLI of mice receiving OV therapy or MAG-OV+M 
on day 12 of treatment showed this marked reduction of the primary tumour. Of note, data are the Mean 
± SEM (n=6-9) and statistical analysis was assessed using one-way Anova test with multiple 




5.2.3 Increased MAG-OV in primary breast tumours following magnetic guidance 
As shown above, MAG-OV+M was the most effective therapy for reducing tumour volume. 
Next, we wanted to confirm the presence of the HSV1716 within the tumours. This was 
performed using two approaches flow cytometry and immunofluorescence and at two 
timepoints (3 days and at end of the experiment). For the former, cells were analysed on a flow 
cytometer to detect the HSV1716-GFP. Tumour chunks were dissociated as described in 
Section 2.2.23.4. Samples were re-suspended in 300ul of FACS buffer (1%FBS/PBS solution) 
and transferred to flow cytometry tubes. A cell viability dye was added to all the samples to 
gate out debris and dead cells. Flow cytometry data was analysed using the BD LSR II flow 
cytometer and GFP expression was measured in FL-1 (488nm). A significant increase in the 
percentage of HSV1716-GFP was observed in MAG-OV compared to the PBS group after 3 
days of infection (MAG-OV 6% vs PBS 0%) (Figure 5.3A). Moreover, a significant increase 
in the percentage of HSV1716-GFP was observed in MAG-OV compared to all other groups 
at the end of the experiment (MAG-OV 13% vs. PBS 0 %) as shown in Figure 5.3B. One of 
the difficulties with the flow cytometry experiment is that the samples contained so much 
debris and dead cells that the data may not be truly representative. It is not clear whether this 
was due to how the samples were processed or because of the necrotic nature of the mammary 
tumours. Therefore, to further confirm the presence of HSV1716-GFP, immunofluorescent 
staining of tumours was performed in sections that were frozen immediately following 
removal. Tumours were first embedded in OCT before freezing and sectioned using a cryostat 
(14μm thick sections). After this, cells were fixed and stained with a sheep antibody to detect 
HSV1716 (Conner et al., 2005). Moreover, 50ng/ml DAPI solution was added for 2 min to 
define the nucleus. Coverslips were mounted onto the microscope slides and a Nikon A1 
confocal microscope was used to take images. HSV1716 positive cells were counted by using 
Fiji (Fiji Is Just ImageJ), as previously published (Schindelin et al., 2012). The number of 
nuclei per FOV needed to be assessed, so cell counts could be normalised to the total number 
of cells in the FOV. As shown in Figure 5.3C, MAG-OV resulted in the greatest expression of 
HSV1716 compared to OV alone (MAG-OV 70.2% vs. OV 14.8% P= 0.0027). No virus was 





Figure 5.3: Increased systemic targeting of MAG-OV to mammary tumours in the presence of an 
external magnetic field. Dissociated tumour chunks were analysed on a flow cytometer to detect 
HSV1716-GFP. GFP expression was measured in FL-1 (488nm) on a LSRII flow cytometer. A. A 
significant increase in percentage of HSV1716-GFP was observed in MAG-OV compared to the all 
other groups after 3 days of infection. B. The presence of the HSV1716 was also measurable at the end 
of the experiment (day 23). C. Immunofluorescence staining of tumours was also used to detect the 
HSV1716-GFP. MAG-OV was able to infect EO771 cells significantly more compared to the OV alone 
and the other groups. A Nikon A1 confocal microscope was used to take images. The density of 
HSV1716 was calculated by dividing the total number of HSV1716 positive cells by the number of 
DAPI+ events in each specified region and multiplying by 100. Of note, data are the Mean ± SEM (n=5) 
and statistical analysis was assessed using the one-way Anova test with multiple comparisons. *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001. 
5.2.4 Increased MAG-OV viral replication following magnetic guidance 
Expression of viral replication genes was determined by qPCR in mammary tumour removed 
from mice post-treatment. RNA was extracted after tumour digestion and used to synthesise 
cDNA. Viral replication genes ICP0 – immediate early, ICP8 – early and gB – late genes (Singh 
et al., 2012), were evaluated. Virus successfully replicated within the tumour 
microenvironment, as shown by the significant increase in all the viral mRNA genes (ICP0, 
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ICP8 and gB) in the MAG-OV treated mice compared to the OV and control groups (Figure 
5.4). This suggests that magnetic guidance enabled virus to replicate more efficiently than the 
other treatment groups. mRNA expression of ICP8 was also significant with OV groups 
compared to the control (Figure 5.4).  Suggesting that OV was able to complete their life cycle 
within EO771 tumour cells.         
                       
Figure 5.4: Increased viral replication of MAG-OV in mammary tumours in the presence of an 
external magnetic field. RNA was isolated from mammary tumours post-treatment and analysed using 
qPCR. Virus successfully replicated within the cells, as shown by the significant increase in viral mRNA 
expression of ICP0, ICP8 and gB in the MAG-OV treated mice when compared to the OV and control 
groups. The expression levels were calculated relative to the untreated cells using the 2-ΔΔCT method 
after the data was normalised to the housekeeping gene, GAPDH. Of note, data are the Mean ± SEM 
(n=3) and statistical analysis was assessed using the one-way Anova test with multiple comparisons. 
*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
5.2.5 MAG-OV induces anti-tumour properties following magnetic guidance  
The anti-tumour effect of MAG-OV was detected by measuring a number of changes within 
tumour microenvironment including tumour vascularity, necrosis, the expression of 
calreticulin (CRT) and pulmonary metastasis. Targeting the tumour vasculature using OVs is 
an attractive strategy in cancer therapy. OV including vaccinia and vesicular stomatitis virus 
can intrinsically target tumour vasculature leading to vessel disruption (Toro Bejarano and 
Merchan, 2015). Tumour vascularity post-treatment was assessed by calculating the number 
of CD31+ve cells per field of view (FOV) using immunofluorescent staining. CD31 is a 
standard marker of blood vessels and used to assess vascularity in tumours (Muthana et al., 
2015b). MAG-OV treated tumours showed a trend of being less vascularised than the other 




Necrosis is a type of cell death caused by external factors such as viruses (Yu et al., 2015). 
Necrosis was assessed by calculating the percentage of necrotic areas in the whole tumour 
section by Haematoxylin and Eosin staining. As shown in Figure 5.5B, tumours treated with 
MAG-OV in the presence of a magnet were significantly more necrotic than those treated with 
PBS (MAG-OV 61.3% vs PBS 21%). While tumours treated with naked OV or MAG showed 
no significant change compared to those treated with PBS (OV 43.2% and MAG 18.3% vs. 
PBS 21%). This was also confirmed by flow cytometric analysis of the percentage of live cells, 
where tumours treated with MAG-OV were significantly less than those treated with PBS, 
(Figure 5.5C). 
Furthermore, CRT is a DAMP that is normally located in the lumen of the endoplasmic 
reticulum. Immunogenic apoptosis leads to translocation of CRT to the surface of dying cells 
as an eat-me indicator for professional phagocytes (Obeid et al., 2006, Gold et al., 2010, Voll 
et al., 1997). The expression of calreticulin was measured by using immunofluorescence 
staining. Figure 5.5D shows that the number of calreticulin positive cells (and Dapi+ve) 
increased significantly in tumours treated with MAG-OV than those treated with PBS or OV. 
In C57BL/6 mice, EO771 cells implanted into the mammary fat pads metastasise to the lungs 
(Johnstone et al., 2015). Therefore, pulmonary metastasis was measured using Haematoxylin 
and Eosin staining. Lungs were prepared as described in Section 2.2.23.6. Pulmonary 
metastases were identified by microscopy and could be seen as tumour nodules greater than 
10 mm in diameter (Kaseda et al., 2016). Many metastases were detected in the lungs of mice 
injected with PBS or MAG alone at day 12 of treatment because of the large size of their 
primary tumours. However, the number of pulmonary metastasis was significantly reduced in 
mice that received MAG-OV compared to those treated with PBS (Figure 5.5E). 
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Figure 5.5: MAG-OV increases tumour necrosis and immunogenic cell death. A. 
Immunofluorescence staining of CD31+ve cells per Field of view (FOV) showed MAG-OV treated 
tumours were less vascularised than the PBS-treated tumours (scale bar = 40 µm). However, this change 
was not significant. B. Haematoxylin and eosin staining (scale bar = 200 µm) indicated that tumours 
treated with MAG-OV were significantly more necrotic than those treated with PBS. C. This was also 
confirmed by flow cytometry analysis of live cells using the Zombie UV viability dye, where tumours 
treated with MAG-OV were significantly less viable than those treated with PBS. D. 
Immunofluorescence staining analysis of CRT showed that the number of CRT+ve cells (& Dapi+ve) 
increased significantly in tumours treated with MAG-OV than those treated with PBS or OV lone (scale 
bar = 40 µm), the density of CRT+ve cells was calculated by dividing the total number of CRT+ve cells 
by the number of DAPI+ events in each specified region and multiplying by 100. E. The number of 
pulmonary metastasis was significantly reduced in mice that received MAG-OV compared to those 
treated with PBS (scale bar = 200 µm). Of note, data are the mean ± SEM (n=3-5) and statistical analysis 




5.2.6 MAG-OV treated tumours induce anti-tumour immunity: NanoString analysis   
Prior studies have revealed that, during oncolytic virotherapy, cellular immune mechanisms 
act jointly with virally mediated tumour damage (Thomas and Fraser, 2003, Miller and Fraser, 
2003, Miller and Fraser, 2000). Therefore, to define the effect of MAG-OV targeting in the 
presence of a magnetic field on the immune pathways, RNA was isolated from tumours of 
treated mice (Section 2.2.17.1). This was analysed using the NanoString murine pan-cancer 
immune profiling panel, which consist of 750 immune related genes and 20 housekeeping 
genes. This work was carried out at the John van Geest Cancer Research Centre in College of 
Science and Technology at Nottingham Trent University in collaboration with Professor 
Graham Pockley and Jayakumar Vadakekolathu. All the RNA samples were quality controlled 
using Nanodrop 8000 and 150ng of total RNA from each sample was used for setting up the 
NanoString analysis. All the data processing was carried out by Mr Jayakumar Vadakekolathu 
in Nottingham. Figure 5.6 shows volcano plots of gene expression in MAG, OV or MAG-OV 
treated tumours compared to the PBS treated group. Interestingly, in the MAG only treated 
group (MAG) >27 genes were up-regulated (e.g. Ctsw, Cmah, C1s1) and 10 genes 
downregulated (e.g. Trp53, Cxcl12). Whilst, the MAG only group did not induce any 
therapeutic changes, this change in gene expression highlights that some consideration should 
be given when using MAG and this will be discussed later.  As expected, the OV treated group 
resulted in up regulation of >35 genes compared to the PBS treated group. In the MAG-OV 
treated tumours, genes related to innate and adaptive immune responses (e.g. Cxcl2, Thbs1, 
Ifitm1, Cxcr2, Ccl3, Cd14, Ccr1, Icos and Clu), T-cell function (CTL-A4, Ccl3, Xcl1, Icos), 
NK Cell Functions (Ccl3), Macrophage Functions (Thbs1), Dendritic Cell Functions (Ccr1), 
Interferon (Runx3) as well as apoptosis (Gzmb, Osm, Gzma, Clu and Runx3) were 
differentially upregulated. These genes are outlined in Table 5.1. For simplicity the table only 
focuses on the MAG-OV vs. PBS treatment groups.  
130 
 
                                                    
                                                      
                                                   
Figure 5.6: Volcano plots show MAG-OV increases expression of genes related to an immune 
response.  To define the effect of MAG-OV on genes related to immunity, RNA was isolated from 
tumours and analysed using the NanoString murine pan-cancer immune profiling panel.  Volcano plots 
show genes that were up regulated (+) or downregulated (-). The volcano plots show gene expression 









Table 5.1: Top 20 genes differentially regulated in MAG-OV treated tumours. Genes related to 
innate and adaptive immune responses (Cxcl2, Thbs1, Ifitm1, Cxcr2, Ccl3, Cd14, Ccr1, Icos and Clu), 
T-cell function (Ctla4, Ccl3, Xcl1, Icos), NK Cell Functions (Ccl3), Macrophage Functions (Thbs1) as 
well as apoptosis (Gzmb, Osm, Gzma, Clu and Runx3) are indicated (n=3) with fold change in 
expression over the control (PBS) and the pathways or gene sets. Data was processed and analysed 
using nSolver Analysis Software, using the Advanced Analysis module. 










1.85 Adaptive, Cell Cycle, Inflammation, Macrophage Functions 
Ifitm1-
mRNA 
2.27 CD molecules, Innate, Interferon 
Ccl22-
mRNA 
2.24 Chemokines & Receptors, Cytokines & Receptors, Humoral, Inflammation 
Cxcr2-
mRNA 




1.95 CD molecules 
Fcgr3-
mRNA 
1.55 Antigen Processing, CD molecules, MHC, Transporter Functions 
Gzmb-
mRNA 
2.02 Apoptosis, T-Cell Functions 
Ctla4-
mRNA 
2.51 B-Cell Functions, CD molecules, T-Cell Functions 
Osm-
mRNA 
3.54 Apoptosis, Cytokines & Receptors 
Ccl3-
mRNA 
2.44 Adaptive, Chemokines & Receptors, Cytokines & Receptors, Humoral, Inflammation, NK Cell 
Functions, T-Cell Functions, Transporter Functions 
Cd14-
mRNA 




-0.997 Adhesion, CD molecules 
Ppbp-
mRNA 






1.87 Adaptive, CD molecules, Chemokines & Receptors, Cytokines & Receptors, Dendritic Cell 
Functions, Inflammation, Innate, Leukocyte Functions, Transporter Functions 
Xcl1-
mRNA 
3.86 Chemokines & Receptors, Cytokines & Receptors, Inflammation, Innate, T-Cell Functions 
Icos-
mRNA 
1.45 CD molecules, T-Cell Functions 
Clu-
mRNA 




2.32 Apoptosis, Cell Cycle, Interferon 
 
Next, we carried out analysis of the different tumour infiltrating immune cells. A heat map 
shows infiltrating immune cells in PBS, MAG, OV or MAG-OV treated tumours. In the heat 
maps orange indicates high cell expression and blue indicates low cell expression (Figure 5.7). 
Cell type scoring and pathway scoring was performed using nSolver advance analysis module 
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V. 2.0.115. This software compares all the different immune cell types and creates scores 
relative to each other. The majority of the immune related cell types in the panel were 
upregulated in MAG-OV treated tumours. Figure 5.7 shows that the T cells (cytotoxic CD8), 
NK cells, neutrophils and macrophages increased significantly in tumours treated with MAG-
OV than those treated with PBS. T cells, CD8 T cells and Treg cells were also increased in 
tumours treated with MAG-OV than those treated with PBS.  However, this change was not 
significant. On the other hand, CD4 vs. T cells were downregulated in tumours treated with 
MAG-OV than those treated with PBS. 
                                                                   
Figure 5.7: MAG-OV upregulates tumour infiltrating immune cells. nSolver 4.0 Analysis Software 
was used to prepare the heat map to show tumour infiltrating immune cells in PBS, MAG, OV or MAG-
OV treated tumours. Orange indicates high cell expression and blue indicates low cell expression. The 
majority of the immune related genes in the panel were upregulated in MAG-OV treated tumours. Of 
note, data are the Mean ± SEM (n=3) and statistical analysis was assessed using the one-way Anova 
test with multiple comparisons.  *p<0.05; **p<0.01; ***p<0.001. 
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Furthermore, we carried out an immune pathway analysis of the genes in the PBS, MAG, OV 
or MAG-OV treated tumours. Notably, we detected a significant increase in expression of a 
range of immune-pathway genes in MAG-OV treated tumours than those treated with PBS 
(Figure 5.8).  These pathways include innate and adaptive immunity, T-cell function, NK cell 
function, chemokines and receptors, cytokines and receptors, inflammation, TLR, leukocyte 
function, macrophage function pathway, transporter function, senescence y, dendritic cell 
function, basic cell function, cell cycle, apoptosis and pathogen response, many of which have 
previously been linked to immune activation by OVs (Miller and Fraser, 2003, Thomas and 
Fraser, 2003, Miller and Fraser, 2000). 
 
Figure 5.8: Magnetic targeting of MAG-OV upregulated the expression of a range of immune-
pathway genes. A significant increase in expression of a range of immune-pathway related genes in 
MAG-OV treated tumours than those treated with PBS including adaptive innate pathway, T-cell 
function pathway, NK cell function pathway, chemokine and receptor pathway, cytokine and receptor 
pathway, inflammation pathway, TLR pathway, leukocyte function pathway, macrophage function 
pathway, transporter function pathway, senescence pathway, dendritic cell function pathway, basic cell 
function pathway, cell cycle pathway, apoptosis pathway and pathogen response pathway. Of note, data 
are the Mean ± SEM (n=3) and statistical analysis was assessed using the one-way Anova test with 
multiple comparisons. *p<0.05; **p<0.01; ***p<0.001. 
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5.2.7 Magnetic targeting of MAG-OV increased immune cell infiltrates – Flow cytometry 
To confirm the data of the NanoString technology, flow cytometry was used to measure the   
recruitment of immune cells into tumours. Tumour chunks were dissociated as described in 
Section 2.2.23.4. Cells were collected and flow cytometry was used to evaluate the percentage 
of CD3, CD4, CD8, NK1.1, LY6G and CD11B immune cell markers. The percentage of T 
cells (CD3+), cytotoxic T cells (CD3+/CD8+), Neutrophils (CD11B+/LY6G+) and NK cells 
(NK1.1) were significantly increased in tumours treated with MAG-OV compared to those 
treated with PBS (Figure 5.9). In contrast, the percentage of T helper cells (CD3+/CD4+) 
decreased in these treated tumours. However, this change was not significant (Figure 5.9). The 
receptor expression of immune cell surface markers, as measured by FACS, mirrors the gene 
expression data measured by NanoString.  
         
Figure 5.9: Magnetic targeting of MAG-OV upregulated infiltration of immune cells into 
tumours. Dissociated tumour chunks were collected and flow cytometry was used to evaluate the 
percentage of CD3, CD4, CD8, NK1.1, LY6G and CD11B. The percentage of CD3+, CD3+/CD8+, 
CD11B+/LY6G+ and NK1.1 significantly increased in tumours treated with MAG-OV compared to 
those treated with PBS. In contrast, the percentage of CD3+/CD4+ decreased in these treated tumours. 
A cell viability dye (Zombie UV dye) was included to gate out any cellular debris. Data was run on the 
LSRII and analysed using FlowJo. Data are the Mean ± SEM (n=5 mice per group) and statistical 
analysis was assessed using the one-way Anova test with multiple comparisons. *p<0.05. 
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5.2.8 Magnetic targeting of MAG-OV increased immune cell infiltrates: Immuno-
fluorescence 
Immunofluorescent staining was also used to evaluate the number of CD3, CD8, CD4, F4/80 
and NK1.1 expression within the tumours. Tumours were first embedded in optimal cutting 
temperature (OCT) before freezing, sectioned using the cryostat (14μm thick sections), fixed 
with ice cold acetone for 10 min at RT and then rehydrated with PBST for 1 min. Sections were 
then stained with anti-CD3, CD4, CD8, F4/80, NK1.1 and (4',6-diamidino-2-phenylindole) 
(DAPI) and analysed using a confocal laser-scanning microscope. The number of CD3+ 
(%Dapi+), CD3+/CD8+ (%Dapi+) and CD3+/CD4+ (%Dapi+) were significantly increased in 
tumours treated with MAG-OV compared to those treated with PBS or OV only, (Figure 
5.10A). Moreover, F4/80+ (%Dapi+) and NK1.1 (%Dapi+) were also significantly increased 
in tumours treated with MAG-OV compared to those treated with PBS or naked OV (Figure 
5.10B&C). Of note, in Figure 5.10B, F4/80 was co-labelled with the endothelial cell marker 
‘CD31’. This showed that macrophages within the TME were located throughout the tumour 
with some around the vascular areas in mice treated with virus, whereas in the control mice, 
most macrophages were in the perivascular areas. This is an interesting topic that warrants 
further investigation, particularly given that perivascular macrophages are thought to have a 













Figure 5.10: Magnetic targeting of MAG-OV increases antitumour immunity. Tumour sections 
were stained with anti-CD3, anti-CD4, anti-CD8, anti-F4/80, anti-NK1.1 and DAPI (4',6-diamidino-2-
phenylindole) and then analysed under a confocal laser-scanning microscope. Three images from two 
slides (6 total) from each mouse. The density of positive cells was calculated by dividing the total 
number of postitive cells by the number of DAPI+ events in each specified region and multiplying by 
100. A. CD3+ (%Dapi+), CD3+/CD8+ (%Dapi+), CD3+/CD4+ (%Dapi+), B. F4/80+ (%Dapi+) and 
CD31+ C. NK1.1 (%Dapi+) were significantly increased in tumours treated with MAG-OV compared 
to those treated with PBS or naked OV. Of note, data are the Mean ± SEM (n=5) and statistical analysis 







5.2.9 Magnetic targeting of MAG-OV increases T cell activation  
Given that CD8+ T cells were recruited into tumours following MAG-OV treatment next the 
activation status of these T cells was determined. IFN-γ production by immune cells is 
considered the hallmark of an active immune response and IFN-γ is released by activated CD8+ 
T cells (Showalter et al., 2017). This is also linked to Programmed Death 1 (PD1) expression 
by activated T cells (Westin et al., 2014). Therefore, T cell activation was assessed by 
measuring the number of CD8+/IFN-γ+ (%Dapi+) and CD8+/PD1+ (%Dapi+) expressing cells 
by immunofluorescence staining. Sections were co-stained with antibodies to anti-CD8, IFN-
γ, PD1 and DAPI and then analysed under a confocal laser-scanning microscope.  As shown in 
Figure 5.11A-C the number of CD8+/IFN-γ+ (%Dapi+) and CD8+/PD1+ (%Dapi+) were 
significantly increased in tumours treated with MAG-OV compared to those treated with PBS 
or naked OV (CD8+/IFN-γ+ (%Dapi+) P= 0.0008, CD8+/PD1+ (%Dapi+) P= 0.0002). Whilst 
the T cells were recruited and activated, the increased expression of PD1 suggests that the cells 
may encounter checkpoint suppression, as we know these tumours express PD-L1 (Crosby et 
al., 2018). This could be why we see tumour re-growth after the 3rd treatment and our therapy 








Figure 5.11: MAG-OV activated T cells to express interferon and PD1. Sections were stained with 
antibodies to anti-CD8, IFN-γ, PD1, and (4', 6-diamidino-2-phenylindole) (DAPI) and then analysed 
under a confocal laser-scanning microscope. The number of A. CD8+ /IFN-γ+ (%Dapi+) and B. 
CD8+/PD1+ (%Dapi+) were significantly increased in tumours treated with MAG-OV compared to 
those treated with PBS or naked OV. The density of positive cells was calculated by dividing the total 
number of positive cells by the number of DAPI+ events in each specified region and multiplying by 
100. Of note, Data are the Mean ± SEM (n=5) and statistical analysis was assessed using the one-way 
Anova test with multiple comparisons. Scale bar= 40µm and a magnet was used with MAG-OV. 
*p<0.05; **p<0.01; ***p<0.001. 
 
5.3 Magnetising HSV1716 protect the virus from neutralisation 
5.3.1 In vivo study design 
Next, we wanted to determine if MAG served to protect the OV from neutralising antibodies 
as was revealed for the in vitro neutralisation experiments in Section 4.2.6. Systemic delivery 
of OV results in low intra-tumoural titres due to pre-existing immunity that has been 
established because of prior exposure to the virus, previous immunisation, or prior oncolytic 
viral therapy (Ferguson et al., 2012). Therefore, in vivo neutralisation experiments were 
performed to determine if MAG could protect OV from neutralising Ab (NAb) in vivo. Sheep 
anti-HSV-1 antiserum was used to neutralise the OV. This antibody was kindly prepared by 
Virttu Biologics as described in section 2.2.19. Mice were injected into the nipple with 5x105 
EO771 cells as described in section 2.2.23.1. Once the tumours reached ~150-200mm3 mice 
received the following intravenously: 
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1. Control: Mice were injected three times i.v. (0, 5, 10 days) with vehicle (PBS) (in a 
volume no more than 0.2 ml). 
2. OV+ NAb (see section 2.2.19): Mice were injected three times i.v. (0, 5, 10 days) with 
100ul HSV1716 (10ul OV at 106 pfu + NAb + 90ul PBS). 
3. MAG-OV+ NAb (see section 2.2.19) + magnet: Mice were injected three times i.v. 
(0, 5, 10 days) with 100ul magnetised HSV1716 (12ul MAG-OV at 106 pfu + NAb + 
88ul PBS) in the presence of an external magnetic field for 30 min. 
The group included in this study consisted of n=3 mice/group. Once the tumours reached 
~1500mm3 mice were culled by cervical dislocation, and the organs and tumour were removed 
and stored in liquid nitrogen for post-mortem analysis. 
5.3.2 MAG-OV protects HSV1716 from neutralising antibodies 
To see if the virus reached the tumour and infected cells within the tumour, GFP expression in 
dissociated tumours was assessed by flow cytometry. As shown in Figure 5.12A, tumours 
treated with MAG-OV+NAb expressed more GFP after three days of infection compared to 
tumours treated with OV+NAb (MAG-OV+NAb 5% and OV+NAb 2%). This decrease in GFP 
expression in tumours treated with OV+NAb is most likely because of OV neutralisation. 
Moreover, the average tumour volume was significantly smaller in the MAG-OV+NAb with 
magnet -treated group than in the OV+NAb or PBS (P= 0.0191) group at day 12 after treatment 
(Figure 5.12B). Furthermore, Figure 5.12C shows all mice in MAG-OV+NAb treated group 
resulted in an increase in survival compared to the OV+NAb or PBS group. From Figure 5.12, 
it is clear that the OV is not able to have any therapeutic effect in the presence of the NAb. 
Together this data suggests that MAG have the potential to protect HSV1716 from neutralising 




Figure 5.12: MAG-OV is protected from neutralising antibodies. In vivo neutralisation experiments 
were performed to determine if MAG could protect OV from NAb. Sheep anti-HSV-1 antiserum was 
used to neutralise the OV. 1 x 107 PFU of OV or MAG-OV were incubated with 100-fold dilution of 
antiserum for 18 h at 4°C prior to the experiment. Mice implanted with EO771 cells were monitored 
daily and weighed every three days after treatment. Tumour volume was measured using calipers and 
also recorded every three days. A. Tumours treated with MAG-OV+NAb expressed significantly more 
GFP after three days of infection compared to tumours treated with OV+NAb (p=0.0260) as assessed 
by flow cytometry on an LSRII. B. The average tumour volume was significantly smaller in the MAG-
OV+NAb treated group than in the OV+NAb or PBS group at day 12 after treatment. C. Mice in the 
MAG-OV+NAb treated group responded to the treatment and resulted in an increase in survival 
compared to the OV+NAb or PBS group. Of note, data are the Mean ± SEM (n=3 mice/group) and 
statistical analysis was assessed using one-way Anova test with multiple comparisons for tumour 
volume and survival curve for mice survival. *p<0.05; **p<0.01.  
5.4 Discussion  
The main goal of OV treatment would be to selectively target and infect tumour cells whilst 
sparing healthy tissues and organs. Therefore, guiding and confining the OV into the tumours 
in circulation is important. A previous study showed that oncolytic adenovirus Ad520 co-
incubated with MNPs (Ad -SO-Mag2) was able to inhibit human pancreatic tumour (181RDB-
fLuc) growth in mice more than naked Ad in both short (3 days) and long-term (25 days) 
treatments in the presence of NeoDelta magnets (NE155, IBS Magnet, Berlin, Germany) for 
30 min immediately after intratumoural injection (Tresilwised et al., 2012a).  The same group 
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also reported that intratumoural injection of Ad in combination with the Core/shell type iron 
oxide MNPs (PEIMag2) displayed a stronger oncolytic effect than naked adenovirus in a 
murine xenograft model of daunorubicin-resistant human pancreatic carcinoma cells 
(Tresilwised et al., 2010a). Together these studies support our study and suggest that OV can 
be magnetised (all studies including ours relied on electrostatic interactions) and can be guided 
to a tumour using a magnetic field.  Of note, all the above studies relied on direct injection of 
the magnetised viruses into the tumour and the presence of an external magnet really only 
served for retention of the therapy within the tumour rather than its delivery. Whereas in this 
study, MAG associated with HSV1716 has been used to target MAG-OV from circulation to 
mammary tumours in mice. MAG-OV was injected intravenously in the presence of an external 
permanent magnetic secured above the tumour (0.7 T) for 30 min. The magnet design, 
assembly and length of time placed above the tumour, were optimised by a post-doctoral 
research fellow in the group (Dr Priya Patel). Tumour targeting and therapeutic efficacy of 
MAG-OV as well as stimulation of immune effector cells by this complex and MAG-OV 
protection from neutralising antibodies have been studied. To our knowledge, this is the first 
study to report delivery of magnetised OV from circulation into tumours using bacterially-
derived MAG. 
5.4.1 Magnetic guidance of MAG-OV shrinks primary mammary tumours and promotes 
survival 
The efficiency of magnetically guiding MAG-OV into mammary tumours in mice was 
demonstrated in the above results (Figure 5.2) where a significant change in average tumour 
volume, increased mouse survival and a reduction in pulmonary metastasis was observed 
compared to the others treatment groups. This therapy was more effective than when the OV 
was administered intravenously. However, whilst the tumour growth was retarded once the 
administration of HSV1716 ceased, the tumours started to regrow. Muthana et al., 
demonstrated that prostate tumour-bearing mice received HSV1716-shielded by macrophages 
(monocyte-derived macrophage (MDM) + OV) resulted in marked reduction of the primary 
tumour than those that received naked OV in the presence of a magnetic field, (Muthana et al., 
2015b). In this study, they did not see the same level of tumour regrowth, however they used 
an immunocompromised mouse model where the adaptive immune system was not present and 
therefore may not have contributed to clearance of the virus.  
We have shown that MAG-OV magnetic guidance into tumours is effective but does not 
completely eradicate tumour growth once the therapy has ceased. This means that the therapy 
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is not so effective alone and should be combined with other cancer treatments or that the virus 
would need to be given continuously. Others have also reported that intatumoural injection of 
recombinant non-pathogenic poliovirus (PVSRIPO) into B6-ovalbumin (OVA) melanoma 
model wasn’t able to completely eradicate tumour growth once the therapy ceased (Brown et 
al., 2017). It would be interesting to try prolonged use of our complex, as there are studies, 
which says that actually the presence of NAb is not a problem.  For example, Melcher have 
shown that piggybacking of the dsRNA, non-genetically modified OV reovirus on the 
monocytes could overcome neutralisation and provide access tumours in patients in the brain 
or liver following systemic injection (Melcher, 2019).  Perhaps we could target monocytes by 
coating our MNPs with a ligand that binds to monocytes in circulation. Already in our 
laboratory this is being attempted with agents like CCL2. CCL2 bind to the CCR2 receptor on 
monocytes and the CCL2/CCR2 combination is important for monocyte recruitment into 
tumours (Lim et al., 2016). In addition, it would be interesting to combine our complex with 
another cancer treatment. As prior studies have shown that combining the oncolytic 
Rhabdovirus Maraba-MG1 with Paclitaxel, one of the most common chemotherapeutics used 
to treat patients with breast cancer, could  improve efficacy in all of the breast cancer models 
they tested, including EMT6, 4T1 and E0771 (Bourgeois-Daigneault et al., 2016). 
We already know HSV1716 increases the mean survival time of mice and reduces the burden 
of 4T1 tumour metastasis in the lungs (Thomas and Fraser, 2003). However, this is the first 
time we have seen efficacy of HSV1716 in the EO771 model of cancer. From our observation, 
the virus on its own is not particularly effective compared to the untreated group. However, by 
using an external magnetic field this improves the anti-tumour efficacy of the virus most likely 
because the virus is reaching the tumour in greater numbers. In the 4T1 study, 5.4 × 10⁵ pfu of 
HSV1716 was injected intratumourly in two or three places with a total volume of 20 μl, while 
in our study 100ul of HSV1716 at 107 pfu was injected into circulation. It is true we have given 
a much higher dose in our study but as a result we have avoided direct tumour injection, which 
comes with significant risk and is not always possible in the metastatic setting. Furthermore, 
studies from our lab have shown that different strains of mice respond differently to HSV1716. 
This research was carried out by a postdoctoral researcher in the group who noticed that Balb/C 
mice (used for the 4T1 model) were unable to tolerate the same dose of HSV1716 (1x107 pfu/ml) 
as the C57BL/6 mice used in this study. Moreover, the FVB strain whilst more tolerant than 
Balb/C mice still required a lower dose than the C57BL/6 strain (Table 5.2). This difference 
in maximum tolerated dose could be attributed to the strains host immune system as C57BL/6 
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mice display a classically Th2 type immune response, whereas Balb/c and FVB mice naturally 
display Th1 type immunity. Th1 immunity is important for the removal of intracellular 
pathogens, whereas Th2 immunity plays a role in the clearance of infectious parasites. Such 
characteristics may explain the differences in dose tolerability in response to HSV1716. 
Hiroyuki and colleagues showed the effects of different immune responses in C57BL/6 and 
Balb/c mice, in response to sepsis. The results indicated that due to the naturally impaired 
macrophage activity in Balb/c mice, tolerability to viral infection was lower than C57BL/6 
mice, this led to the activation of systemic inflammation to viral antigens and the mice 
experienced multiple organ failure and shock, which could explain data the generated in Table 
5.2 (Hiroyuki et al., 2004). It is interesting that different mouse models respond differently to 
HSV1716 and perhaps patients will also respond differently and this should definitely be 
considered in future clinical application of oncolytic virtotherapy. As we did not see any 
difference with MAG-OV without magnet and OV alone and chose to assess MAG-OV with 




















Table 5.2: Different mouse stains respond differently to HSV1716. Dr Faith Howard carried out 
this research.   
 
5.4.2 Increased MAG-OV targeting in primary breast tumours following magnetic 
guidance          
We found a significant increase in the percentage of HSV1716-GFP in the MAG-OV with 
magnet treatment group compared to the all other groups after day 3 of treatment and also at 
the end of the experiment (day 23) using flow cytometry and immunofluorescence staining 
(Figure 5.3A&B). Suggesting that MAG under the guidance of the external magnet could 
deliver the virus to the tumour. In our study, we used a magnet (0.7 T) to target the mammary 
tumour and whilst this is a relatively weak magnetic field, the magnetic was placed directly 
above the tumour due to its superficial location. A stronger magnet may have improved the 
targeting. However, these are often heavier compared to the size of the mouse and most studies 
reported in mice use weaker magnets. For example, Chao et al. established that growing  
tumours could be shrunk significantly in mice with hepatocellular carcinomas using 
doxorubicin-coupled MNPs and an external magnetic devices of 0.5 T  applied on the tumour 
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(for 2 hrs) to achieve local enhancement (Chao et al., 2012b). Another study showed that an 
Ad vector tagged with MNPs (Ad-mag) using a biotinylated adenovirus vector with a 
streptavidin-conjugated MNP localised to the head of a mouse embryo following injection into 
the ventricle of the embryo in the presence of a weak neodymium–iron–boron magnet (260 
mT) placed closed to the head (Hashimoto and Hisano, 2011).  
In our study only the primary tumours were targeted with MAG-OV, however metastasis is the 
major cause of breast cancer mortality (Scully et al., 2012). Therefore, it would be more 
appropriate to target breast tumours in common metastatic sites (e.g. brain, lungs, bone). 
However, as these are tumours located deep in the body a weak external magnetic field would 
not successfully target the therapy. As an alternative, it would be interesting to use the powerful 
magnetic gradients of MRI scanners to guiding our MAG-OV in vivo. Our laboratory has 
already demonstrated that the powerful magnets present in MRI machines could guide 
magnetised macrophages loaded with HSV1716 and iron oxide MNPs to tumours in the 
prostate and lungs of mice. The number of macrophages gathering within tumours was 
amplified using this strategy, resulting in tumour shrinkage (Muthana et al., 2015b). Cell 
therapy is complicated and very personalised thus by eliminating the cells and magnetising the 
virus directly makes this approach more amenable and suited to all patients. The data from this 
PhD have been used to successfully secure funding from CRUK to develop magnetised 
HSV1716 for targeting metastatic breast cancer using MRI.  
5.4.3 Increased MAG-OV viral replication following magnetic guidance         
To confirm that the reduction in tumour size in the MAG-OV treatment group (Figure 5.2B), 
was in response to HSV1716 the mRNA expression of viral replication genes within EO771 
tumour cells was measured using qPCR.  Interestingly, we found mRNA expression of these 
genes in the tumour tissue was significantly higher in the MAG-OV group than in the OV only 
and control groups (Figure 5.4). Suggesting that the MAG did not prevent viral replication and 
the OV was able to complete its life cycle within EO771 tumour cells. This result was in 
agreement with previous study that found a significant increase (p < 0.05) in the expression of 
adenoviral DNA (hexon gene) in the tumour tissue in the magnetofection group compared with 
the group that received virus alone using regular PCR analysis (Tresilwised et al., 2012a). Also, 
another study showed that infectious progeny virus particles of Ad520-PEIMag2 complex was 
increased compared with the virus alone (Tresilwised et al., 2010a). In contrast, a previous 
study showed that HSV1716 was only temporarily able to reduce the progress of primary 
tumours in 4T1 mouse mammary carcinoma model; mainly this absence of efficacy was 
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because of poor replication of HSV1716 in 4T1 tumours as measured by the plaque assay (Toda 
et al., 1998, Toda et al., 1999). Further studies would be needed to accurately understand why 
HSV-1 has a reduced capability to replicate in this tumour cell line, while it can successfully 
replicate in EO771 tumour cells.  
There is always concern that manipulation of OV may influence viral properties such as  host 
cell recognition, virus growth and oncolytic activity mainly by reducing replication rates 
(Campbell and Gromeier, 2005). However, Tresilwised et al., have shown that shielding the 
oncolytic adenovirus Ad520 with SO-Mag2 nanoparticles resulted in a significant increase the 
replication of adenoviral DNA in the tumour xenografts, mainly in the short-term treatments 
(Tresilwised et al., 2012a). We also found that by magnetising HSV1716 we see improved viral 
replication (Figure 5.4).  
 5.4.4 MAG-OV induces anti-tumour immunity following magnetic guidance         
Previous studies showed that HSV could directly infect tumour endothelium in vivo and 
significantly decrease the mean vessel density in preclinical tumour models of ovarian, glioma, 
and rhabdomyosarcoma (Benencia et al., 2005, Huszthy et al., 2009). We used 
immunofluorescence staining to assess tumour vascularity and measured the No. of CD31+ 
cells per FOV. As expected magnetic guidance of MAG-OV treated tumour cells were less 
vascularised than the PBS-treated tumours (Figure 5.5A). This result agreed with our in vitro 
study where we found expression of VEGF was significantly downregulated in both MDA-
MB-231 and MCF7 cells treated with OV and MAG-OV compared to the untreated cells 
(section 4.8). VEGF is one of the most potent vascular permeability factors and is important in 
tumour angiogenesis (Adams et al., 2000), reducing VEGF and vessel numbers is one of the 
mechanisms by which OV target tumours.  Prior studies revealed that intratumoral injection of 
the third generation oHSV, G47∆-mIL12, significantly changed the tumour microenvironment 
of GSC-derived intracerebral tumours (Cheema et al., 2013). They revealed that G47∆-mIL12 
downregulated VEGF expression and upregulated CXCL10. 
Necrosis is a type of cell death caused by external factors such as infection and toxins. OVs 
induce cell death by many mechanisms including necrosis (Wang et al., 2014b). Muthana et al, 
demonstrated that tumours from prostate tumour-bearing mice that received HSV1716-
carrying macrophages (monocyte-derived macrophage (MDM) + OV) were significantly more 
necrotic than those that received naked OV (Muthana et al., 2015b). Therefore, tumour necrosis 
was measured after MAG-OV magnetic targeting and was found to be significantly more 
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necrotic than those treated with PBS (Figure 5.5B). This was also confirmed by flow 
cytometric analysis, where tumours treated with MAG-OV were significantly less viable than 
those treated with PBS (Figure 5.5C). This result was also in agreement with our in vitro 
studies in the earlier chapters where cell death was observed and this was accompanied with 
the expression of TNF in both MDA-MB-231 and MCF7 cells treated with OV or MAG-OV 
compared to the untreated cells. Proinflammatory cytokines including TNF-α is released in 
response to cell necrosis (Fadok et al., 2001). Suggesting that MAG-OV therapy could 
successfully promote tissue necrosis and cell death.   
The expression of calreticulin was also measured using immunofluorescence staining. We 
found that the number of calreticulin+ cells increased significantly in tumours treated with 
MAG-OV than those treated with PBS or OV alone (Figure 5.5D). This data agreed with our 
in vitro study that found CRT accumulated at the plasma membrane 24 h after infection with 
OV or MAG-OV compared to the untreated cells (Section 4.6). Infection of human non-small 
cell lung cancer cells with the Coxsackievirus B3 OV resulted in inducing ICD and led to the 
expression of abundant cell surface CRT (Miyamoto et al., 2012). Also, another study showed 
that oncolytic HSV-1 RH2 induced the translocation of CRT to the cell membrane of the mouse 
squamous cell carcinoma  cell line SCCVII (Takasu et al., 2016).  They suggested that HSV 
induce ICD in this cell line. 
One limitation of the data presented in this chapter is that the in vivo studies only focused on 
CRT expression. HMGB1 and ATP levels were not measured in the in vivo studies, as in the 
in vitro studies described in Chapter 4. In our in vitro studies, we assayed secreted HMGB1 
and ATP in the cell culture supernatants according to the manufacturer’s protocol; however, 
we cannot do this in the tumour. It would be interesting to measure the level of HMGB1 and 
ATP in the serum sample from each mouse. Recently, serum HMGB1 levels in mice treated 
with lipopolysaccharides (LPS) and/or ATP or LPS and high‐fat diet to induce NLRP3 
inflammasome activation have been measured using the HMGB1 ELISA kit (Wang et al., 
2018b).  
5.4.5 MAG-OV treated tumours induce expression of immune-related genes     
Nanostring analysis revealed that magnetically guided MAG-OV induced a number of 
immune-related pathways. Genes related to innate and adaptive immune responses (Cxcl2, 
Thbs1, Ifitm1, Cxcr2, Ccl3, Cd14, Ccr1, Icos and Clu), T-cell function (CTLA4, Ccl3, Xcl1, 
Icos), NK cell Functions (Ccl3), macrophage functions (Thbs1), dendritic cell functions (Ccr1), 
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Interferon (Runx3) as well as apoptosis (Gzmb, Osm, Gzma, Clu and Runx3) were elevated 
after treatment with magnetically targeted MAG-OV. This suggests that MAG-OV treatment 
could elevate the majority of the immune-related genes in the NanoString immune profiling 
panel. OVs are known to activate the immune system. A study by Zamarin et al., showed that 
injection of Newcastle disease virus (NDV) into the bilateral flanks of B16-F10 melanoma-
bearing mice upregulated the majority of the immune-related genes we describe including those 
related to T-cell function, DC function and type I IFN (Zamarin et al., 2017). Some researchers 
have engineered OV so that they can be more immunogenic via the expression of genes that 
recruit or activate immune cells. For example, the recruitment of antigen-presenting cells 
(APCs) by production of granulocyte macrophage colony-stimulating factor (GM-CSF) 
expressing HSV and vaccinia virus has been demonstrated (Breitbach et al., 2011b, Andtbacka 
et al., 2015). Indeed the FDA approved T-VEC (genetically modified HSV1 designed to 
produce GM-CSF) demonstrated antitumour immunity, where tumour gene expression data 
from the Phase 1b clinical trial resulted in elevated CD8a and IFN- mRNA in advanced 
melanoma patients (Ribas et al., 2018). Our data confirmed that MAG-OV not only induces 
tumour necrosis, ICD but also activated antitumour immunity.   
Interestingly in the MAG only treated group (MAG) >27 genes were up-regulated (e.g. Ctsw, 
Cmah, C1s1) and 10 genes dow-nregulated (e.g. Trp53, Cxcl12). Whilst, the MAG only group 
did not induce any therapeutic changes some of these genes such as Xcl1, Ido1, IL21r and Ctsw 
hve been linked to Chemokines & Receptors, Cytokines & Receptors, Inflammation, Innate 
and T-Cell Function pathways suggesting that the MAG may have immunogenic properties. 
We used stringent wash steps to purify our MAG (>10 washes) but perhaps this is not adequate. 
A previous study suggested that intravenous injection of 40mg/kg of bacterial MAG into rats 
revealed absence of immunotoxicity (Sun et al., 2010b). They found that no difference in the 
number of white blood cells and lymphocytes to those in untreated rats.  However, they 
mentioned that ‘it is not yet clear whether purified MAG contain antigens or pyrogens. 
Therefore, some consideration should be given when using MAG. Because, the MAG are 
derived from bacteria and contain biological impurities, such as bacterial proteins, nucleic acids 
and polysaccharides this could lead to immunotoxicity. This will need to be considered in great 
detail before using MAG in the clinical setting.  As previously suggested the MAG membrane 
could be stripped to remove bacterial endotoxins by detergent treatment (Xie et al., 2009). We 
have also not measured the endotoxin levels in our preparations and this is something we plan 
to do in the future (Wong et al., 2016). 
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5.4.6 MAG-OV recruits immune cells into the tumour microenvironment       
HSV therapy of CT-26 tumours inhibited the growth of contralateral tumours or of a second 
challenge of tumour cells in immune-competent mice (Toda et al., 1999, Toda et al., 1998, 
Toda et al., 2002). This suggests that anti-tumour immune responses have developed after the 
virotherapy.  HSV1716 therapy of primary 4T1 mammary tumours with lacking RAG2, CD4, 
CD8, and NK cells is ineffective in immune-competent mice, suggesting a role for the T cell 
infiltrate in attacking the tumour (Thomas and Fraser, 2003). Another report by Miller and 
Fraser confirmed the importance of T cells following OV therapy. They showed that 
cyclophosphamide administration (before and during HSV1716 administration) in SCID mice 
with brain tumours in an experimental model of metastatic melanoma was also ineffective 
(Miller and Fraser, 2000).  
We used, flow cytometry to measure the percentage of immune cell infiltration after MAG-OV 
infection. Consistent with our tumour gene expression data, flow cytometry data showed that 
the percentage of CD3, CD3+ CD8+, CD11B+ LY6G+ and NK1.1 significantly increased in 
tumours treated with MAG-OV compared to those treated with PBS (Figure 5.9), with 
reduction in the percentage of CD3+ CD4+ cells, albeit the latter was not significant. This was 
also confirmed by immunofluorescence staining. The data suggest that MAG-OV increased the 
infiltration of immune cells and is in agreement with Thomas and Fraser, who demonstrated 
that HSV1716 therapy of 4T1 tumours increased the percentage of CD4+ and CD8+ T cells in 
immune competent mice (Thomas and Fraser, 2003).   
Given that MAG-OV increased the percentage of CD3+ CD8+ cells, it was important to 
measure their activation status within the tumours. As IFN-γ can be released by activated CD8+ 
T cells in a typical response (Showalter et al., 2017) and PD1 is expressed by activated T cells 
(Westin et al., 2014) we therefore measured the expression of both IFN-γ and PD1 to evaluate 
T cell activation after MAG-OV therapy.  Our data suggested that following MAG-OV 
targeting into tumours, cytotoxic T cells (CD8+) had elevated IFN-γ and PD1 expression 
compared to mice treated with PBS or naked OV (Figure 5.11). This data implies that MAG-
OV induces T cell activation. This increase in the number of T cells expressing PD-1 after 
MAG-OV infection offered a possible explanation as to why our complex did not show 
complete tumour remissions. Perhaps the increase in PD-1 resulted in checkpoint inhibtion of 
the activated T cells via checkpoint inhibition (Pfannenstiel et al., 2019). Likewise, it has been 
suggested that T cells expressing PD-1 in the presence of tumuors positive for PD-L1 may 
negatively influence the antitumour activity of single-agent T-VEC (Ribas et al., 2018). It 
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would be intersting to combine MAG-OV therapy with anti-programmed death protein 1 (PD-
1) or anti-PD-L1 antibody therapy to overcome some of these limitations. As long-lasting 
antitumour responses in patients with a variety of cancers with PD-1 or anti- PD-L1 antibodies 
therapy has been demonstrated (Sharma and Allison, 2015). Recently, it was suggested that  
HSV-1 and PD-1 blockade combination therapy could be a successful treatment strategy for 
childhood soft tissue sarcoma. They found a significant increase in the number of  CD4+ and 
CD8+ T cells but not with the CD4+CD25+Foxp3+ regulatory T cell populations in M3-9-M 
(MHC I high) tumour models that received combination therapy (intratumoral HSV1716 
injection followed by intraperitoneal injection of anti-PD-1) (Chen et al., 2017). 
5.4.7 MAG-OV protection from neutralising antibodies   
Many strategies have been used before to protect viruses from inactivating immune 
mechanisms they encounter in circulation resulting in improved tumour targeting following 
systemic delivery. Our in vitro experiments have shown that adding neutralising Ab to the 
naked HSV1716 resulted in significant inhibition of oncolytic activity. While the oncolytic 
potential of MAG-OV was not changed when adding the neutralising Ab because of the MAG 
shielding of the virus. Neutralisation experiments were performed to determine if MAG could 
protect OV from neutralizing Ab in vivo following injection into the circulation. Interestingly, 
we found that the average tumour volume was significantly smaller in the MAG-OV+NAb 
treated group than in the OV+NAb or PBS group at day 12 after treatment (Figure 5.12A). 
Further, most of the mice in MAG-OV+NAb treated group responded to the treatment survived 
for longer compared to the others groups (Figure 5.12B). This also correlated with an increase 
in GFP expressing virus in the MAG-OV treated group.  This suggests that MAG-OV could 
minimize the interaction of HSV1716 with neutralising Ab because of magnetosome shielding. 
The use of magnetised HSV provides an opportunity to not only guide the virus to the tumour 
in the presence of a magnetic field but to also protect from immune attack whilst in the 
bloodstream. The limitation of this experiment is that only n=3 mice were used in each 
treatment group. Moreover, it would be interesting to use other inhibitory mechanisms to 
neutralise HSV1716, such as using human serum containing neutralising antibodies to HSV 
instead of the sheep antibody.   
In summary, we have shown that MAG-OV can be guided to mouse mammary tumours using 
an external magnetic field and this reduces tumour growth, tumour blood vessels and increases 
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6.1 Summary of main outcomes and general conclusion 
So far, systemic delivery of OVs has been obstructed by low intra-tumoural titres due to strong 
anti-viral host immune responses and sequestration by the liver and spleen resulting in poor 
tumour targeting (Ferguson et al., 2012). Several studies have proposed to use different ways 
for improving the targeting of OV to tumours. This is the first study using bacterial derived 
MAG to target viruses to tumours after systemic delivery and evaluate the anti-tumour immune 
response. In chapter 3, We showed that MAG are small and uniform in size compared to 
synthetic MNPs used by other researchers (Almstätter et al., 2015a). This is agreement with a 
recent study that also confirmed that MAG purified from Magnetospirillum gryphiswaldense 
MSR-1 displayed uniform arrangement of particles whereas MNPs were clustered (Raguraman 
and Suthindhiran, 2019).  
Interestingly, the electrokinetic potential of the MAG was negative (-9 ± 2.3 mV) (Table 3.1). 
Since the MAG display a negative electrokinetic potential we did not expect the self-assembly 
with the OV.  As Almstatter et al., showed that creating the magnetic viral complexes using 
synthetic MNPs relies on the positive electrokinetic potential of the MNP so that complex 
formation depends on electrostatic interactions with negatively charged viral particles (OV) 
(Almstätter et al., 2015a). However, our complex formation is most likely a result of MAG 
possessing polarisable primary amino groups, enabling self-assembly based on the 
homobifunctional cross linking agents for example aliphatic binary aldehyde, 
diisothiocyanates, diisocyanates, di(succinimido) aliphatic esters, and their derivatives (Sun et 
al., 2008). Using TEM and flow cytometry, we found that they form complexes with OV 
without having any impact on the oncolytic potential of the virus. The complexes were also 
still ‘nm’ in size and could infect and kill tumour cells. Afterward, we examined the oncolytic 
potential of MAG-OV in 3D spheroid cultures. We showed that MAG-OV can damage the 
spheroid of MDA-MB-231s and MCF7 cells as good as OV alone (Figure 3.12A, Figure 
3.13A). We observed ruffled edges and a flattened morphology, indicating damaging and cell 
death of the three-dimensional spheroid structure on day 6 of infection with both OV and 
MAG-OV treatment compared to untreated spheroids and MAG only. This suggests that MAG-
OV is as efficient as OV on its own with respect to infectivity and cell death in both monolayer 
and 3D cultures. 
In chapter 4, the replication potential and cell death mechanisms of the virus were assessed. 
MAG-OV was able to enter and replicate inside breast cancer cells, at the same time inducing 
tumour cell death as good as OV alone. We also showed that OV and MAG-OV in both MDA-
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MB-231 and MCF7 cells appeared to induce a significant increase in Caspase 3, Caspase 8, 
FASL and HSPA1A gene expression when compared to the control (Figure 4.5). While Bcl-2 
and NF-ĸB were significantly decreased (Figure 4.5, Figure 4.8). We assume that HSV1716 
was able to induce apoptosis by downregulating anti-apoptotic factors and the data of high 
expression of heat shock protein ‘HSPA1A’ gene suggest immunogenic apoptotic cell death. 
Viral infection appeared also to induce a significant increase in LC3B gene expression when 
compared to the control at both OV and MAG-OV in both MDA-MB-231 and MCF7 cells 
(Figure 4.5). This suggests that HSV1716 can induce apoptosis, necrosis and autophagy in a 
coordinated fashion. Immunogenic cell death (ICD) following MAG-OV infection was also 
measured in infected breast cancer cells. We showed that extracellular ATP levels and HMGB1 
levels were significantly increased at both OV and MAG-OV when compared with control and 
MAG alone (Figure 4.6). We also noticed the expression of CRT around the plasma membrane 
significantly increased with both OV and MAGOV, whereas untreated cells presented the 
diffuse distribution of CRT (Figure 4.7). This suggests that MAG-OV infection was able to 
produce DAMPs from breast cancer cells as effectively as OV alone. 
Next, we attempted to understand the impact of HSV1716 on the surrounding environment. 
qPCR and cytokine bead array (CBA) were used to measure a panel of pro-inflammatory and 
anti-inflammatory cytokines. The expression of CXCL10, IFNg and TNF were upregulated in 
both MDA-MB-231 and MCF7 cells treated with OV or MAG-OV compared to the untreated 
cells (Figure 4.8). On the other hand, the level of anti-inflammatory cytokines IL-1B, NF-KB 
and VEGF were decreased. Suggesting that OV or MAG-OV influenced the tumour 
microenvironment by increasing the level of pro-inflammatory cytokines. 
We also hypothesised that MAG would protect the virus from neutralisation. So next we tried 
to test the efficacy of our complex in the presence of neutralizing Ab in vitro. We showed that 
cells incubated with OV+Nab expressed significantly less GFP after 24h of culture compared 
to MAG-OV+ NAb. This decrease in GFP expression is most likely because of OV 
neutralisation and indeed statistically significant reduced cell death was observed with 
OV+Nab compared to the MAG-OV+ NAb after 24h of culture (Figure 4.10). Suggesting that 
MAG-OV could minimize the interaction of HSV1716 with neutralising Ab because of MAG 




In chapter 5, we attempted to understand whether MAG will improve targeting of OV in the 
presence of external magnetic field gradients and examine whether our complex could 
stimulate immune effector cells in an in vivo model. All the previous studies relied on direct 
injection of the magnetised viruses into the tumour and the presence of an external magnet 
really only served for retention of the therapy within the tumour rather than its delivery. 
Whereas in this study, MAG associated with HSV1716 was used to target MAG-OV from 
circulation to mammary tumours in mice. We showed that MAG-OV resulted in a significant 
change in average tumour volume, increased mouse survival and a reduction in pulmonary 
metastasis compared to the others treatment groups. We have shown that MAG-OV guidance 
into tumours is effective but does not completely eradicate tumour growth once the therapy has 
ceased. This means that the therapy is not so effective alone and should be combined with other 
cancer treatments or that the virus would need to be given continuously. This is the first time 
we have seen efficacy of HSV1716 in the EO771 model of cancer. From our observation, the 
virus on its own is not particularly effective compared to the untreated group. However, by 
using an external magnetic field this improves the anti-tumour efficacy of the virus most likely 
because the virus is reaching the tumour in greater numbers. 
Interestingly, we found a significant increase in the percentage of HSV1716-GFP in the MAG-
OV with magnet treatment group compared to the all other groups after day 3 of treatment and 
also at the end of the experiment (day 23) using flow cytometry and immunofluorescence 
staining (Figure 5.3A&B). Suggesting that MAG under the guidance of the external magnet 
could deliver the virus to the tumour. To confirm that the reduction in tumour size of MAG-
OV treatment group observed in Figure 5.2B, was in response to HSV1716 replication the 
mRNA expression of viral replication genes within EO771 tumour cells were measured using 
qPCR.  Moreover, we found mRNA expression of these genes in the tumour tissue was 
significantly higher in the MAG-OV group than in the OV only and control groups (Figure 
5.4). Suggesting that the MAG did not prevent viral replication and the OV was able to 
complete its life cycle within EO771 tumour cells. In doing this, MAG-OV also increased 
tumour necrosis and immunogenic cell death. Interestingly, the number of pulmonary 
metastasis was significantly reduced in mice that received MAG-OV compared to those treated 
with PBS (Figure 5.5E). The number of pulmonary metastasis was also reduced in mice that 
received MAG-OV compared to those treated with OV alone, but this change was not 
significant.  Suggesting that MAG-OV therapy of the primary tumour could reduce the number 
of metastases in the lungs. 
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The study then addressed whether MAG-OV could induce anti-tumour immunity. Nanostring, 
flow cytometry and immunofluorescence staining analysis revealed that magentically guided 
MAG-OV signefecantly incresed the  number of T cells and myeloid cells. The data suggest 
that MAG-OV increased the infiltration of immune cells. Then, it was important to measure 
the activaton status of CD3+ CD8+ cells. Therefore, we tried to measure the expression of both 
IFN-γ and PD1 to assess T cell activation after MAG-OV therapy.  Our data suggested that  
Cytotxic T cells (CD8+) had elevated IFN-γ and PD1 expression following MAG-OV targeting 
into tumours compared to mice treated with PBS or naked OV (Figure 5.11). This data suggests 
that MAG-OV induces T cell activation and this is important for induing anti-tumour 
immunity.  
Finally, we aimed to determine whether MAG was able to protect OV against neutralising Ab 
in vivo following injection into the circulation. Interestingly, we showed that a significant 
change in average tumour volume was observed in mice receiving MAG-OV+NAb with 
magnet compared to the mice receiving OV+NAb or PBS on day 12 after treatment (Figure 
5.12A). Figure 5.12B showed most of the mice in the MAG-OV+NAb group resulted in a 
significant increase in survival compared to the others groups. This was also associated with 
an increase in GFP expressing virus in the MAG-OV treated group. This data suggests that 
MAG-OV could reduce the interaction of OV with neutralising Ab because of the shielding 
provided by the MAG. 
This study represents a novel therapeutic approach for delivering OV to tumours in circulation 
whilst protecting the virus from unwanted immune attack. Not only does this overcome the 
challenge of systemic delivery of OVs it also provides an opportunity for many cancer types to 
be treated particularly those cancers that are not responsive to conventional therapies or the 
new exciting immunotherapies (e.g. checkpoint inhibitors) due to the low abundance of 
immune cells within the tumour. This particularly applies to breast cancers which are thought 
to be immunologically ‘cold’.  MAG-OV provides the opportunity to re-programme the tumour 
microenvironment to be immunologically ‘hot’ (have more activated T cells) and therefore 
responsive to immunotherapies. The combination of MAG-OV with such immunotherapies is 
exciting and will no doubt be explored in the future. 
6.2 Limitations of studies  
One of the limitations of this study is that cultures of MTB often took weeks to grow and 
resulted in a low yield of magnetite that limited the number of experiments that could be 
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performed. Therefore, it would be important to use different strategies for cultivation of MTB 
in the future. The use of bioreactors is an attractive alternative and could produce much higher 
magnetite yields. A previous study showed that magnetosome production of the marine 
magnetotactic vibrio Magnetovibrio blakemorei strain MV-1 could improve using statistics-
based experimental factorial design (Silva et al., 2013). They obtained maximum magnetite 
yields of 64.3 mg/liter in batch cultures and 26 mg/liter in a bioreactor. Recent study also 
showed that  the growth and magnetosome production of the of Magnetospirillum 
gryphiswaldense MSR-1 could optimize using simple pH-stat fed-batch fermentation strategy 
(Fernández-Castané et al., 2018). The highest biomass concentration, which was an optical 
density at 565 nm of 15.5 (equivalent to 4.2 g DCW·L−1), and the highest cellular iron content, 
which was 33.1 mg iron·g−1 DCW, were obtained.  
Another limitation to this study is that we relied on a change in cell size to confirm uptake of 
the MAG by the cells. The uptake and accumulation of MAG within mammalian cells has not 
been well studied. Cypriano et al., recently showed that following magnetosome uptake by 
HeLa cells the magentosomes were either inside or outside the cell’s endosomes (suggesting 
different routes of internalisation) and that they persisted in culture for 120 h without any 
structural or chemical change. Furthermore, no toxicity to the Hela cells was observed. This 
was carried out using transmission electron microscopy and high spatial resolution nano-
analysis techniques (Cypriano et al., 2019). We did use TEM and detected MAG both in the 
cytoplasm and in the vesicles of the cell (e.g. endosomes). However, it would have been 
interesting to both quantify and visualise MAG uptake by MDA-MB-231 by fluorescence 
uptake using flow cytometry and immunofluorescence microscopy and to track this over time. 
This could be achieved by fluorescently labelling the MAG (e.g. fluorescent dyes or infrared 
probes) and carrying out time-lapse microscopy. It would also have been interesting to 
determine what the fate of the MAG and virus was after cell uptake. By labelling the MAG we 
could have performed co-localisation studies using antibodies to cytoplasmic components such 
as the endosomes and lysosomes and high-resolution confocal microscopy. A post-doctoral 
researcher (Dr Faith Howard) in our group has recently demonstrated that the MAG can be 
labelled with DiD (lipophilic carbocyanine DiD) and detected by both flow cytometry and 
immune fluorescence.  
Another important consideration for biomedical application is the level of endotoxins on MAG. 
Since these are extracted from gram negative magnetotactic bacteria they are likely to possess 
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endotoxins at their surface. To reduce endotoxins the MAG were washed extensively however, 
it would be useful to quantify remaining endotoxins using the Limulus amebocyte lysate (LAL) 
assay but due to the time limitation, it was not possible to achieve during this study but is 
currently being investigated by other group members. 
Another limitation of this study is that the interactions between the OV and MAG were not 
quantified in this study. For example, the concentration of bound virus. Quantification of bound 
virus and unbound virus could be estimated via titration of the supernatant containing free virus 
using a plaque assay. This can then be compared to the MAG-OV after magnetic selection.   
In the neutralisation studies we used sheep serum to inhibit the oncolytic activity of HSV1716. 
Other approaches could be used such as using human serum derived from blood of patients or 
health volunteers. A comparison of serum with high, medium or little/no HSV antibodies could 
be compared to assess MAG-OV neutralisation.  Using breast cancer patient derived serum 
could provide valuable information on the clinical applicability of this approach.  
6.3 Future work 
In future, it would be useful to create a stable MAG-OV complex using new conjugation 
techniques, such as antibodies or chemical linkers. Already in our group research using 
Genipin, a chemical compound found in gardenia fruit extract. This is an excellent natural 
cross-linker for proteins, collagen, gelatin and chitosan. Others are looking into antibodies on 
the surface of the OV (e.g. HSV-1 gB Antibodies) and creating virus-antibody-magnetosome 
linkers. Here it is important to select an antibody that does not interfere with viral infection or 
replication.  This would help in the development of a stable complex that has the potential for 
long-term storage and would be attractive to the pharmaceutical industry. It would also be 
interesting to experiment with magnetosomes from different strain of MTB, particularly those 
with different shapes. It could be that MAG of different shapes lead to better binding with the 
virus. 
In addition, this study only used the Eo771 model of mammary carcinoma. It would be useful 
to administer our magnetic viral complexes in other breast cancer models (e.g. TS-1 derived 
from polyoma middle T antigen (PyMT) mice) (Tan, 2014) or a humanised model of breast 
cancer (Arendt, 2016).  Using breast cancer models that reflect the different subtypes of breast 
cancer could provide information on response to this therapy.  As metastasis is the major cause 
of breast cancer mortality (Scully et al., 2012). Targeting breast tumours in common metastatic 
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sites (e.g. brain, lungs, and bone) should be considered in the future. For example, intracardiac 
injection of (E0771/Pa) results in bone metastases in C57BL/6 mice within 2 weeks (Hiraga 
and Ninomiya, 2018). Whilst this route of administration enable colonisation studies at specific 
sites without complications of primary tumour growth, it is an artificial route of administration 
that requires the implantation of large tumour cell numbers. 
Finally, combining MAG-OV therapy with anti-programmed death protein 1 (PD-1) or anti-
PD-L1) antibody therapy would be also interesting. Particularly, given that we showed a 
significant increase in the number of T cells expressing PD-1 after MAG-OV infection. The 
presence of checkpoint inhibitors within the tumour will lead to inactivation of the T cells and 
this offers a possible explanation as to why our complex did not show complete tumour 
inhibition. Using MAG-OV to recruit T cells and turn a tumour from ‘cold’ to ‘hot’, followed 
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Table 1: The physicochemical properties of the MNPs  






MAG 46 ± 5 - 9 ± 2.3 8.164e-5 0.17 ± 0.5 
10%PEI90%SF 
MNPs  
70 ± 10 28 ± 8.3 4.635e-5 1.13 
50%PEI50%SF 
MNPs 
180  ± 16 47± 10.4 5.7166e-5 0.67 
100%PEI MNPs 101  ± 13 68± 2  8.3362e-5 3.1 
100%SF MNPs 77 ± 35 -23 ± 1.5  6.5280e-5 1.1 


















              
      
 
Figure 1: High-resolution Transmission electron microscopy. A TEM images of AMB-1 
magnetotactic bacteria, grown in cabinet within micro-anaerobic conditions in 1% O2 gas and 99% 
nitrogen at 30.1 C° in liquid culture medium which is specific to AMB-1 bacteria (Left image: scale 
bar-0.2um). Magnetosomes were purified from AMB-1 and displayed typical cuboidal crystal shapes 
(Right image: scale bar-100nm). B The SF100%, SF10% PEI 90%, SF50%PEI 50% and PEI 100% 





































































































Figure 2: MNPs are internalised by MDA-MB-231 cells. MDA-MB-231 cells were incubated with 
0.3mg/ml coated MNPs and purified magnetosomes for 24 hours A Flow cytometrical analysis of cells 
revealed uptake of coated MNPs (SF100%, SF 50%PEI 50%, SF 10% PEI 90%, PEI 100%) and 
magnetosomes resulted in an important increase in cell size and granularity compared to the control 
(untreated cells). Data are the mean ± SEM of n=3. B Representative Prussian blue images of MDA-
MB-231 cells incubated with coated MNPs and magnetosomes. Dark blue staining is the presence of 
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Figure 3: MDA-MB-231 viability following incubation with MNPs. MDA-MB-231 cells were 
incubated with coated MNPs and purified magnetosomes for 24 hours. Cells were collected and flow 
cytometry as used to evaluate cell death by the addition of PI immediately prior to analysis. A Cell 
death (PI+ cells) in the presence of MNPs coated with 50% and 100% PEI was significant when 
compared to the control B MTT assay also revealed a significant difference between the control and 
MNPs coated with 50%PEI/50%SF (P ≤ 0.05and 100% PEI (P ≤ 0.01). No significant change in cell 
viability was noticed in the presence of 10%PEI90%SF MNPs or magnetosomes. Data are the mean ± 
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